ModivCare (MODV) 10-K 6 Mar 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 21, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-34221
Entity Registrant Name	ModivCare Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0845127
Entity Address, Address Line One	6900 E Layton Avenue,
Entity Address, Address Line Two	12th Floor,
Entity Address, City or Town	Denver,
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	258-2130
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	MODV
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 291.8
Entity Common Stock, Shares Outstanding		14,340,049
Documents Incorporated by Reference	The following documents are incorporated by reference into Part III of this Annual Report on Form 10-K: the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission under cover of Schedule 14A with respect to the registrant’s 2025 Annual Meeting of Stockholders; provided, however, that if such proxy statement is not filed on or before April 30, 2025, such information will be included in an amendment to this Annual Report on Form 10-K filed on or before such date.
Entity Central Index Key	0001220754
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Denver, Colorado
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 112,581	$ 2,217
Accounts receivable, net of allowance of $1,439 and $969, respectively	222,317	222,537
Contract receivables	117,795	143,960
Other receivables	16,732	8,616
Prepaid expenses and other current assets	25,419	27,028
Restricted cash	535	565
Total current assets	495,379	404,923
Property and equipment, net	82,409	85,629
Goodwill	680,252	785,554
Payor network, net	269,020	330,738
Other intangible assets, net	13,300	30,197
Equity investment	31,427	41,531
Operating lease right-of-use assets	36,597	39,776
Other assets	45,948	48,927
Total assets	1,654,332	1,767,275
Current liabilities:
Accounts payable	83,068	55,241
Accrued contract payables	22,639	117,488
Accrued transportation costs	96,745	97,245
Accrued expenses and other current liabilities	139,176	127,901
Current portion of operating lease liabilities	8,616	8,727
Short-term debt	274,250	113,800
Total current liabilities	624,494	520,402
Long-term debt, net of deferred financing costs of $30,689 and $16,243, respectively	986,436	983,757
Deferred tax liabilities	13,557	39,584
Operating lease liabilities, less current portion	32,905	33,784
Other long-term liabilities	35,414	33,553
Total liabilities	1,692,806	1,611,080
Commitments and contingencies (Note 17)
Stockholders’ equity (deficit)
Common stock: Authorized 40,000,000 shares; $0.001 par value; 19,882,026 and 19,775,041, respectively, issued and outstanding (including treasury shares)	20	20
Additional paid-in capital	457,406	450,945
Accumulated deficit	(225,715)	(24,437)
Treasury shares, at cost, 5,558,898 and 5,571,004 shares, respectively	(270,185)	(270,333)
Total stockholders’ equity (deficit)	(38,474)	156,195
Total liabilities and stockholders’ equity (deficit)	$ 1,654,332	$ 1,767,275

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 1,439	$ 969
Debt financing fees	$ 30,689	$ 16,243
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, par (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, issued (in shares)	19,882,026	19,775,041
Common stock, shares, outstanding (in shares)	19,882,026	19,775,041
Treasury stock, shares (in shares)	5,558,898	5,571,004

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Service revenue, net	$ 2,787,586	$ 2,751,170	$ 2,504,393
Grant income (Note 2)	0	5,037	7,351
Operating expenses:
Service expense	2,367,215	2,304,218	2,032,074
General and administrative expense	298,391	304,564	322,171
Depreciation and amortization	109,465	104,271	100,415
Impairment of goodwill	105,302	183,100	0
Total operating expenses	2,880,373	2,896,153	2,454,660
Operating income (loss)	(92,787)	(139,946)	57,084
Interest expense, net	94,053	69,120	61,961
Loss on debt extinguishment	11,797	0	0
Loss before income taxes and equity method investment	(198,637)	(209,066)	(4,877)
Income tax benefit	5,506	4,319	3,035
Equity in net income (loss) of investee, net of tax	(8,147)	287	(29,964)
Net income (loss)	$ (201,278)	$ (204,460)	$ (31,806)
Loss per common share:
Basic (in dollars per share)	$ (14.14)	$ (14.43)	$ (2.26)
Diluted (in dollars per share)	$ (14.14)	$ (14.43)	$ (2.26)
Weighted-average number of common shares outstanding:
Basic (in shares)	14,239,549	14,173,957	14,061,839
Diluted (in shares)	14,239,549	14,173,957	14,061,839

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net loss	$ (201,278)	$ (204,460)	$ (31,806)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	30,927	25,038	20,055
Amortization	78,538	79,233	80,360
Stock-based compensation	6,682	6,456	6,872
Deferred income taxes	(26,027)	(17,652)	(36,663)
Impairment of goodwill	105,302	183,100	0
Loss on debt extinguishment	11,797	0	0
Amortization of deferred financing costs and debt discount	6,668	5,246	5,125
Equity in net loss (income) of investee	9,645	(398)	40,916
Reduction of right-of-use assets	11,444	12,344	11,640
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(7,436)	(5,268)	(9,130)
Contract receivables	26,164	(72,828)	(46,651)
Prepaid expenses and other assets	1,828	6,830	6,416
Accrued contract payables	(94,849)	(76,798)	(87,299)
Accounts payable and accrued expenses	39,101	(7,677)	57,249
Accrued transportation costs	(500)	394	(6,443)
Other changes in operating assets and liabilities	(4,414)	(16,531)	(21,083)
Net cash used in operating activities	(6,408)	(82,971)	(10,442)
Investing activities
Purchase of property and equipment	(27,630)	(42,288)	(33,004)
Acquisitions, net of cash acquired	0	0	(78,809)
Net cash used in investing activities	(27,630)	(42,288)	(111,813)
Financing activities
Net proceeds from short-term borrowings	155,200	113,800	0
Proceeds from issuance of long-term debt	525,000	0	0
Repayment of long-term debt	(509,970)	0	0
Payment of debt issuance costs	(25,786)	(376)	(2,415)
Restricted stock surrendered for employee tax payment	(620)	(899)	(792)
Proceeds from common stock issued pursuant to stock option exercise	0	31	6,789
Other financing activities	548	510	226
Net cash provided by financing activities	144,372	113,066	3,808
Net change in cash, cash equivalents and restricted cash	110,334	(12,193)	(118,447)
Cash, cash equivalents and restricted cash at beginning of year	2,782	14,975	133,422
Cash, cash equivalents and restricted cash at end of year	113,116	2,782	14,975
Supplemental cash flow information
Cash paid for interest	76,767	64,200	59,392
Cash paid for income taxes	9,106	9,078	15,660
Assets acquired under operating leases	8,265	12,715	7,295
Acquisitions:
Purchase price	0	0	79,200
Less:
Cash acquired	0	0	(391)
Acquisitions, net of cash acquired	$ 0	$ 0	$ 78,809

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021		19,589,422
Beginning balance at Dec. 31, 2021	$ 373,267	$ 20	$ 430,449	$ 211,829	$ (269,031)
Beginning balance (in shares) at Dec. 31, 2021					5,568,983
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(31,806)			(31,806)
Stock-based compensation	6,491		6,491
Exercise of employee stock options (in shares)		109,731
Exercise of employee stock options	6,789		6,789
Restricted stock issued (in shares)		27,251
Restricted stock issued	0
Restricted stock surrendered for employee tax payment (in shares)					7,486
Restricted stock surrendered for employee tax payment	(792)				$ (792)
Shares issued for bonus settlement and director stipends (in shares)		3,519
Shares issued for bonus settlement and director stipends	340		340
Shares issued for ESPP (in shares)					(2,940)
Shares issued for ESPP	267		186		$ 81
Ending balance (in shares) at Dec. 31, 2022		19,729,923
Ending balance at Dec. 31, 2022	354,556	$ 20	444,255	180,023	$ (269,742)
Ending balance (in shares) at Dec. 31, 2022					5,573,529
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(204,460)			(204,460)
Stock-based compensation	6,061		6,061
Exercise of employee stock options (in shares)		549
Exercise of employee stock options	31		31
Restricted stock issued (in shares)		37,609
Restricted stock issued	0
Restricted stock surrendered for employee tax payment (in shares)					10,565
Restricted stock surrendered for employee tax payment	(899)				$ (899)
Shares issued for bonus settlement and director stipends (in shares)		6,960
Shares issued for bonus settlement and director stipends	316		316
Shares issued for ESPP (in shares)					(13,090)
Shares issued for ESPP	$ 590		282		$ 308
Ending balance (in shares) at Dec. 31, 2023	19,775,041	19,775,041
Ending balance at Dec. 31, 2023	$ 156,195	$ 20	450,945	(24,437)	$ (270,333)
Ending balance (in shares) at Dec. 31, 2023	5,571,004				5,571,004
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (201,278)			(201,278)
Stock-based compensation	$ 6,518		6,518
Exercise of employee stock options (in shares)	0
Restricted stock issued (in shares)		100,973
Restricted stock issued	$ 0
Restricted stock surrendered for employee tax payment (in shares)					22,827
Restricted stock surrendered for employee tax payment	(620)				$ (620)
Shares issued for bonus settlement and director stipends (in shares)		6,012
Shares issued for bonus settlement and director stipends	106		106
Shares issued for ESPP (in shares)		0			(34,933)
Shares issued for ESPP	$ 605		(163)		$ 768
Ending balance (in shares) at Dec. 31, 2024	19,882,026	19,882,026
Ending balance at Dec. 31, 2024	$ (38,474)	$ 20	$ 457,406	$ (225,715)	$ (270,185)
Ending balance (in shares) at Dec. 31, 2024	5,558,898				5,558,898

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Description of Business ModivCare Inc. ("ModivCare" or the "Company") is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. Its value-based solutions address the social determinants of health ("SDoH") by connecting members to essential care services. By doing so, ModivCare helps health plans manage risks, reduce costs, and improve health outcomes. ModivCare is a provider of non-emergency medical transportation ("NEMT"), personal care services ("PCS"), and in-home monitoring solutions ("Monitoring"), which serve similar, highly vulnerable patient populations. The technology-enabled operating model in its NEMT segment includes the coordination of non-emergency medical transportation services supported by an infrastructure of core competencies in risk underwriting, contact center management, network credentialing and claims management. Additionally, its personal care services in its PCS segment include placements of non-medical personal care assistants, home health aides and nurses primarily to Medicaid patient populations in need of care monitoring and assistance performing daily living activities in the home setting. ModivCare’s in-home monitoring solutions in its Monitoring segment include in-home clinical monitoring and quality improvement services that leverage personal emergency response systems, vitals monitoring devices, relationship-based care, and data-driven patient engagement solutions. ModivCare also holds a 43.6% minority interest in CCHN Group Holdings, Inc. and its subsidiaries, which operate under the Matrix Medical Network brand (“Matrix”). Matrix, which is included in our Corporate and Other segment, maintains a national network of community-based clinicians who deliver in-home and on-site services. Basis of Presentation The Company follows accounting standards established by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under the authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. References to GAAP issued by the FASB in these notes are to the FASB Accounting Standards Codification (“ASC”), which serves as the single source of authoritative accounting and applicable reporting standards to be applied for non-governmental entities. All amounts are presented in U.S. dollars unless otherwise noted. The Company accounts for its investment in Matrix using the equity method, as the Company does not control the decision-making process or business management practices of Matrix. While the Company has access to certain information and performs certain procedures to review the reasonableness of information, the Company relies on the management of Matrix to provide accurate financial information prepared in accordance with GAAP. The Company receives audit reports relating to such financial information from Matrix’s independent auditors on an annual basis. The Company is not aware of any errors in or possible misstatements of the financial information provided by Matrix that would have a material effect on the Company’s consolidated financial statements. See Note 6, Equity Investment , for further information. Reclassifications: Certain prior year amounts have been reclassified to conform to current year presentation. Going Concern In accordance with ASC 205-40, Presentation of Financial Statements – Going Concern , Management evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of financial statement issuance and to provide related footnote disclosures in certain circumstances. The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP, assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2024, the Company has experienced financial challenges, including increased transportation and caregiver costs that have not been offset by corresponding reimbursement rate increases from payors, the loss of certain contracts, and membership declines. These factors have negatively impacted cash flow generation and liquidity. Additionally, the Company has experienced lengthened collection periods due to complexities in Medicare, Medicaid, and nongovernmental payor arrangements, resulting in delays between recognizing revenue for services rendered and collecting cash owed for our services. This prolonged cash conversion cycle places further strain on liquidity and working capital. As a result, the Company is likely to require additional liquidity in order to support ongoing operations over the next year. As of the issuance date of these consolidated financial statements, the Company also entered into Amendment No. 5 (the "Fifth Amendment") to its Credit Agreement (see Note 11, Debt for further details) which, among other things, established an incremental term loan facility in an aggregate principal amount of $75.0 million (the “Incremental Term Loan”). The Incremental Term Loan is a short-term facility with a maturity date of January 10, 2026 and, as a result of the factors described above, the Company is likely to require additional liquidity in order to satisfy its existing debt obligations due within one year from the date of the issuance of these consolidated financial statements. As a result of the foregoing, the Company is not expected to have the ability to meet one or more financial covenants under its existing credit agreements. Failure to meet these covenants or others could cause obligations under the Revolving Credit Facility (as defined in Note 11, Debt ), the Term Loan Facility (as defined in Note 11, Debt ), the Incremental Term Loan (as defined above), and the Company’s Notes due 2029 (as defined in Note 11, Debt ), to become immediately due and payable, and the Company would not have sufficient liquidity to satisfy such obligations. In such event, the Company would be required to restructure its existing debt or to seek additional equity or debt financing to meet its obligations. Furthermore, these factors raise substantial doubt about the Company's ability to satisfy its obligations as they become due within one year from the issuance date of these financial statements. Accordingly, Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. To address these concerns, Management has implemented cost optimization measures, renegotiated contract terms, and secured amendments to its credit agreements, including a temporary financial covenant holiday. Management is actively pursuing further financing options, evaluating strategic asset divestitures, long-term covenant relief and implementing operational efficiencies to improve liquidity. There can be no assurance that additional financing, additional liquidity from asset divestitures or long-term covenant relief will be available on terms acceptable to the Company, or at all, or in amounts sufficient to enable the Company to satisfy its obligations as they become due or to sustain operations in the future. Impact of the COVID-19 Pandemic On May 11, 2023, the Department of Health and Human Services ("HHS") declared the end of the public health emergency ("PHE") for the COVID-19 pandemic. While the Company has continued to experience increased trip volume, service hours, and patient engagement each year following the pandemic, structural changes in the industry as a result of the pandemic, as well as ongoing constraints on the labor market, specifically related to the strain on healthcare professionals, could continue to have an adverse impact on the Company's financial statements. The Company continues to actively monitor the structural changes to the industry and the impact these have on our business and results of operations with an emphasis on protecting the health and safety of its employees, maximizing the availability of its services and products to support SDoH, and supporting the operational and financial stability of its business.

Significant Accounting Policies

Significant Accounting Policies and Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies and Recent Accounting Pronouncements	Significant Accounting Policies and Recent Accounting Pronouncements Principles of Consolidation The accompanying consolidated financial statements include ModivCare Inc., its wholly-owned subsidiaries, and entities it controls, or in which it has a variable interest and is the primary beneficiary of expected cash profits or losses. The Company records its investments in entities that it does not control, but over which it has the ability to exercise significant influence, using the equity method. The Company has eliminated significant intercompany transactions and accounts. Accounting Estimates The Company uses estimates and assumptions in the preparation of the consolidated financial statements in accordance with GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the Company’s consolidated financial statements. These estimates and assumptions also affect the reported amount of net income or loss during any period. The Company’s actual financial results could differ significantly from these estimates. The significant estimates underlying the Company’s consolidated financial statements include revenue recognition; accrued transportation costs; income taxes; recoverability of current and long-lived assets, including equity method investments; intangible assets and goodwill; loss contingencies; accounting for business combinations, including amounts assigned to definite and indefinite lived intangibles and contingent consideration; and loss reserves for reinsurance and self-funded insurance programs. Fair Value Measurements The Company follows FASB ASC Topic 820, Fair Value Measurement (“ASC 820”) which establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy categorizes assets and liabilities measured at fair value into one of three different levels depending on the observability of the inputs employed in the measurement. The three levels are defined as follows: – Level 1: Quoted Prices in Active Markets for Identical Assets – inputs to the valuation methodology are quoted prices in active markets as of the measurement date for identical assets or liabilities. – Level 2: Significant Other Observable Inputs – inputs to the valuation methodology are based upon quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. – Level 3: Significant Unobservable Inputs – inputs to the valuation methodology are unobservable and significant to the fair value measurement. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. As of December 31, 2024 and 2023, the carrying amount for cash and cash equivalents, accounts receivable (net of allowance for credit losses), current assets and current liabilities was equal to or approximated fair value due to their short-term nature or proximity to current market rates. Fair values for the Company's publicly traded debt securities are based on quoted market prices, when available, and for the Company's nonpublic debt are based on lender quotes, when available. See Note 11, Debt , for the fair value of the Company's long-term debt. Cash and Cash Equivalents Cash and cash equivalents include all cash balances and highly liquid investments with an initial maturity of three months or less. Investments in cash equivalents are carried at cost, which approximates fair value. The Company places its temporary cash investments with high credit quality financial institutions. At times, such investments may be in excess of the federally insured limits. Restricted Cash Restricted cash primarily relates to amounts held in trusts for reinsurance claims losses under the Company’s insurance operation for historical workers’ compensation, general and professional liability and auto liability reinsurance programs, as well as amounts restricted for withdrawal under our self-insured medical and benefits plans. Accounts Receivable and Allowance for Credit Losses The Company records accounts receivable amounts at the contractual amount, less contractual revenue adjustments based on amounts expected to be due from payors and less an allowance for credit losses. The Company maintains an allowance for credit losses at an amount it estimates to be sufficient to cover the risk that an account will not be collected due to credit risk. In order to establish the amount of the allowance related to the credit risk of accounts receivable, the Company considers information related to receivables that are past due, past loss experience, current and forecasted economic conditions, and other relevant factors. In circumstances where the Company is aware of a customer’s inability to meet its financial obligation, the Company records a specific allowance for credit losses to reduce its net recognized receivable to an amount the Company reasonably expects to collect. As the Company primarily contracts with Medicaid and Medicare governmental payors, the Company is not subject to significant credit risk in the collection of accounts receivable. The Company’s bad debt expense for the years ended December 31, 2024, 2023 and 2022 was $4.4 million, $4.0 million and $2.7 million, respectively. Business Combinations The Company accounts for acquisitions in accordance with ASC Topic 805, Business Combinations . The acquisition method of accounting requires the Company to make significant estimates and assumptions as of the date of the acquisition related to the determination of the fair values (primarily Level 3) of the tangible and intangible assets acquired and liabilities assumed, and related to the determination of estimated lives of the depreciable assets acquired. The Company recognizes goodwill at the amount by which the purchase price exceeds the fair value of identified assets acquired and liabilities assumed. See Note 3, Acquisitions , for further discussion of the Company’s acquisitions. Property and Equipment Property and equipment are stated at historical cost, net of accumulated depreciation, or at fair value if the assets were initially recorded as the result of a business combination or if the asset was remeasured due to an impairment. Depreciation is calculated using the straight-line method over the estimated useful life of the asset to the Company. Maintenance and repairs are expensed as incurred. Gains and losses resulting from the disposition of an asset are reflected in results of operations. Internal-use Software The Company develops and implements software for internal use to enhance the performance and capabilities of the technology infrastructure. The costs incurred for the development of the internal-use software are capitalized when they meet the internal-use software capitalization criteria outlined in ASC 350-40 and are included within "Property and equipment, net" on the consolidated balance sheets. The capitalized costs are amortized using the straight-line method over the estimated useful life of the software, ranging from 3 to 10 years. As of December 31, 2024 and 2023, capitalized costs associated with the internal-use software, net of accumulated amortization were $26.1 million and $21.3 million, respectively. The amount of accumulated amortization as of December 31, 2024 and 2023 was $7.8 million and $2.6 million, respectively. Amortization expense during the years ended December 31, 2024, 2023, and 2022 totaled $5.2 million, $2.5 million, and $0.1 million respectively. In addition to acquired software, the Company capitalizes costs associated with cloud computing arrangements (“CCA”) that are service contracts. The CCA includes services which are used to support certain internal corporate functions as well as technology associated with revenue-generating activities. The capitalized costs are amortized using the straight-line method over the term of the related CCA. As of December 31, 2024 and 2023, capitalized costs associated with CCA, net of accumulated amortization were $11.9 million and $14.6 million, respectively. The amount of accumulated amortization as of December 31, 2024 and 2023 was $10.3 million and $5.2 million, respectively. Amortization expense during the years ended December 31, 2024, 2023, and 2022, totaled $5.1 million, $2.9 million and $1.7 million, respectively. Recoverability of Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other , the Company reviews goodwill for impairment annually, and more frequently if events and circumstances indicate that an asset may be impaired. Such circumstances could include, but are not limited to: (1) the loss or modification of significant contracts, (2) a significant adverse change in legal factors or in business climate, (3) unanticipated competition, (4) an adverse action or assessment by a regulator, or (5) a significant decline in the Company’s stock price. When evaluating goodwill for impairment, the Company first performs a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative assessment and compares the fair value of the reporting unit to its carrying value and to the extent the carrying value is greater than the fair value, the difference is recorded as an impairment in the consolidated statements of operations. The Company performed a quantitative test comparing the carrying value of the Company's reporting units with their respective fair value. The fair value of the Company's reporting units is estimated using either an income approach, a market valuation approach, or a blended approach. The income approach produces an estimated fair value of a reporting unit based on the present value of the cash flows the Company expects the reporting unit to generate in the future. Estimates included in the discounted cash flow model are primarily Level 3 inputs and include the discount rate, which the Company determines based on adjusting an industry-wide weighted-average cost of capital for size, geography, risk free rates, and company specific risk factors, long-term rates of growth and profitability of the Company’s business, working capital effects and planned capital expenditures. The market approach produces an estimated fair value of a reporting unit based on a comparison of the reporting unit to comparable publicly traded entities in similar lines of business. The Company’s significant estimates in the market approach include the selected similar companies with comparable business factors such as size, growth, profitability, risk and return on investment and the multiples the Company applies to earnings before interest, taxes, depreciation and amortization (“EBITDA”) to estimate the fair value of the reporting unit. As a result of the Company's annual goodwill assessments during the years 2024 and 2023, the Company determined that based on its qualitative assessment for each reporting unit, factors existed which required the Company to test its goodwill and indefinite-lived intangible assets for impairment. Accordingly, the Company performed a quantitative assessment during each annual testing period which resulted in the Company recording a non-cash goodwill impairment charge of $105.3 million within its Monitoring reporting unit during the 2024 annual period and recording a non-cash goodwill impairment charge of $183.1 million, of which $137.3 million was recorded in the PCS reporting unit and $45.8 million was recorded in the Monitoring reporting unit during the 2023 annual period. See Note 9, Goodwill and Intangible Assets , for additional details. Recoverability of Intangible Assets Subject to Amortization and Other Long-Lived Assets Intangible assets subject to amortization and other long-lived assets are carried at cost and are amortized or depreciated on a straight-line basis over their estimated useful lives of 2 to 10 years. In accordance with ASC 360, Property, Plant, and Equipment , the Company reviews the carrying value of long-lived assets or groups of assets to be used in operations whenever events or changes in circumstances indicate that the carrying amount of the assets may be impaired. Factors that may necessitate an impairment assessment include, among others, significant adverse changes in the extent or manner in which an asset or group of assets is used, significant adverse changes in legal factors or the business climate that could affect the value of an asset or group of assets or significant declines in the observable market value of an asset or group of assets. The presence or occurrence of those events indicates that an asset or group of assets may be impaired. In those cases, the Company assesses the recoverability of an asset or group of assets by determining whether the carrying value of the asset or group of assets exceeds the sum of the projected undiscounted cash flows expected to result from the use and eventual disposition of the assets over the remaining economic life of the asset or the primary asset in the group of assets. If such testing indicates the carrying value of the asset or group of assets is not recoverable, the Company estimates the fair value of the asset or group of assets using appropriate valuation methodologies, which would typically include an estimate of discounted cash flows. If the fair value of those assets or groups of assets is less than carrying value, the Company records an impairment loss equal to the excess of the carrying value over the estimated fair value. Accrued Transportation Costs The Company generally contracts with third-party providers to provide transportation services to customers. The cost of transportation is recorded in the month the services are rendered based upon contractual rates and mileage estimates. Once a trip is completed, the third-party transportation providers will furnish invoices for actual mileage incurred. Any trips that have not been invoiced require an accrual based upon the expected cost of the trips as well as an estimated number of cancellations, as the Company is generally only obligated to pay the transportation provider for completed trips. These estimates are based upon the historical trend associated with each contract’s population and the transportation provider network servicing the program. There may be differences between actual invoiced amounts and estimated costs, and any resulting adjustments are included in expense. Accrued transportation costs were $96.7 million and $97.2 million at December 31, 2024 and 2023, respectively. Deferred Financing Costs and Debt Discounts The Company capitalizes costs incurred in connection with its credit facilities and other borrowings, referred to as deferred financing costs, and amortizes such costs over the life of the respective credit facility or other borrowings. Costs associated with the revolving facility are capitalized as deferred financing costs and included in "Prepaid expenses and other current assets" on the consolidated balance sheets. Costs associated with term loans are capitalized and included as a reduction to the debt balance on the consolidated balance sheets. Deferred financing costs for the Revolving Credit Facility, net of amortization, totaled $2.9 million and $2.6 million as of December 31, 2024 and 2023, respectively. A debt discount for the $500.0 million Senior Unsecured Notes due 2025 of $6.0 million was netted against the outstanding balance of the long-term debt on the consolidated balance sheets as of December 31, 2023, with no corresponding debt discount netted against the outstanding balance of December 31, 2024 due to the redemption of the 2025 Notes during the year ended December 31, 2024. Debt discounts for the $500.0 million Senior Unsecured Notes due 2029 of $8.7 million and $10.3 million are netted against the outstanding balance of the long-term debt on the consolidated balance sheets as of December 31, 2024 and 2023, respectively. Deferred financing costs associated with the Term Loan Facility that was entered into in 2024 of $22.0 million are netted against the outstanding balance of the long-term debt on the consolidated balance sheets as of December 31, 2024, with no corresponding deferred financing costs as of December 31, 2023. Revenue Recognition Under ASC 606, the Company recognizes revenue as it transfers promised services directly to its customers at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing these services. The Company's performance obligations are driven by its different segments of business and primarily consist of integrated service offerings to provide non-emergency medical transportation, personal care services, or remote monitoring services directly to its customers. The Company receives payment for providing these services from third-party payors that include federal, state, and local governmental agencies, managed care organizations, and private consumers. In the NEMT segment, the Company's performance obligation is to stand ready to perform transportation-related activities, including the management, fulfillment, and recordkeeping activities associated with such services. In the PCS segment, the Company's performance obligation is to deliver patient care services in accordance with the nature and frequency of services outlined in each contract. In the Monitoring segment, the Company's performance obligation is to stand ready to perform in-home clinical monitoring and quality improvement services that leverage personal emergency response systems, vitals monitoring devices, relationship-based care, and data-driven patient engagement solutions, as contractually agreed upon. The Company satisfies substantially all of its performance obligations over time and recognizes revenue over time instead of at points in time which aligns the pattern of transfer of promised services with the value received by the customer for the performance completed to date. The Company holds different contract types under its different segments of business. In the NEMT segment, there are both capitated contracts, under which payors pay a fixed amount monthly per eligible member and revenue is recognized over each distinct service period, and fee-for-service ("FFS") contracts, under which the Company bills and collects a specified amount for each service that is provided and revenue is recognized using the right to invoice practical expedient. In the PCS segment, contracts are also FFS and service revenue is reported at the estimated net realizable amount from patients and third-party payors for services rendered and revenue is recognized using the right to invoice practical expedient. Under Monitoring contracts, payors pay per-enrolled-member-per-month, based on enrolled membership, and revenue is recognized ratably over the contract term. For each contract type, the Company determines the transaction price based on the gross charges for services provided, reduced by estimates for contractual adjustments due to settlements of audits and payment reviews from third-party payors. The Company determines the estimated revenue adjustments at each segment based on its historical experience with various third-party payors and previous results from the claims and adjudication process. The PCS segment uses the portfolio approach to determine the estimated revenue adjustments. See further information in Note 5, Revenue Recognition . Government Grants The Company periodically receives government grants and other forms of government assistance which are not generated from the Company's contractual performance obligations under ASC 606, Revenue from Contracts with Customers . Funding received from governmental entities under government programs generally requires that the recipient attests to and complies with certain terms and conditions of receiving the funding. Government grant distributions have been received primarily under the CARES Act Public Health and Social Services Emergency Fund ("Provider Relief Fund" or "PRF") and the American Rescue Plan Act of 2021 ("ARPA") Coronavirus State and Local Fiscal Recovery Fund ("SLFRF"). These funds were established to provide economic relief payments and stimulus to companies to address the health and economic impacts of the COVID-19 pandemic. During the third quarter of 2023, the Company also filed amended payroll tax returns for 2020 and 2021 to claim refunds for Employee Retention Credits ("ERC"). ERC is a U.S. federal tax credit introduced to support businesses and organizations during the COVID-19 pandemic that was initially established under the CARES Act in 2020 and was later expanded and extended by subsequent legislation, including the Consolidated Appropriations Act of 2021 and the American Rescue Plan Act of 2021. The Company has also received government grant distributions from other entities that provide funds with specific stipulations on the usage of these funds. Distributions received under the CARES Act PRF and the ARPA SLFRF are targeted to assist with incremental health care related expenses or lost revenue attributable to the COVID-19 pandemic and/or provide stimulus to support long-term growth and recovery. When received, these government grants are generally recorded on the consolidated balance sheets in "Accrued expenses and other current liabilities" until the time at which there is reasonable assurance the conditions of the grant will be met, at which point they are recognized on the consolidated statement of operations. Once recognized, the Company records these government grants as "Grant income" if the grant is related to the loss of revenues, or as an offset to "Service expense" if the grant is used to offset certain costs for which the grants are intended to compensate. The Company received distributions from government grants of approximately $19.5 million, $21.8 million, $16.3 million during the years ended December 31, 2024, 2023, and 2022, respectively. During the year ended December 31, 2024, no funds were recognized as grant income and $24.1 million were recognized as an offset to " Service expense Grant income Accrued Expenses and Other Current Liabilities . The payments from these acts are subject to certain restrictions and possible recoupment if not used for designated purposes. As a condition to receiving PRF distributions, providers must agree to certain terms and conditions, including, among other things, that the funds are being used for healthcare related expenses and lost revenues attributable to COVID-19, as defined by HHS. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. The Company has submitted the required documents to meet reporting requirements for the applicable reporting periods. The Company received an audit inquiry letter from HHS related to one of the business units that received PRF payments, to which the Company has responded and submitted all requested information and believes that the payments received are substantiated and within the terms and conditions defined by HHS and continues to recognize these amounts as grant income. At this time, the Company is unaware of any other pending or upcoming audits or inquiries related to amounts received under PRF. As a condition to receiving SLFRF distributions, providers must agree to use the funds to respond to the Public Health Emergency ("PHE") or its negative economic impacts, to respond to workers performing essential work by providing premium pay to eligible workers and to offset reduction in revenue due to the COVID-19 PHE as stipulated by the states in which the funds were received. All recipients of SLFRF distributions are required to comply with the reporting requirements that the state in which the funds originated requests in order for the states to meet the requirements as described in the terms and conditions as determined by the Department of the Treasury. The Company is in the process of complying with all known reporting requirements to date. Stock-Based Compensation The Company follows the fair value recognition provisions of ASC Topic 718 – Compensation – Stock Compensation (“ASC 718”), which requires companies to measure and recognize compensation expense for all share-based payments at fair value. • The Company calculates the fair value of stock options using the Black-Scholes option-pricing formula and determines the fair value of restricted stock awards or units ("RSAs" or "RSUs") based on the closing market price of the Company’s Common Stock on the date of grant. Forfeitures for stock options, RSAs, and RSUs are recorded as they occur. The expense for stock-based compensation awards is amortized on a straight-line basis over the requisite service period, which is typically the vesting period. • The Company issues performance-based RSUs ("PRSUs") that vest upon achievement of pre-established company specific performance conditions and a service period. The fair value of the PRSUs is determined based on the closing market price of the Company’s Common Stock on the grant date and an assessment of the probability the performance targets will be achieved. Forfeitures are recorded as they occur. The expense for such awards is recognized over the requisite service period. Income Taxes Deferred income taxes are determined by the asset and liability method in accordance with ASC Topic 740 - Income Taxes . Under this method, deferred tax assets and liabilities are determined based on differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings experience by jurisdiction, expectations of future taxable income, and the carryforward periods available for tax reporting purposes, as well as other relevant factors. The Company establishes a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The net amount of deferred tax liabilities and assets, net of the valuation allowance, is presented as non-current in the Company's consolidated balance sheets. Due to inherent complexities arising from the nature of the Company’s businesses, future changes in income tax law or variances between the Company’s actual and anticipated operating results, the Company makes certain judgments and estimates. Therefore, actual income taxes could materially vary from these estimates. The Company has recorded a valuation allowance which includes amounts for certain carryforwards and deferred tax assets, as more fully described in Note 16, Income Taxes, for which the Company has concluded that it is more likely than not that these carryforwards and deferred tax assets will not be realized in the ordinary course of operations. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. The Company accounts for uncertain tax positions based on a two-step process of evaluating recognition and measurement criteria. The first step assesses whether the tax position is more likely than not to be sustained upon examination by the tax authority, including resolution of any appeals or litigation, based on the technical merits of the position. If the tax position meets the more likely than not criteria, the portion of the tax benefit greater than 50.0% likely to be realized upon settlement with the tax authority is recognized in the consolidated financial statements. Loss Reserves for Certain Reinsurance Programs The Company historically reinsured a substantial portion of its automobile, general and professional liability and workers’ compensation costs under certain reinsurance programs. The Company utilizes a report prepared by an independent actuary to estimate the gross expected losses related to these reinsurance policies, including the estimated losses in excess of insured limits, which would be reimbursed to the Company to the extent such losses were incurred. As of December 31, 2024 and 2023, the Company had reserves of $30.0 million and $20.2 million, respectively, for the automobile, general and professional liability and workers’ compensation reinsurance policies. The gross reserve as of December 31, 2024 and 2023 of $58.0 million and $45.7 million, respectively, is classified as current liabilities and other long-term liabilities in the consolidated balance sheets. The estimated amount to be reimbursed to the Company as of December 31, 2024 and 2023 was $28.0 million and $25.5 million, respectively, and is classified as other long-term assets in the consolidated balance sheets. The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, judgment is involved in assessing these reserves, such as in assessing historical paid claims, average lag times between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. Self-Funded Insurance Programs The Company also maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims generally to $0.3 million per person, subject to an aggregating stop-loss limit of $0.4 million. In addition, the program has a total stop-loss limit for total claims, in order to limit the Company’s exposure to catastrophic claims. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2024 and 2023, the Company had $3.3 million and $1.8 million, respectively, in reserves for its self-funded health insurance programs. The reserves are classified as “Accrued expenses and other current liabilities” in the consolidated balance sheets. Earnings (Loss) Per Share The Company computes basic earnings (loss) per share by taking net income (loss) attributable to the Company available to common stockholders divided by the weighted average number of common shares outstanding during the period, including restricted stock and stock held in escrow if such shares are participating securities. Diluted earnings (loss) per share includes the potential dilution that may occur from stock-based awards and other stock-based commitments using the treasury stock or the as-if converted methods, as applicable. For additional information on how the Company computes earnings (loss) per share, see Note 14, Earnings (Loss) Per Share . Recent Accounting Pronouncements During the year ended December 31, 2024, the Company adopted the following accounting pronouncement: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). This update improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit or loss, require disclosure of other segment items by reportable segment and a description of the composition of other segment items , req

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions Business Combinations Guardian Medical Monitoring On May 11, 2022, the Company acquired Guardian Medical Monitoring ("GMM"), a provider of remote patient monitoring solutions that manages a comprehensive suite of services including in-home clinical monitoring and quality improvement services that leverage personal emergency response systems and vitals monitoring devices. The acquisition of GMM supports the Company's strategy to expand its Monitoring segment and enhances the Company's suite of supportive care solutions that address SDoH. The stock transaction was accounted for in accordance with ASC 805, Business Combinations in which a wholly-owned subsidiary of the Company acquired 100.0% of the equity securities of GMM for $71.2 million (a purchase price of $71.6 million less $0.4 million of cash that was acquired). The following table summarizes the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities as of the acquisition date of May 11, 2022 (in thousands): Cash (1) $ 391 Accounts receivable (2) 2,355 Prepaid expenses and other (3) 771 Property and equipment (4) 2,639 Intangible assets (5) 21,950 Goodwill (6) 44,346 Accounts payable (7) (281) Accrued expenses and other current liabilities (7) (577) Total of assets acquired less liabilities assumed $ 71,594 (1) During 2022, the Company received an additional $0.1 million of cash related to net working capital adjustments, and therefore, the initial balance of $0.3 million was increased to $0.4 million. (2) Management has valued accounts receivable based on the estimated future collectability of the receivables portfolio. During 2022, it was determined that $0.6 million of the initial accounts receivable balance was uncollectible, and therefore, the initial balance of $3.0 million was decreased to $2.4 million. (3) Given the short-term nature of the balance of prepaid expenses and other assets, the carrying value represents the fair value. (4) The acquired property and equipment consists primarily of personal emergency response system devices, with the remainder consisting of computer equipment and furniture and fixtures. The Company valued the personal emergency response system devices utilizing the cost approach. Through this valuation, it was determined that $0.1 million of acquired property and equipment did not exist, and therefore, the initial balance of $2.7 million was decreased to $2.6 million. The carrying value of the remainder of the property and equipment, consisting primarily of computer equipment and furniture and fixtures, is assumed to represent the fair value. (5) The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands, except useful lives): Type Useful Life Value Payor network Amortizable 7 years $ 21,600 Trade name Amortizable 2 years 350 $ 21,950 The Company valued the payor network utilizing the multi-period excess earnings method and trade names utilizing the relief-from-royalty method. The weighted average useful life of the acquired intangible assets is approximately 6.9 years. (6) The acquisition initially resulted in $43.7 million of goodwill as a result of expected synergies due to future customers driven by expansion into different markets and an increase in market share. During the measurement period, accounts receivable was reduced by $0.6 million which caused a corresponding increase to goodwill. Also during the measurement period, cash increased by $0.1 million related to working capital adjustments, which caused a corresponding decrease to goodwill, and acquired property and equipment decreased by $0.1 million, which caused a corresponding increase to goodwill. The result of these adjustments was a total goodwill balance of $44.3 million. All of the acquired goodwill is deductible for tax purposes. (7) Due to the short-term nature of the accounts, the carrying value is assumed to represent the fair value for accounts payable and accrued expenses and other current liabilities as of the acquisition date. Since the date of the acquisition, GMM revenue of $11.9 million and net income of $1.8 million are included in the Company's consolidated results of operations. Asset Acquisitions On May 30, 2022, the Company entered into an asset purchase agreement with a private entity to purchase certain customer contracts within our PCS segment. Pursuant to the purchase agreement, the contracts were acquired for total consideration of $7.6 million in cash, subject to certain adjustments. The transaction was accounted for as an asset acquisition in accordance with ASC 805, Business Combinations . The fair value of the net consideration is as follows (in thousands, except useful lives): Type Useful Life Value Payor network Amortizable 6 years $ 7,297 Assembled workforce Amortizable 6 years 309 $ 7,606

Segments

Segments	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segments	Segments The Company’s reportable segments are identified based on a number of factors related to how its Chief Operating Decision Maker ("CODM") determines the allocation of resources and assesses the performance of the Company’s operations. The Company's CODM is its President and Chief Executive Officer. The Company's reportable segments are strategic business units that offer different healthcare-related services to the Company’s members. They are managed separately because each segment has its own distinct revenue generating activities and core business processes, which requires different technology and strategies in order to serve the varying needs of its members. The Company's CODM manages the Company under four reportable segments, the services of each are discussed in detail below. For each of the segments, the CODM uses operating income as the measure of profit or loss to assess segment performance and allocate resources (including personnel, financial, and capital resources) during periodic budgeting and forecasting processes and budget-to-actual variance reviews. The Company's operating income for the reportable segments includes an allocated portion of corporate expenses to the respective segments and includes revenues and all other costs directly attributable to the specific segment. The CODM uses total assets as the measure of assets attributable to each segment and reviews this measure in conjunction with segment performance to allocate capital to technology investments and projects in each segment in order to identify the best deployment of resources. • NEMT - The Company's NEMT segment is the largest manager of non-emergency medical transportation programs for state governments and managed care organizations, or MCOs, in the U.S. This segment also holds the results of the Company's captive insurance program; • PCS - The Company's PCS segment provides in home personal care services to State and Managed Medicaid, Medicare, and Private Pay patient populations in need of care monitoring and assistance performing activities of daily living; • Monitoring - The Company's Monitoring segment provides in-home monitoring solutions, including in-home clinical monitoring and quality improvement services that leverage personal emergency response systems, vitals monitoring devices, relationship-based care, and data-driven patient engagement solutions; and • Corporate and Other - The Company's Corporate and Other segment includes the costs associated with the Company's corporate operations as well as the results of an investment in innovation related to expanding our virtual care, digital engagement, monitoring capabilities, and member insights and analytics that the Company made at the end of the first quarter of 2023, which contributes to service revenue and service expense. The operating results of the Corporate and Other segment include activities related to executive, accounting, finance, internal audit, tax, legal, debt and the related interest expense, and certain strategic and corporate development functions for each segment, the results of this investment in innovation, as well as the results of the Company's Matrix investment. The following table sets forth certain financial information attributable to the Company’s business segments for the years ended December 31, 2024, 2023 and 2022 (in thousands): Year Ended December 31, 2024 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,957,275 $ 745,299 $ 77,739 $ 7,273 $ 2,787,586 Purchased services 1,504,970 — — — 1,504,970 Payroll and related costs 172,800 594,150 17,077 556 784,583 Other service expense 50,214 5,108 15,207 7,133 77,662 Service expense 1,727,984 599,258 32,284 7,689 2,367,215 General and administrative expense 124,475 92,738 20,439 60,739 298,391 Depreciation and amortization 30,170 51,252 26,788 1,255 109,465 Impairment of goodwill — — 105,302 — 105,302 Operating income (loss) 74,646 2,051 (107,074) (62,410) (92,787) Interest expense, net — — — 94,053 94,053 Loss on extinguishment of debt — — — 11,797 11,797 Income (loss) before income taxes and equity method investment 74,646 2,051 (107,074) (168,260) (198,637) Income tax benefit (provision) (14,482) 866 726 18,396 5,506 Equity in net loss of investee, net of tax (316) — — (7,831) (8,147) Net income (loss) $ 59,848 $ 2,917 $ (106,348) $ (157,695) $ (201,278) Balance Sheet Information Equity investment $ 1,441 $ — $ — $ 29,986 $ 31,427 Goodwill $ 135,186 $ 415,444 $ 129,592 $ 30 $ 680,252 Total assets $ 490,947 $ 720,620 $ 232,794 $ 209,971 $ 1,654,332 Year Ended December 31, 2023 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,951,447 $ 715,615 $ 77,941 $ 6,167 $ 2,751,170 Grant income (2) — 5,037 — — 5,037 Purchased services 1,456,796 — — — 1,456,796 Payroll and related costs 203,199 555,606 13,539 285 772,629 Other service expense 49,795 6,313 13,486 5,199 74,793 Service expense 1,709,790 561,919 27,025 5,484 2,304,218 General and administrative expense 115,355 86,767 22,971 79,471 304,564 Depreciation and amortization 27,409 51,402 24,536 924 104,271 Impairment of goodwill — 137,331 45,769 — 183,100 Operating income (loss) 98,893 (116,767) (42,360) (79,712) (139,946) Interest expense, net — — — 69,120 69,120 Income (loss) before income taxes and equity method investment 98,893 (116,767) (42,360) (148,832) (209,066) Income tax benefit (provision) (26,602) (5,403) (1,459) 37,783 4,319 Equity in net income (loss) of investee, net of tax 1,057 — — (770) 287 Net income (loss) $ 73,348 $ (122,170) $ (43,819) $ (111,819) $ (204,460) Balance Sheet Information Equity investment $ 1,653 $ — $ — $ 39,878 $ 41,531 Goodwill $ 135,186 $ 415,444 $ 234,894 $ 30 $ 785,554 Total assets $ 542,100 $ 763,366 $ 344,527 $ 117,282 $ 1,767,275 Year Ended December 31, 2022 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,768,442 $ 667,674 $ 68,277 $ — $ 2,504,393 Grant income (2) — 7,351 — — 7,351 Purchased services 1,267,006 — — — 1,267,006 Payroll and related costs 180,382 513,748 12,086 — 706,216 Other service expense 40,059 6,317 12,476 — 58,852 Service expense 1,487,447 520,065 24,562 — 2,032,074 General and administrative expense 146,935 91,365 23,156 60,715 322,171 Depreciation and amortization 28,709 51,025 19,854 827 100,415 Operating income (loss) 105,351 12,570 705 (61,542) 57,084 Interest expense, net — — — 61,961 61,961 Income (loss) before income taxes and equity method investment 105,351 12,570 705 (123,503) (4,877) Income tax benefit (provision) (26,855) (2,810) (208) 32,908 3,035 Equity in net income (loss) of investee, net of tax 71 — — (30,035) (29,964) Net income (loss) $ 78,567 $ 9,760 $ 497 $ (120,630) $ (31,806) Balance Sheet Information Equity investment $ 186 $ — $ — $ 41,117 $ 41,303 Goodwill $ 135,186 $ 552,775 $ 280,663 $ 30 $ 968,654 Total assets $ 496,605 $ 950,181 $ 396,944 $ 100,542 $ 1,944,272 (1) The service revenue generated for the Corporate and Other segment relates to service revenue from an investment in innovation related to expanding our virtual care, digital engagement, monitoring capabilities, and member insights and analytics that the Company made at the end of the first quarter of 2023. (2) Grant income for the PCS segment includes funding received on a periodic basis from the PRF in relation to relief under the CARES Act and funding received from the SLFRF under ARPA in relation to economic recovery to combat health and economic impacts of the COVID-19 pandemic. See Note 2, Significant Accounting Policies and Recent Accounting Pronouncements.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Under ASC 606, the Company recognizes revenue as it transfers promised services to its customers and generates all of its revenue from contracts with customers. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these services. The Company satisfies substantially all of its performance obligations over time and recognizes revenue over time instead of at points in time. Revenue Contract Structure NEMT Capitated Contracts (per-member-per-month) Under capitated contracts, payors pay a fixed amount per eligible member per month. Capitation rates are generally based on expected costs and volume of services. The Company assumes the responsibility of meeting the covered healthcare related transportation requirements based on per-member per-month fees for the number of eligible members in the payor’s program. Revenue is recognized based on the population served during the period. Certain capitated contracts have provisions for reconciliations, risk corridors or profit rebates. For contracts with reconciliation provisions, capitation payment is received as a prepayment during the month service is provided. These prepayments are reconciled based on actual cost and/or trip volume and may result in refunds to the payor, or additional payments due from the payor. Contracts with risk corridor or profit rebate provisions allow for profit within a certain corridor and once the Company reaches profit level thresholds or maximums, it discontinues recognizing revenue and instead records a liability within the accrued contract payable account. This liability may be reduced through future increases in trip volume or periodic settlements with the payor. While a profit rebate provision could only result in a liability from this profit threshold, a risk corridor provision could potentially result in a receivable if the Company does not reach certain profit minimums, which would be recorded in the reconciliation contract receivables account. NEMT Fee-for-service Contracts Fee-for-service ("FFS") revenue represents revenue earned under non-capitated contracts in which the Company bills and collects a specified amount for each service that it provides. FFS revenue is recognized in the period in which the services are rendered and is reduced by the estimated impact of contractual allowances. PCS Fee-for-service Contracts PCS FFS revenue is reported at the estimated net realizable amount from clients, patients and third-party payors for services rendered based on actual personal care hours provided. Payment for services received from third-party payors includes, but is not limited to, insurance companies, governmental agencies and other home health care providers who subcontract work to the Company. Certain contracts are subject to retroactive audit and possible adjustment by those payors based on the nature of the contract or costs incurred. The Company makes estimates of adjustments and considers these in the recognition of revenue in the period in which the related services are rendered. The difference between estimated settlement and actual settlement is reported in net service revenues as adjustments become known or as years are no longer subject to such audits, reviews, or investigations. Monitoring per-member-per-month Contracts Monitoring per-member-per-month ("PMPM") revenue consists of revenue from monitoring services provided to the customer. Under Monitoring contracts, payors pay per-enrolled-member-per-month based on enrolled membership. Consideration is generally fixed for each type of monitoring service and revenue is recognized ratably over the contract term based on the monthly fee paid by customers. Disaggregation of Revenue by Contract Type The following table summarizes disaggregated revenue from contracts with customers by contract type for the years ended December 31, 2024, 2023 and 2022 (in thousands): Year Ended December 31, 2024 2023 2022 NEMT capitated contracts $ 1,583,347 $ 1,663,987 $ 1,553,407 NEMT FFS contracts 373,928 287,460 215,035 Total NEMT service revenue, net 1,957,275 1,951,447 1,768,442 PCS FFS contracts 745,299 715,615 667,674 Monitoring PMPM contracts 77,739 77,941 68,277 Other service revenue 7,273 6,167 — Total service revenue, net $ 2,787,586 $ 2,751,170 $ 2,504,393 Payor Information Service revenue, net, is derived from state and managed Medicaid contracts, managed Medicare contracts, as well as a small amount from private pay and other contracts. Of the NEMT segment’s revenue, 10.9%, 11.2% and 10.9% were derived from one payor for the years ended December 31, 2024, 2023 and 2022, respectively. Of the PCS segment's revenue, 12.5%, 11.3% and 12.0% were derived from one payor for the years ended December 31, 2024, 2023 and 2022, respectively. Of the Monitoring segment's revenue, 18.9%, 18.5%, and 19.9% were derived from one payor for the years ended December 31, 2024, 2023 and 2022, respectively. Revenue Adjustments During the years ended December 31, 2024, 2023, and 2022 the Company recognized an increase of $1.7 million, a reduction of $2.8 million, and a reduction of $0.9 million in service revenue, respectively, from contractual adjustments relating to performance obligations satisfied in previous periods to which the payor agreed. Related Balance Sheet Accounts The following table provides information about accounts receivable, net as of December 31, 2024 and 2023 (in thousands): December 31, 2024 December 31, 2023 Accounts receivable $ 223,756 $ 223,506 Allowance for credit losses (1,439) (969) Accounts receivable, net $ 222,317 $ 222,537 The following table provides information about other revenue related accounts included on the accompanying consolidated balance sheets (in thousands): December 31, 2024 December 31, 2023 Accrued contract payables (1) $ 22,639 $ 117,488 Contract receivables (2) $ 117,795 $ 143,960 Deferred revenue, current $ 300 $ 2,629 (1) Accrued contract payables primarily represent overpayments and liability reserves on certain risk corridor, profit rebate and reconciliation contracts. See the contract payables and receivables activity below. (2) Contract receivables primarily represent underpayments and receivables on certain risk corridor, profit rebate, and reconciliation contracts. See the contract payables and receivables activity below. The following tables provide the summary activity of total contract payables and receivables as reported within the consolidated balance sheets (in thousands): December 31, 2023 Additional Amounts Recorded Amounts Paid or Settled December 31, 2024 Reconciliation contract payables $ 12,294 $ 7,167 $ (16,042) $ 3,419 Profit rebate/corridor contract payables 94,775 (13,257) (68,923) 12,595 Overpayments and other cash items 10,419 45,131 (48,925) 6,625 Total contract payables $ 117,488 $ 39,041 $ (133,890) $ 22,639 Reconciliation contract receivables $ 57,002 $ 99,203 $ (122,456) $ 33,749 Corridor contract receivables 86,958 86,707 (89,619) 84,046 Total contract receivables $ 143,960 $ 185,910 $ (212,075) $ 117,795 December 31, 2022 Additional Amounts Recorded Amounts Paid or Settled December 31, 2023 Reconciliation contract payables $ 25,853 $ 17,723 $ (31,282) $ 12,294 Profit rebate/corridor contract payables 155,161 61,623 (122,009) 94,775 Overpayments and other cash items 13,273 23,322 (26,176) 10,419 Total contract payables $ 194,287 $ 102,668 $ (179,467) $ 117,488 Reconciliation contract receivables $ 48,153 $ 59,184 $ (50,335) $ 57,002 Corridor contract receivables 23,405 64,009 (456) 86,958 Total contract receivables $ 71,558 $ 123,193 $ (50,791) $ 143,960

Equity Investment

Equity Investment	12 Months Ended
	Dec. 31, 2024
Equity Method Investment, Summarized Financial Information [Abstract]
Equity Investment	Equity Investment As of December 31, 2024 and 2023, the Company owned a 43.6% non-controlling interest in Matrix. Pursuant to a Shareholder’s Agreement, affiliates of Frazier Healthcare Partners hold rights necessary to control the fundamental operations of Matrix. The Company accounts for this investment in Matrix under the equity method of accounting and the Company’s share of Matrix’s income or losses are recorded as “Equity in net (income) loss of investee, net of tax” in the accompanying consolidated statements of operations. During the years ended December 31, 2024 and 2023, Matrix recorded no asset impairment charges. During the year ended December 31, 2022, Matrix recorded an asset impairment charge of $82.2 million. The Company's gross share of Matrix's operations for the years ended December 31, 2024, 2023 and 2022 was a loss of $9.4 million, $1.1 million and $41.0 million, respectively, which is presented net of tax on the consolidated statements of operations for a loss of $7.8 million, $0.8 million and $30.0 million, respectively. The carrying amount of the assets included in the Company’s consolidated balance sheets and the maximum loss exposure related to the Company’s interest in Matrix as of December 31, 2024 and 2023 totaled $30.0 million and $39.9 million, respectively. Summary financial information for Matrix on a standalone basis is as follows (in thousands): December 31, 2024 December 31, 2023 Current assets $ 52,583 $ 112,090 Long-term assets $ 344,977 $ 351,143 Current liabilities $ 38,356 $ 41,584 Long-term liabilities $ 272,354 $ 314,316 Year ended December 31, 2024 Year ended December 31, 2023 Year ended December 31, 2022 Revenue $ 301,084 $ 325,192 $ 300,306 Operating income (loss) $ 9,730 $ 30,418 $ (83,110) Net loss $ (18,963) $ (1,689) $ (98,187)

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of the following (in thousands): December 31, 2024 December 31, 2023 Prepaid insurance $ 6,272 $ 7,231 Deferred ERP implementation costs 3,528 2,875 Deferred financing costs on credit facility 2,858 2,638 Other prepaid expenses 12,761 14,284 Total prepaid expenses and other current assets $ 25,419 $ 27,028

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consisted of the following (in thousands, except useful lives): Estimated December 31, Life (years) 2024 2023 Software 3 — 10 $ 66,252 $ 57,658 Computer, office and telecommunications equipment 2 — 7 38,930 39,201 Monitoring equipment 3 39,381 33,547 Leasehold improvements Shorter of useful life or lease term 16,834 12,848 Construction and development in progress N/A 6,213 7,136 Automobiles 5 4,899 5,334 Furniture and fixtures 3 — 10 3,643 4,486 Buildings 30 — 40 388 1,886 Land N/A 12 292 Total property and equipment 176,552 162,388 Less accumulated depreciation (94,143) (76,759) Total property and equipment, net $ 82,409 $ 85,629

Goodwill and Intangibles

Goodwill and Intangibles	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangibles	Goodwill and Intangible Assets The Company tests goodwill for impairment for its reporting units annually as of July 1 or more frequently when events or changes in circumstances indicate that impairment may have occurred. The Company reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable. Goodwill During the second quarter of 2024, the Company determined that based on its qualitative assessment for each reporting unit, factors existed which required the Company to test its goodwill and indefinite-lived intangible assets for impairment. These factors included changes in key assumptions from the prior year annual goodwill assessment as a result of lower than anticipated operating results during the first half of 2024 as compared to forecast which resulted in a decrease in the fair value of the Company's Monitoring reporting unit such that the fair value was less than its carrying value. As a result, the Company performed a quantitative assessment using a blend of both the income approach and the market approach to estimate the fair value of the reporting units and determined that the goodwill at its Monitoring reporting unit was impaired. As such, during the second quarter of 2024, the Company recorded a non-cash goodwill impairment charge of $105.3 million in the Monitoring reporting unit resulting in $129.6 million of remaining goodwill as of December 31, 2024. This impairment is recorded in “Impairment of goodwill” on the Company’s consolidated statement of operations. During the second quarter of 2023, the Company determined that based on its qualitative assessment for each reporting unit, factors existed which required the Company to test its goodwill and indefinite-lived intangible assets for impairment. These factors included a decline in the market price of the Company's common stock, industry specific regulatory pressures such as Medicaid redetermination and the Centers for Medicare and Medicaid Services ("CMS") proposed ruling on Ensuring Access to Medicaid Services , and general economic and market volatility. As a result, the Company performed a quantitative assessment using a blend of both the income approach and the market approach to estimate the fair value of the reporting units and determined that the goodwill at its PCS and Monitoring reporting units was impaired. As such, during the second quarter of 2023, the Company recorded a non-cash goodwill impairment charge of $183.1 million, of which $137.3 million was recorded in the PCS reporting unit and $45.8 million was recorded in the Monitoring reporting unit resulting in $415.4 million and $234.9 million of remaining goodwill, respectively, as of December 31, 2023. After recording the impairment charges discussed above during the years ending December 31, 2024 and 2023, respectively, the PCS and Monitoring reporting units have $545.0 million of goodwill remaining as of December 31, 2024. In the future, if, among other factors, (i) the Company's equity values were to decline significantly, (ii) the Company experienced additional adverse impacts associated with macroeconomic factors, including increases in our estimated weighted average cost of capital, or (iii) the adverse impacts stemming from competition, economic, regulatory or other factors were to cause the Company's results of operations or cash flows to be worse than currently anticipated, the Company could conclude in future periods that additional impairment charges of certain reporting units are required in order to reduce the carrying values of goodwill. Any such impairment charges could be significant. Changes in the carrying amount of goodwill by reportable segment are presented in the following table (in thousands): NEMT PCS Monitoring Corporate and Other Total Goodwill balances as of December 31, 2022, before cumulative loss Goodwill $ 231,186 $ 552,775 $ 280,663 $ 30 $ 1,064,654 Accumulated impairment losses (96,000) — — — (96,000) Goodwill balances as of December 31, 2022, after cumulative loss $ 135,186 $ 552,775 $ 280,663 $ 30 $ 968,654 Balances as of December 31, 2023 Impairment of goodwill — (137,331) (45,769) — (183,100) $ 135,186 $ 415,444 $ 234,894 $ 30 $ 785,554 Balances as of December 31, 2024 Impairment of goodwill — — (105,302) — (105,302) $ 135,186 $ 415,444 $ 129,592 $ 30 $ 680,252 The total amount of goodwill that was deductible for income tax purposes related to acquisitions as of December 31, 2024 and 2023 was $219.8 million and $317.3 million, respectively. Impairment The Company recorded goodwill impairment charges of $105.3 million for the year ended December 31, 2024 and $183.1 million for the year ended December 31, 2023, and did not record any goodwill or intangible asset impairment charges for the year ended December 31, 2022. The accumulated impairment losses on goodwill totaled $384.4 million and $279.1 million as of December 31, 2024 and 2023, respectively. Intangible Assets Intangible assets are comprised of acquired payor networks, trademarks and trade names, developed technology, non-compete agreements, licenses, and an assembled workforce. Finite-lived intangible assets are amortized using the straight-line method over the estimated economic lives of the assets. These finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Indefinite-lived intangible assets are not amortized, but are tested for impairment annually and more frequently if events occur or circumstances change that indicate an asset may be impaired. Based on the continued value of the definite-lived and indefinite-lived intangible assets acquired, the Company did not identify any circumstances during the years ended December 31, 2024 or 2023 that would require an impairment test for our intangible assets. As of December 31, 2024 and 2023, intangible assets consisted of the following (in thousands, except estimated useful lives): December 31, 2024 2023 Estimated Gross Accumulated Gross Accumulated Payor networks 3 - 10 $ 540,309 $ (271,289) $ 540,298 $ (209,560) Trademarks and trade names 2 - 10 48,541 (48,541) 48,541 (34,978) Developed technology 3 - 10 29,301 (17,593) 29,389 (14,732) Non-compete agreement 2 - 5 1,610 (1,050) 1,610 (730) New York LHCSA Permit Indefinite 770 — 770 — Assembled workforce 6 - 10 444 (182) 444 (117) Total $ 620,975 $ (338,655) $ 621,052 $ (260,117) The weighted-average amortization period at December 31, 2024 for intangibles was 7.7 years. No significant residual value is estimated for these intangible assets. Amortization expense was $78.5 million, $79.2 million and $80.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. The total amortization expense is estimated to be as follows for the next five years as of December 31, 2024 (in thousands): Year Amount 2025 $ 64,352 2026 55,774 2027 51,226 2028 44,439 2029 23,036 Total $ 238,827

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): December 31, 2024 2023 Accrued compensation and related liabilities $ 35,018 $ 48,033 Insurance reserves 33,350 22,014 Accrued interest 21,187 10,498 Accrued legal fees 15,794 10,148 Accrued operating expenses 10,602 15,884 Accrued government grants (1) 6,284 9,156 Union pension obligation 886 1,573 Deferred revenue 300 2,629 Other 15,755 7,966 Total accrued expenses and other current liabilities $ 139,176 $ 127,901 (1) Accrued government grants include payments received from government entities in relation to the PRF and SLFRF to offset lost revenue or increased expenditures for which the related expenditure has not yet been incurred and thus the related payments are deferred as of December 31, 2024 and 2023.

Debt

Debt	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Debt	Debt The Company's long-term debt and short-term debt as of December 31, 2024 and 2023 consisted of the following (in thousands): December 31, Description Date of Issuance 2024 2023 Senior Unsecured Notes $500.0 million 5.875% due November 15, 2025 11/4/2020 $ — $ 494,011 $500.0 million 5.000% due October 1, 2029 (effective interest rate 5.401%) 8/24/2021 491,311 489,746 Term Loan Facility $525.0 million SOFR + 4.750% due July 1, 2031 (1) 7/1/2024 495,125 — Total long-term debt $ 986,436 $ 983,757 Revolving Credit Facility 2/3/2022 $ 269,000 $ 113,800 Current Portion of Term Loan Facility (2) 7/1/2024 5,250 — Total short-term debt $ 274,250 $ 113,800 (1) The $525.0 million Term Loan Facility bears interest at (i) a SOFR-based benchmark plus 4.75% or (ii) a prime rate (or other alternate base rate) benchmark plus 3.75%% in the case of ABR Loans (as such terms are defined in the amended Credit Agreement) and matures on the earlier of (a) July 1, 2031 and (b) July 2, 2029 if any of the Company's 2029 Notes (as defined below) remain outstanding on that date. (2) The Term Loan Facility requires principal payments of $1.3 million on a quarterly basis and accordingly, a portion of the Term Loan Facility in the amount of $5.3 million is classified as a current liability within the "Short-term debt" line item on the consolidated balance sheets as of December 31, 2024. Senior Unsecured Notes The Senior Notes due 2025 (the "2025 Notes") and the Senior Notes due 2029 (the "2029 Notes") were issued pursuant to two indentures, dated November 4, 2020 and August 24, 2021, respectively, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2025 Notes were issued in relation to the Company’s acquisition of Simplura and the 2029 Notes were issued in relation to the Company’s acquisition of VRI. The Company pays interest on the Notes semi-annually in arrears. Principal payments are not required until the maturity date when 100.0% of the outstanding principal will be required to be repaid. Debt issuance costs of $14.5 million in relation to the issuance of the 2025 Notes were incurred and these costs were deferred and are amortized to interest cost over the term of the 2025 Notes. In connection with the redemption of the 2025 Notes on July 1, 2024 (discussed below), the remaining unamortized debt issuance costs were recognized as a loss on debt extinguishment that was recorded during the third quarter of 2024. Debt issuance costs of $13.5 million were incurred in relation to the issuance of the 2029 Notes and these costs were deferred and are amortized to interest cost over the term of the 2029 Notes. As of December 31, 2024, the 2029 Notes had $8.7 million of unamortized deferred issuance costs that were netted against the long-term debt balance on the consolidated balance sheets. The 2025 Notes were redeemed in full on July 1, 2024 prior to contractual maturity, at a redemption premium of 1.469% on the aggregate original principal amount of the 2025 Notes for a total redemption of $507.3 million, plus the payment of approximately $3.8 million in accrued and unpaid interest on the 2025 Notes. As a result of the early redemption of the 2025 Notes, the Company recorded a loss on debt extinguishment of $11.8 million on the consolidated statements of operations. This loss consisted of the redemption premium of 1.469% on the aggregate original principal amount of the 2025 Notes for $7.3 million plus the recognition of the unamortized deferred issuance costs on the 2025 Notes of $4.5 million. The 2025 Notes were redeemed in connection with the funding of the Term Loan Facility discussed below. As of December 31, 2024, the 2025 Notes were fully redeemed and thus had no associated fair value as of that date and as of December 31, 2023, had a fair value of $499.2 million. The fair value of the 2029 Notes as of December 31, 2024 and 2023 was $294.2 million and $410.0 million, respectively. The fair value of the Notes was determined based on quoted prices in active markets, and therefore designated as Level 1 within the fair value hierarchy. The 2029 Notes are senior unsecured obligations and rank senior in right of payment to all of the Company's future subordinated indebtedness, rank equally in right of payment with all of the Company's existing and future senior indebtedness, are effectively subordinated to any of the Company's existing and future secured indebtedness, including indebtedness under the Credit Agreement, which governs the Revolving Credit Facility and Term Loan Facility discussed below, to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all of the existing and future liabilities (including trade payables) of each of the Company’s non-guarantor subsidiaries. The indenture for the 2029 Notes contains covenants that, among other things, restrict the Company’s ability and the ability of its restricted subsidiaries to, among other things: incur additional indebtedness or issue disqualified capital stock; make certain investments; create or incur certain liens; enter into certain transactions with affiliates; merge, consolidate, amalgamate or transfer substantially all of its assets; agree to dividend or other payment restrictions affecting its restricted subsidiaries; and transfer or sell assets, including capital stock of its restricted subsidiaries. The indenture covering the 2029 Notes also contains a cross-default provision in the event any of the Company’s other indebtedness having a principal amount that aggregates $50.0 million or more is accelerated prior to its express maturity. These covenants, however, are subject to a number of important exceptions and qualifications, and certain covenants may be suspended in the event the 2029 Notes are assigned an investment grade rating from two of three rating agencies. The indentures for the 2029 Notes provide that the notes may become subject to redemption under certain circumstances. Pursuant to the Fifth Amendment to the Credit Agreement discussed in detail in the Revolving Credit Facility section below, the Company was granted covenant relief in the form of a covenant holiday for the fourth quarter of 2024 through and including the second fiscal quarter of 2025. On or after October 1, 2024, the Company may redeem all or a part of the 2029 Notes upon not less than ten plus accrued and unpaid interest, if any, on the 2029 Notes redeemed, to, but excluding, the applicable redemption date, if redeemed during the 12-month period beginning on October 1 of the years indicated below: Year Percentage 2025 101.250% 2026 and thereafter 100.000% Pursuant to the 2029 Notes, the Company will pay interest on the notes at 5.0% per annum until maturity. Interest is payable semi-annually in arrears on April 1 and October 1 of each year. Principal payments are not required until the maturity date on October 1, 2029 when 100.0% of the outstanding principal will be required to be repaid. Credit Agreement Revolving Credit Facility On February 3, 2022, the Company entered into the Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, swing line lender and an issuing bank, Wells Fargo Bank, National Association, as an issuing bank, Truist Bank and Wells Fargo Bank, National Association, as co-syndication agents, Deutsche Bank AG New York Branch, Bank of America, N.A., Regions Bank, Bank of Montreal and Capital One, National Association, as co-documentation agents, and JPMorgan Chase Bank, N.A., Truist Securities, Inc. and Wells Fargo Securities, LLC, as joint bookrunners and joint lead arrangers, and the other lenders party thereto. The Credit Agreement provides the Company with the Revolving Credit Facility in an aggregate principal amount of $325.0 million. The Revolving Credit Facility includes sublimits for swingline loans, letters of credit and alternative currency loans in amounts of up to $25.0 million, $60.0 million and $75.0 million, respectively. The Revolving Credit Facility matures on February 3, 2027 and the proceeds may be used (i) to finance working capital needs of the Company and its subsidiaries and (ii) for general corporate purposes of the Company and its subsidiaries (including to finance capital expenditures, permitted acquisitions and investments). On June 26, 2023, the Company entered into Amendment No. 1 (the "First Amendment") to the Credit Agreement which amended the maximum permitted Total Net Leverage Ratio under the Credit Agreement as follows: for the fiscal quarters ending June 30, 2023 through September 30, 2023, 5.25:1.00; for the fiscal quarters ending December 31, 2023 through March 31, 2024, 5.00:1.00; for the fiscal quarter ending June 30, 2024, 4.75:1.00; and for the fiscal quarters ending September 30, 2024 and for the fiscal quarters ending thereafter, 4.50:1.00. On February 22, 2024, the Company entered into Amendment No. 2 (the "Second Amendment") to the Credit Agreement, which amended the maximum permitted Total Net Leverage Ratio under the Credit Agreement as follows: for the fiscal quarters ending March 31, 2024 through June 30, 2024, 5.50:1.00; for the fiscal quarters ending September 30, 2024 through December 31, 2024, 5.25:1.00; for the fiscal quarters ending March 31, 2025 through September 30, 2025, 5.00:1.00, and for the fiscal quarters ending December 31, 2025 through March 31, 2026, 4.75:1.00. The Second Amendment also restricts the Company from permitting its Liquidity (as defined in the Second Amendment and which is determined generally to be, as of any date of determination, the sum of the Company's available borrowing capacity under the Revolving Credit Facility plus the amount of its unencumbered cash), to be less than $100.0 million as of the last day of each fiscal quarter. On July 1, 2024, the Company entered into Amendment No. 3 (the "Third Amendment") to the Credit Agreement, which, among other things, extended with respect to the lenders identified in the Third Amendment the maturity date covering $255.0 million in the aggregate principal amount of the commitments under the Revolving Credit Facility to February 3, 2028. The existing financial covenants under the amended Credit Agreement were retained for the benefit solely of the Revolving Credit Facility lenders, and the minimum liquidity level required by the Liquidity Covenant was decreased from $100.0 million to $75.0 million. Certain other financial covenants and restrictions were also modified under the amended Credit Agreement, as previously disclosed. The fees associated with the Third Amendment of $0.3 million will be amortized over the life of the Revolving Credit Facility. On September 30, 2024, the Company entered into Amendment No. 4 (the "Fourth Amendment") to its Credit Agreement, which increased the maximum permitted Total Net Leverage Ratio under the amended Credit Agreement for the fiscal quarter ended September 30, 2024 (the "Relief Period") to 6.50:1.00 from 5.25:1.00. In addition, the Fourth Amendment reduced the minimum interest coverage ratio for the quarter ended September 30, 2024 to 2.00:1.00 and increased the applicable margin on the Revolving Credit Facility by 0.25% until the Company delivers the required financial statements and compliance certificate for the fiscal year ending December 31, 2024. On January 9, 2025, the Company entered into Amendment No. 5 (the "Fifth Amendment") to its Credit Agreement, which, among other things, (i) amended the interest rate on the existing Revolving Credit Facility commitments under the Credit Agreement to a SOFR-based benchmark plus 4.25%, with a 1.00% SOFR Floor, (ii) amended the 2.0% default rate under the Credit Agreement so that it applies on all obligations upon the election of the administrative agent at the direction of the Required Lenders if an event of default has occurred and continuing and automatically if a specified event of default has occurred and is continuing, (iii) amended the Term Loan Facility maturity date to spring to July 2, 2029 if the second lien senior secured PIK toggle notes remain outstanding as of such date, (iv) included enhanced reporting requirements, and (v) eliminated or reduced certain baskets, which included the elimination of reinvestment rights with respect to certain asset sales and reduction of the de minimis exception for certain asset sale prepayments to $5,000,000. Consenting lenders also agreed to provide financial covenant relief in the form of (i) a covenant holiday with respect to the maximum net leverage ratio and interest coverage ratio from the fourth fiscal quarter of 2024 through and including the second fiscal quarter of 2025, (ii) resetting the maximum total net leverage ratio covenant to 6.75:1.00 for the third fiscal quarter of 2025 and the fourth fiscal quarter of 2025 and (iii) resetting the minimum interest coverage ratio to 1.65:1.00 for the third fiscal quarter of 2025 and the fourth fiscal quarter of 2025. The Company will also be required to maintain minimum liquidity of $25.0 million pursuant to the terms of the amended minimum liquidity covenant in the Credit Agreement, which will be tested each week through the week ending April 11, 2025, each month through the month ending June 30, 2025 and, thereafter, each fiscal quarter. In addition, the Company will be subject to a cash variance compliance test with respect to aggregate disbursements and aggregate receipts, subject to customary cures. As of December 31, 2024, the Company had $269.0 million of short-term borrowings outstanding on the Revolving Credit Facility and had $55.6 million of outstanding letters of credit under the Revolving Credit Facility. The interest rate for short-term borrowings outstanding as of December 31, 2024 was 8.8% per annum. As of December 31, 2023, the Company had $113.8 million of short-term borrowings outstanding on the Revolving Credit Facility and had $40.4 million of outstanding letters of credit under this Facility. Under the amended Credit Agreement, the Company has an option to request an increase in the amount of the Revolving Credit Facility so long as, after giving effect to the incremental facility, the pro forma secured net leverage ratio does not exceed 2.70:1.00. The Company may prepay the Revolving Credit Facility in whole or in part, at any time without premium or penalty, subject to reimbursement of the lenders’ breakage and redeployment costs in connection with prepayments. The unutilized portion of the commitments under the Revolving Credit Facility may be irrevocably reduced or terminated by the Company at any time without penalty. Interest on the outstanding principal amount of the loans accrues at a per annum rate equal to the Alternate Base Rate, the Adjusted Term SOFR Rate, the Adjusted Daily Simple SOFR Rate, the Adjusted EURIBOR Rate or the Adjusted Daily Simple SONIA Rate, as applicable and each as defined in the Credit Agreement, in each case, plus an applicable margin. The applicable margin ranges from 1.75% to 3.50% in the case of Term Benchmark loans or RFR loans, and 0.75% to 2.50% in the case of the Alternate Base Rate loans, in each case, based on the Company’s total net leverage ratio as defined in the Credit Agreement. Interest on the loans is payable quarterly in arrears in the case of Alternate Base Rate loans, on the last day of the relevant interest period in the case of Term Benchmark loans, and monthly in arrears in the case of RFR loans. In addition, the Company is obligated to pay a quarterly commitment fee based on a percentage of the unused portion of the revolving credit facility and quarterly letter of credit fees based on a percentage of the maximum amount available to be drawn under each outstanding letter of credit. The commitment fee and letter of credit fee range from 0.30% to 0.50% and 1.75% to 3.50%, respectively, in each case, based on the Company’s total net leverage ratio. As of December 31, 2024 and 2023, the Company paid quarterly commitment fees of $2.3 million and $2.6 million, respectively. The amended Credit Agreement contains customary representations and warranties, affirmative and negative covenants and events of default. The negative covenants include restrictions on the Company’s ability to, among other things, incur additional indebtedness, create liens, make investments, give guarantees, pay dividends, sell assets and merge and consolidate. The Company's borrowing capacity under the Revolving Credit Facility is currently limited by, among other covenants, compliance with the Total Net Leverage Ratio covenant and the Liquidity Covenant for each fiscal period. The Company’s obligations under the Revolving Credit Facility are guaranteed by all of the Company’s present and future material domestic subsidiaries, excluding certain material domestic subsidiaries that are excluded from being guarantors pursuant to the terms of the Credit Agreement. The Company’s obligations under, and each guarantor’s obligations under its guaranty of, the Revolving Credit Facility are secured by a first priority lien on substantially all of the Company’s or such guarantor’s respective assets. If an event of default occurs, the required lenders may cause the administrative agent to declare all unpaid principal and any accrued and unpaid interest and all fees and expenses under the Revolving Credit Facility to be immediately due and payable. All amounts outstanding under the Revolving Credit Facility will automatically become due and payable upon the commencement of any bankruptcy, insolvency or similar proceedings. The Credit Agreement also contains a cross default to any of the Company’s indebtedness having a principal amount in excess of $40.0 million. Pursuant to the Fifth Amendment to the Credit Agreement, the Company was granted covenant relief in the form of a covenant holiday for the fourth quarter of 2024 through and including the second fiscal quarter of 2025. Term Loan Facility On July 1, 2024, the Company, pursuant to the Third Amendment to the Credit Agreement, established a new term loan facility (the "Term Loan Facility") in the aggregate principal amount of $525.0 million with the Term Loan Facility lenders named therein. The proceeds of the Term Loan Facility were used to (i) redeem the Company's 2025 Notes, (ii) repay a portion of the Revolving Credit Facility outstanding immediately prior to the effective date of the Third Amendment, and (iii) pay fees and expenses associated with such transactions. The Company paid approximately $24.4 million of deferred issuance costs with respect to the Term Loan Facility. As of December 31, 2024, the Term Loan Facility had $22.0 million of unamortized deferred issuance costs that were netted against the long-term balance on the consolidated balance sheets. The fair value of the Term Loan Facility as of December 31, 2024 was $500.2 million, which was determined based on lender quotes for the Company's debt, and therefore designated as Level 2 within the fair value hierarchy. On January 9, 2025, pursuant to the Fifth Amendment to the Credit Agreement, the Company made certain amendments to the Credit Agreement which are discussed in the Revolving Credit Facility section above. The Term Loan Facility matures on the earlier of (a) July 1, 2031 and (b) July 2, 2029 if any of the Company's 2029 Notes remain outstanding on that date. Principal payments on the Term Loan Facility are required on a quarterly basis, commencing with the quarter ending September 30, 2024, in the amount equal to 0.25% of the aggregate principal amount of the Term Loan Facility outstanding on the date of issuance. All unpaid amounts of the Term Loan Facility shall be paid in full on the maturity date. The Term Loan Facility requires annual prepayments of a percentage of Excess Cash Flow (as defined in the amended Credit Agreement); commencing with the year ending December 31, 2025 as follows: (i) 75.0% if the Total Net Leverage Ratio as of the last day of such period was greater than 4.40:1.00, (ii) 50.0% if the Total Net Leverage Ratio as of the last day of such period was greater than 3.90:1:00, but less than or equal to 4.40:1.00, (iii) 25.0% if the Total Net Leverage Ratio as of the last day of such period was greater than 3.40:1.00, but less than or equal to 3.90:1.00, and (iv) zero percent if the Total Net Leverage Ratio as of the last day of such period was less than or equal to 3.40:1.00. The Term Loan Facility also requires mandatory prepayments in the event of certain asset dispositions or casualty events. In addition, the Term Loan Facility is subject to a prepayment premium for the first six months after entering into the Third Amendment in the event of any repricing transaction. Interest on the Term Loan Facility is generally payable quarterly, in arrears, on the outstanding principal amount of the Term Loan Facility at the following rates for the interest period in effect for such borrowing: (i) a SOFR-based benchmark plus 4.75% or (ii) a prime rate (or other alternate base rate) benchmark plus 3.75% in the case of ABR Loans (as such terms are defined in the amended Credit Agreement). The Term Loan Facility is subject to customary representations and warranties, affirmative and negative covenants, and events of default, as defined in the amended Credit Agreement. As of December 31, 2024, the weighted average interest rate on the Term Loan Facility was 9.08%. The amended Credit Agreement, as it relates to the Term Loan Facility, also contains a cross-default to any of the Company’s indebtedness having a principal amount in excess of $40.0 million. Pursuant to the Fifth Amendment to the Credit Agreement, the Company was granted covenant relief in the form of a covenant holiday for the fourth quarter of 2024 through and including the second fiscal quarter of 2025. Incremental Term Loan On January 9, 2025, the Company, pursuant to the Fifth Amendment to the Credit Agreement, established an incremental term loan facility in an aggregate principal amount of $75.0 million (the “Incremental Term Loan”). The Incremental Term Loan was priced at a SOFR-based benchmark plus 7.50%, with 1.00% SOFR Floor (no CSA) with a maturity of January 10, 2026 (the “Maturity Date”) and original issue discount of 2 points. The Company has the option to prepay the Incremental Term Loan, in whole or in part, at any time prior to the Maturity Date, subject to a prepayment fee equal to the present value of all scheduled interest payments on the fully committed amount that would accrue through the Maturity Date calculated based on a discount rate equal to the treasury rate plus 50 basis points. The proceeds of the Incremental Term Loan are required to be deposited in a collateral account subject to a blocked account control agreement in favor of the administrative agent and may be disbursed subject to delivery of a disbursement request, no default or event of default, the representations and warranties in Article II of the Credit Agreement being true and correct in all material respects and receipt by the administrative agent and lenders of reimbursement for invoiced expenses. The Incremental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its subsidiaries. Annual maturities on all debt outstanding at December 31, 2024, are as follows: Maturities 2025 $ 274,250 2026 — 2027 — 2028 — 2029 500,000 Thereafter 517,125 Total maturities 1,291,375 Unamortized deferred issuance costs 30,689 Total debt outstanding, short-term and long-term 1,260,686 Less short-term debt 274,250 Total long-term debt outstanding $ 986,436

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity At December 31, 2024 and 2023 there were 19,882,026 and 19,775,041 shares of the Company’s Common Stock issued, respectively, including 5,558,898 and 5,571,004 treasury shares at December 31, 2024 and 2023, respectively. Subject to the rights specifically granted to holders of any then outstanding shares of the Company’s Preferred Stock, the Company’s common stockholders are entitled to vote together as a class on all matters submitted to a vote of the Company’s common stockholders, and are entitled to any dividends that may be declared by the Board. The Company’s common stockholders do not have cumulative voting rights. Upon the Company’s dissolution, liquidation or winding up, holders of the Company’s Common Stock are entitled to share ratably in the Company’s net assets after payment or provision for all liabilities and any preferential liquidation rights of the Company’s Preferred Stock then outstanding. The Company’s common stockholders do not have preemptive rights to purchase shares of the Company’s stock. The issued and outstanding shares of the Company’s Common Stock are not subject to any redemption provisions and are not convertible into any other shares of the Company’s capital stock. The rights, preferences and privileges of holders of the Company’s Common Stock will be subject to those of the holders of any shares of the Company’s Preferred Stock the Company may issue in the future. As of December 31, 2024, 619,204 shares of the Company’s common stock were reserved for future issuances related to the exercise of stock options that were outstanding and restricted stock units and awards that were unvested as of December 31, 2024. Equity Award Withholding During the years ended December 31, 2024, 2023 and 2022, the Company withheld 22,827, 10,565 and 7,486 shares, respectively, from employees to cover the settlement of income tax and related benefit withholding obligations arising from vesting of restricted stock awards and units.

Stock-Based Compensation and Si

Stock-Based Compensation and Similar Arrangements	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Stock-Based Compensation and Similar Arrangements	Stock-Based Compensation and Similar Arrangements The Company provides stock-based compensation to employees, non-employee directors, consultants and advisors under the Company’s 2006 Long-Term Incentive Plan (“2006 Plan”). The 2006 Plan allows the flexibility to grant or award stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units including restricted stock units and performance awards to eligible persons. The following table summarizes the activity under the 2006 Plan as of December 31, 2024: Number of shares Number of shares Number of shares of the Company’s Common Stock subject to issuance future grants Stock Options Stock Grants 2006 Plan 5,400,000 601,519 46,579 572,625 Stock-based compensation for share settled awards is recorded in the "General and administrative expense" line item on the consolidated statement of operations for a total expense of $6.8 million, $6.5 million, and $6.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. These amounts exclude tax benefits of $1.6 million, $1.8 million and $1.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. Stock Options The fair value of each stock option awarded to employees is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following assumptions for the years ended December 31, 2023 and 2022. No stock options were awarded to employees during the year ended December 31, 2024. Year Ended December 31, 2023 2022 Expected dividend yield 0.0% 0.0% Expected stock price volatility 49.6% - 49.6% 39.6% - 46.5% Risk-free interest rate 3.7% - 3.7% 1.6% - 4.4% Expected life of options (years) 3.5 - 3.5 3.5 - 4.5 The risk-free interest rate was based on the U.S. Treasury security rate in effect as of the date of grant which corresponds to the expected life of the award. The expected stock price volatility and expected lives of the stock options were based on the Company’s historical data. Stock options granted under the 2006 Plan vest ratably in equal annual installments over 3 to 4 years and expire after 5 to 7 years. During the year ended December 31, 2024, no shares of the Company's Common Stock were issued in connection with the exercise of employee stock options under the Company’s 2006 Plan. The following table summarizes the stock option activity for the year ended December 31, 2024: Year ended December 31, 2024 Number Weighted- Weighted- Aggregate Balance at beginning of year, January 1 82,586 $ 104.89 Granted — — Exercised — — Forfeited/Canceled (13,623) 74.81 Expired (22,384) 100.05 Outstanding at end of year, December 31 46,579 $ 116.01 1.51 $ — Vested or expected to vest at end of year, December 31 46,579 $ 116.01 1.51 $ — Exercisable at end of year, December 31 39,656 $ 118.08 1.38 $ — As of December 31, 2024, there was approximately $0.4 million of unrecognized compensation cost related to share settled stock options that is expected to be recognized over a weighted-average remaining contractual term of 1.51 years, using the simplified method as permitted for plain vanilla options. The weighted-average grant date fair value for options granted, total intrinsic value and cash received by the Company related to options exercised during the years ended December 31, 2023 and 2022 were as follows (in thousands, except for fair value per share). The Company did not grant any stock options to employees and no stock options were exercised by employees during the year ended December 31, 2024: Year ended December 31, 2023 2022 Weighted-average grant date fair value per share $ 56.43 $ 106.90 Options exercised: Total intrinsic value $ (7) $ 3,057 Restricted Stock Awards and Restricted Stock Units The Compensation Committee of the Board grants restricted stock awards (RSAs) and restricted stock units (RSUs) under the 2006 Plan. RSAs and RSUs vest ratably in equal annual installments over 1 to 4 years, or, for certain grants, over periods designated in the respective employee’s agreements or as determined by the Compensation Committee. During the year ended December 31, 2024, the Company issued 100,235 shares of its Common Stock to non-employee directors, executive officers and key employees upon the vesting of certain RSAs and RSUs granted under the Company’s 2006 Plan. The following table summarizes the activity of the shares and weighted-average grant date fair value of the Company’s unvested RSAs and RSUs during the year ended December 31, 2024: Shares Weighted-average Non-vested at beginning of year, January 1 298,074 $ 44.65 Granted 231,429 $ 41.01 Vested (100,235) $ 52.49 Forfeited or cancelled (113,922) $ 45.04 Non-vested at end of year, December 31 315,346 $ 39.35 As of December 31, 2024, there was approximately $14.4 million of unrecognized compensation cost related to non-vested RSAs and RSUs that is expected to be recognized over a weighted average remaining contractual term of 1.23 years. Performance-Based Restricted Stock Units The Compensation Committee of the Board grants performance-based restricted stock units (PRSUs) to certain executive officers and key employees. PRSUs primarily have a three-year performance period, after which the number of underlying RSUs earned is determined based on the achievement of pre-established performance targets. The following table summarizes the activity of the shares and weighted-average grant date fair value of the Company's unvested PRSUs during the year ended December 31, 2024: Shares Weighted-average Non-vested at beginning of year, January 1 206,036 $ 43.24 Granted 148,395 $ 53.43 Vested — $ — Forfeited or cancelled (97,152) $ 51.74 Non-vested at end of year, December 31 257,279 $ 45.91 As of December 31, 2024, there was approximately $4.7 million of unrecognized compensation cost related to non-vested PRSUs that is expected to be recognized over a weighted-average remaining contractual term of 1.83 years, assuming that the performance conditions continue to be probable of achievement. The total fair value of vested stock options, RSUs and RSAs, and PRSUs was $10.0 million, $11.7 million and $2.6 million for the years ended December 31, 2024, 2023 and 2022, respectively. Employee Stock Purchase Plan During the fourth quarter of 2022, the Company began offering an Employee Stock Purchase Plan ("ESPP") available to eligible employees. Under terms of the plan, eligible employees may designate a dollar value or percentage of their compensation to be withheld through payroll deductions, up to a maximum of $25,000 in each plan year, for the purchase of common stock at 85.0% of the lower of the market price on the first or last day of the offering period. Purchases under this plan were for a total of 50,963 shares and 16,030 shares as of December 31, 2024 and 2023, respectively. As of December 31, 2024, 949,037 shares remain available for future issuance under this plan.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Loss Per Share	Loss Per Share The following table details the computation of basic and diluted loss per share (in thousands, except share and per share data): Year ended December 31, 2024 2023 2022 Numerator: Net loss $ (201,278) $ (204,460) $ (31,806) Denominator: Denominator for basic and diluted earnings per share -- weighted-average shares 14,239,549 14,173,957 14,061,839 Loss per share: Basic loss per share $ (14.14) $ (14.43) $ (2.26) Diluted loss per share $ (14.14) $ (14.43) $ (2.26) In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and diluted loss per share. The following weighted-average shares were not included in the computation of diluted earnings per share as the effect of their inclusion would have been anti-dilutive: Year ended December 31, 2024 2023 2022 Stock options to purchase common stock 64,561 100,499 118,260 Restricted stock awards and restricted stock units 308,171 87,056 58,831

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases The Company has non-cancelable operating leases primarily associated with office space and other facilities. The leases expire in various years and generally provide for renewal options. In the normal course of business, management expects that these leases will be renewed or replaced by leases on other properties. Certain operating leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Several of these lease agreements contain provisions for periods in which rent payments are reduced. The total amount of rental payments due over the lease term is recorded as rent expense on a straight-line basis over the term of the lease. To determine whether a contract contains a lease, the Company evaluates its contracts and verifies that there is an identified asset and that the Company, or the tenant, has the right to obtain substantially all the economic benefits from the use of the asset throughout the contract term and has the right to direct the use of the identified asset. If a contract is determined to contain a lease and the Company is a lessee, the lease is evaluated to determine whether it is an operating or financing lease. The discount rate used for each lease is determined by estimating an appropriate incremental borrowing rate. In estimating an incremental borrowing rate, the Company considers the debt information, credit rating, and interest rate on the revolving credit facility, which is collateralized by the Company's assets. Accordingly, the Company continues discounting its remaining operating lease payments for calculating its lease liability using a weighted-average discount rate of 5.62%. The Company applies this rate to its entire portfolio of leases on the basis that any adjustments to the rate for lease term or asset classification would not affect the interest rate charged under the debt or have a material effect on the discounted lease liability. A summary of all lease classifications in our consolidated balance sheets is as follows (in thousands): Leases Classification December 31, 2024 December 31, 2023 Assets Operating lease assets Operating lease ROU assets $ 36,597 $ 39,776 Liabilities Current: Operating Current portion of operating lease liabilities $ 8,616 $ 8,727 Long-term: Operating Operating lease liabilities, less current portion 32,905 33,784 Total lease liabilities $ 41,521 $ 42,511 As of December 31, 2024, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2025 $ 10,891 2026 8,910 2027 7,276 2028 6,598 2029 5,075 Thereafter 10,509 Total lease payments 49,259 Less: interest and accretion (7,738) Present value of minimum lease payments 41,521 Less: current portion (8,616) Long-term portion $ 32,905 As of December 31, 2023, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2024 $ 10,434 2025 8,664 2026 7,275 2027 5,894 2028 5,403 Thereafter 13,121 Total lease payments 50,791 Less: interest and accretion (8,280) Present value of minimum lease payments 42,511 Less: current portion (8,727) Long-term portion $ 33,784 The weighted-average remaining lease terms and weighted-average discount rates are as follows: December 31, 2024 December 31, 2023 Weighted-average remaining lease term (years): Operating lease costs 3.60 4.18 Weighted-average discount rate: Operating lease costs 5.62 % 5.43 % For the years ended December 31, 2024 and 2023, our operating lease cost was $12.2 million and $13.0 million, respectively, and is primarily included in "Service expense” on our accompanying consolidated statements of operations. A summary of other lease information is as follows (in thousands): Year Ended December 31, 2024 Year Ended December 31, 2023 Operating cash flows from operating leases $ (10,049) $ (12,636) Amortization of operating lease ROU assets $ 11,444 $ 12,344 ROU assets obtained through operating lease liabilities $ 8,265 $ 12,715
Leases	Leases The Company has non-cancelable operating leases primarily associated with office space and other facilities. The leases expire in various years and generally provide for renewal options. In the normal course of business, management expects that these leases will be renewed or replaced by leases on other properties. Certain operating leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Several of these lease agreements contain provisions for periods in which rent payments are reduced. The total amount of rental payments due over the lease term is recorded as rent expense on a straight-line basis over the term of the lease. To determine whether a contract contains a lease, the Company evaluates its contracts and verifies that there is an identified asset and that the Company, or the tenant, has the right to obtain substantially all the economic benefits from the use of the asset throughout the contract term and has the right to direct the use of the identified asset. If a contract is determined to contain a lease and the Company is a lessee, the lease is evaluated to determine whether it is an operating or financing lease. The discount rate used for each lease is determined by estimating an appropriate incremental borrowing rate. In estimating an incremental borrowing rate, the Company considers the debt information, credit rating, and interest rate on the revolving credit facility, which is collateralized by the Company's assets. Accordingly, the Company continues discounting its remaining operating lease payments for calculating its lease liability using a weighted-average discount rate of 5.62%. The Company applies this rate to its entire portfolio of leases on the basis that any adjustments to the rate for lease term or asset classification would not affect the interest rate charged under the debt or have a material effect on the discounted lease liability. A summary of all lease classifications in our consolidated balance sheets is as follows (in thousands): Leases Classification December 31, 2024 December 31, 2023 Assets Operating lease assets Operating lease ROU assets $ 36,597 $ 39,776 Liabilities Current: Operating Current portion of operating lease liabilities $ 8,616 $ 8,727 Long-term: Operating Operating lease liabilities, less current portion 32,905 33,784 Total lease liabilities $ 41,521 $ 42,511 As of December 31, 2024, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2025 $ 10,891 2026 8,910 2027 7,276 2028 6,598 2029 5,075 Thereafter 10,509 Total lease payments 49,259 Less: interest and accretion (7,738) Present value of minimum lease payments 41,521 Less: current portion (8,616) Long-term portion $ 32,905 As of December 31, 2023, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2024 $ 10,434 2025 8,664 2026 7,275 2027 5,894 2028 5,403 Thereafter 13,121 Total lease payments 50,791 Less: interest and accretion (8,280) Present value of minimum lease payments 42,511 Less: current portion (8,727) Long-term portion $ 33,784 The weighted-average remaining lease terms and weighted-average discount rates are as follows: December 31, 2024 December 31, 2023 Weighted-average remaining lease term (years): Operating lease costs 3.60 4.18 Weighted-average discount rate: Operating lease costs 5.62 % 5.43 % For the years ended December 31, 2024 and 2023, our operating lease cost was $12.2 million and $13.0 million, respectively, and is primarily included in "Service expense” on our accompanying consolidated statements of operations. A summary of other lease information is as follows (in thousands): Year Ended December 31, 2024 Year Ended December 31, 2023 Operating cash flows from operating leases $ (10,049) $ (12,636) Amortization of operating lease ROU assets $ 11,444 $ 12,344 ROU assets obtained through operating lease liabilities $ 8,265 $ 12,715

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The federal and state tax benefit (provision) is summarized as follows (in thousands): Year Ended December 31, 2024 2023 2022 Federal income tax benefit (provision): Current $ (9,909) $ (10,296) $ (22,651) Deferred 16,596 14,431 25,291 Total federal income tax benefit 6,687 4,135 2,640 State income tax benefit (provision): Current (5,374) (3,067) (11,500) Deferred 4,193 3,251 11,895 Total state income tax benefit (provision) (1,181) 184 395 Total benefit for income taxes $ 5,506 $ 4,319 $ 3,035 A reconciliation of the benefit (provision) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (in thousands): Year Ended December 31, 2024 2023 2022 Federal statutory rates 21.0 % 21.0 % 21.0 % Federal income tax benefit at statutory rates $ 41,714 $ 43,904 $ 1,024 Change in valuation allowance (21,728) (507) 648 Goodwill impairment (22,113) (38,451) — State income taxes, net of federal benefit 3,825 637 (521) Rate change 3,168 — — Tax credits 1,669 2,258 1,864 Life insurance expense 136 128 (183) Stock-based compensation (507) (791) 1,282 Political activities (357) (149) (197) Meals and entertainment (84) (154) (48) Change in uncertain tax positions (59) 396 (390) Compensation expense — (1,220) (251) Legal settlements — (1,608) — Subsidiary deconsolidation gain — — (148) Other (158) (124) (45) Income tax benefit $ 5,506 $ 4,319 $ 3,035 Effective income tax rate 2.8 % 2.1 % 62.2 % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): December 31, 2024 2023 Deferred tax assets: Interest expense carryforward $ 40,317 $ 22,847 Accrued items and reserves 16,638 9,289 Software development/implementation costs 10,426 7,147 Deferred rent 9,914 1,543 Accounts receivable allowance 4,596 3,341 Net operating loss carryforwards 3,233 2,989 Stock-based compensation 2,363 1,861 Deferred financing costs 327 — Tax credit carryforwards 186 412 Deferred revenue 76 2,691 Capital loss carryforward — 957 Project costs — 223 Other 424 — Total deferred tax assets 88,500 53,300 Deferred tax liabilities: Goodwill and intangible assets 41,315 57,115 Property and equipment 15,116 19,051 Right of use asset 8,657 — Equity investment 8,058 11,604 Prepaid expenses 3,859 1,683 Deferred financing costs — 98 Other — 46 Total deferred tax liabilities 77,005 89,597 Net deferred tax assets (liabilities) 11,495 (36,297) Less valuation allowance (25,052) (3,287) Net deferred tax liabilities $ (13,557) $ (39,584) At December 31, 2024, the Company had no federal net operating loss (“NOL”) carryforwards. The Company also had approximately $49.7 million of state NOL carryforwards which expire as follows (in thousands): 2025 $ — 2026 — 2027 — 2028 — 2029 84 2030 and thereafter 49,658 Total state net operating loss carryforwards $ 49,742 Realization of the Company’s net operating loss carryforwards is dependent on reversing taxable temporary differences and on generating sufficient taxable income. Although realization is not assured, management believes it is more likely than not that all of the deferred tax assets will be realized to the extent they are not covered by a valuation allowance. The amount of the deferred tax assets considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced. The net change in the total valuation allowance for the year ended December 31, 2024 was an increase of $21.8 million. The valuation allowance of $25.1 million includes amounts primarily for state NOLs and IRC Section 163(j) Limitation on Business Interest Expense carryforward for which the Company has concluded that it is more likely than not that these carryforwards will not be realized in the ordinary course of operations per a deferred scheduling exercise. The Company will continue to assess the valuation allowance, and to the extent it is determined that the valuation allowance should be changed, an appropriate adjustment will be recorded. Unrecognized Tax Benefits The Company recognizes interest and penalties as a component of income tax expense. During the years ended December 31, 2024, 2023, and 2022 the Company did not recognize a tax benefit or expense from interest or penalties. As of December 31, 2024 and 2023, the Company had accrued an immaterial amount, respectively, for the payment of penalties and interest. A reconciliation of the liability for unrecognized income tax benefits is as follows (in thousands): December 31, 2024 2023 2022 Unrecognized tax benefits, beginning of year $ 1,284 $ 1,680 $ 1,290 Increase (decrease) related to prior year tax positions (47) 44 108 Increase related to current year tax positions 332 374 415 Statute of limitations expiration (195) (814) (133) Unrecognized tax benefits, end of year $ 1,374 $ 1,284 $ 1,680 The entire ending balance in unrecognized tax benefits of $1.4 million as of December 31, 2024 would reduce tax expense and the Company's effective tax rate. The Company expects no material amount of the unrecognized tax benefits to be recognized during the next twelve months. The Company is subject to taxation in the U.S. and various state jurisdictions. The statute of limitations is generally three years for the U.S. and between three

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Surveys, Audits and Governmental Investigations In the ordinary course of business, the Company may from time to time be or become subject to surveys, audits and governmental investigations under or with respect to various governmental programs and state and federal laws. Agencies associated with the programs and other third-party commercial payors periodically conduct extensive pre-payment or post-payment medical reviews or other audits of claims data to identify possible payments made or authorized other than in compliance with the requirements of Medicare or Medicaid. In order to conduct these reviews, documentation is requested from the Company and then that documentation is reviewed to determine compliance with applicable rules and regulations, including the eligibility of clients to receive benefits, the appropriateness of the care provided to those clients, and the documentation of that care. Similarly, other state and federal governmental agencies conduct reviews and investigations to confirm the Company's compliance with applicable laws where it operates, including regarding employment and wage related regulations and matters. The Company cannot predict the ultimate outcome of any regulatory reviews or other governmental surveys, audits or investigations, but management does not expect any ongoing surveys, audits or investigations involving the Company to have a material adverse effect on the business, liquidity, financial condition, or results of operations of the Company. Regardless of the Company's expectations, however, surveys and audits are subject to inherent uncertainties and can have a material adverse impact on the Company due to, among other reasons, potential regulatory orders that inhibit its ability to operate its business, amounts paid as reimbursement or in settlement of any such matter, diversion of management resources and investigative costs. Legal Proceedings In the ordinary course of business, the Company may from time to time be or become involved in various lawsuits, some of which may seek monetary damages, including claims for punitive damages. Management does not expect any ongoing lawsuits involving the Company to have a material impact on the business, liquidity, financial condition, or results of operations of the Company. Legal proceedings are subject to inherent uncertainties, however, and unfavorable rulings or other events could occur. Unfavorable resolutions could involve substantial monetary damages. In addition, in matters for which conduct remedies are sought, unfavorable resolutions could include an injunction or other order precluding particular business practices or requiring other remedies. An unfavorable outcome might result in a material adverse impact on our business, liquidity, financial position, or results of operations. The Company records accruals for loss contingencies related to legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. If the Company determines that a range of reasonably possible losses can be estimated, the Company records an accrual for the most probable amount in the range. Due to the inherent difficulty in predicting the outcome of any legal proceeding, it may not be reasonably possible to estimate a range of potential liability until the matter is closer to resolution. Legal fees related to all legal matters are expensed as incurred. On January 29, 2025, a class action complaint for purported violation of federal securities laws was filed by Dinesh Kalera, individually and on behalf of a putative class of purchasers of our common stock between November 3, 2022 and September 15, 2024 (the “Alleged Class Period”), in the United States District Court for the District of Colorado against the Company and three of its officers who served as chief financial officer of the Company during the Alleged Class Period. The complaint alleges claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and asserts, among other things, that the Company’s public statements concerning its NEMT segment accounts receivable collections efforts and effectiveness, cash flow results, and contractual payment and collection terms were materially false and misleading or contained material omissions. The Company denies the allegations in all respects and believes its public disclosure at all times has been true, correct and complete in all material respects in compliance with all federal securities and other laws and intends to defend itself vigorously in this case. The Company cannot predict with any degree of certainty the outcome of this matter or determine the extent of any potential liability or damages that may result from this matter, if any, but the Company does not believe in any event that the ultimate outcome of this matter will have a material adverse effect on the Company’s business, liquidity, financial condition or results of operations. On September 27, 2022, Daniel Greenleaf, the Company’s former Chief Executive Officer, asserted claims in an arbitration against the Company. His claims alleged that the Company breached Mr. Greenleaf’s employment agreement and included a tort claim against the Company. Mr. Greenleaf’s arbitration complaint sought contractual, extra-contractual, and statutory damages. In May 2023, Mr. Greenleaf and the Company executed a settlement agreement related to both sides' claims in arbitration and a general release of all claims and the Company agreed to pay Mr. Greenleaf $9.6 million. The Company paid the settlement amount in full in May of 2023. On August 6, 2020, the Company’s subsidiary, ModivCare Solutions, LLC (“ModivCare Solutions”), was served with a putative class action lawsuit filed against it by Mohamed Farah, the owner of transportation provider Dalmar Transportation, in the Western District of Missouri, seeking to represent all non-employee transportation providers contracted with ModivCare Solutions. The lawsuit alleged claims under the Fair Labor Standards Act of 1938, as amended (the “FLSA”), and the Missouri Minimum Wage Act, and asserted that all transportation providers to ModivCare Solutions in the putative class should have been considered ModivCare Solutions’ employees rather than independent contractors. Following motions regarding class certification and related matters and the transfer of the matter to binding arbitration, the parties agreed on a settlement arrangement, which the arbitrator approved final on October 30, 2023. The class settlement payment was made in full on December 1, 2023. Notwithstanding the settlement payment, ModivCare Solutions believes that it is and has been in compliance with all material aspects with the laws and regulations regarding the characterization of the transportation providers as independent contractors, and does not believe that the settlement arrangement has had a material adverse effect on the Company’s business, liquidity, financial condition or results of operations. Since 2017, one of the Company's PCS segment subsidiaries, All Metro Home Care Services of New York, Inc. d/b/a All Metro Health Care (“All Metro”), has been subject to a class action lawsuit in state court claiming that, among other things, All Metro failed to properly pay live-in caregivers who stay in patients’ homes for 24 hours per day (“live-ins”). The Company pays live-ins for 13 hours per day as supported through a written opinion letter from the New York State Department of Labor (“NYSDOL”). The New York Court of Appeals (New York's highest court) in a similar case involving this issue issued an order in 2019 that agreed with the NYSDOL’s interpretation to pay live-ins for 13 hours per day instead of 24 hours if certain conditions were being met. Notwithstanding the court of appeals' order in the similar case, the parties to date have been unable to settle their dispute through mediation or otherwise, and therefore discovery in the matter is continuing. If the plaintiffs prove successful in this class action lawsuit, All Metro may be liable for back wages and liquidated damages dating back to November 2011. All Metro believes that it is and has been in compliance in all material respects with the laws and regulations covering pay for live-in caregivers (including the conditions described by the New York Court of Appeals in its order), intends to continue to defend itself vigorously with respect to this matter, and the Company does not believe in any event that the ultimate outcome of this matter will have a material adverse effect on the Company’s business, liquidity, financial condition or results of operations. Deferred Compensation Plan The Company has one deferred compensation plan for management and highly compensated employees of NEMT Services as of December 31, 2024. The deferred compensation plan is unfunded, and benefits are paid from the general assets of the Company. The total of participant deferrals, which is reflected in “Other long-term liabilities” in the consolidated balance sheets, was $2.3 million and $2.2 million at December 31, 2024 and 2023, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company has evaluated events and transactions subsequent to the Company's consolidated balance sheet date and prior to the date of issuance. Exchange Agreement On January 9, 2025, pursuant to the Fifth Amendment to the Credit Agreement, the Company entered into an exchange agreement (the “Exchange Agreement”), with certain lenders party to the Amended Credit Agreement (the “Exchanging Noteholders”). The Exchange Agreement provides for the exchange (the “Exchange”) of up to $251.0 million in aggregate principal amount of the Company’s 5.000% Notes due 2029 held by the Exchanging Noteholders for an equivalent principal amount of second lien senior secured PIK toggle notes to be issued by the Company (the “Second Lien Notes”), pursuant to the terms and subject to the conditions set forth therein, subject to the receipt of requisite consents to make certain amendments to the indenture governing the Notes due 2029 to permit the Exchange and remove certain other covenants. Purchase and Exchange Agreement On January 9, 2025, the Company entered into a Purchase and Exchange Agreement (the “Purchase and Exchange Agreement”) with Coliseum Capital Partners, L.P., a Related Party, and Blackwell Partners LLC – Series A (together, the “Coliseum Investors”), which provides, among other things, for the Coliseum Investors (a) to purchase (the “Purchase”) $30.0 million in aggregate principal amount of the Second Lien Notes, at a purchase price equal to 100% of the principal amount of the Second Lien Notes plus any accrued and unpaid interest thereon from, and including, October 1, 2024 to, but excluding, the closing date of the Purchase and (b) to exchange approximately $20.0 million in aggregate principal amount of the Company’s Notes due 2029 held by the Coliseum Investors for an equivalent principal amount of the Second Lien Notes (the “Coliseum Exchange” and, together with the Purchase, the “Coliseum Transactions”), in each case pursuant to the terms and subject to the conditions set forth in the Purchase and Exchange Agreement. The Coliseum Transactions are conditioned upon the receipt of approval from 66-2/3% of the Company’s stockholders other than Coliseum pursuant to Section 203 of the Delaware General Corporation Law. Based on our evaluation, the Company is not aware of any other events or transactions that occurred subsequent to the consolidated balance sheet date and prior to the date of issuance that would require recognition or disclosure in these financial statements.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	Schedule II Valuation and Qualifying Accounts Additions Balance at Charged to Charged to Deductions Balance at Year Ended December 31, 2024: Allowance for credit losses $ 969 $ 4,395 $ — $ (3,925) (1) $ 1,439 Year Ended December 31, 2023: Allowance for credit losses $ 2,078 $ 4,001 $ — $ (5,110) (1) $ 969 Year Ended December 31, 2022: Allowance for credit losses $ 2,296 $ 2,690 $ — $ (2,908) (1) $ 2,078 Notes: (1) Write-offs, net of recoveries. All other schedules are omitted because they are not applicable or the required information is shown in our financial statements or the related notes thereto.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (201,278)	$ (204,460)	$ (31,806)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Risk Management and Strategy. Our information technology ("IT") systems are critically important to our existing business operations and growth strategy. We provide services to individuals and others that require us to collect, process, maintain and retain sensitive and personal client confidential information in our IT systems, including protected health information ("PHI"), personally identifiable information ("PII"), financial information and other personal information about our customers and end-users, such as names, addresses, phone numbers, email addresses, identification numbers, sensitive health data, and payment account information. As a result, we are subject to complex and evolving United States privacy laws and regulations, including those pertaining to the handling of personal data, such as HIPAA and CCPA. In addition to protecting the privacy of all health-related information for our members, our IT infrastructure supports the operations of all aspects of our business and ensures that we are able to continue to serve our members' transportation, personal care, and monitoring needs and execute our strategy to better connect people with care. The Company's Enterprise Risk Management Team (the "ERM Team"), led by Internal Audit, works in collaboration with the Company's Information Security Team to set the enterprise risk strategy and make risk-informed decisions, which include the assessment and response to cybersecurity risk. The Company maintains an information security, technology, and cybersecurity risk management program overseen by the Chief Information Security Officer (the "CISO") that uses a risk-based methodology to support the security, confidentiality, integrity, and availability of its information. Controls over security, confidentiality, integrity, and availability are tested by external audit agencies, resulting in the Company's HITRUST, ISO 27007/27701, SOC2, and HIPAA certifications. The Company's information security, technology, and cybersecurity risk management program provides the structure for managing the respective risks utilizing a combination of automated tools, documented processes, and third-party assessments to identify and assess potential cybersecurity risks. As part of the risk program, third parties engaged by the Company are subject to initial and continuous security monitoring activities including the use of Security Information Event Monitoring ("SIEM") software and regularly scheduled vulnerability assessments performed by an independent third-party to capture and identify vulnerabilities, security events, and potential incidents. The Company also maintains a formal information security training program that includes training on matters such as phishing and email security best practices as well as data privacy which is required for all employees on an annual basis. While processes are in place to minimize the chance of a successful cyberattack, the Company has established incident response policies and procedures to address a cyber threat that may occur despite these safeguards. In these instances, the Company maintains a cybersecurity incident response policy (the "Incident Response Policy") and cybersecurity incident response plan (the "Incident Response Plan") to help ensure a timely, consistent and compliant response to actual or attempted cybersecurity incidents impacting the Company. The Incident Response Plan includes (1) detection, (2) analysis, which may include timely notice to the Audit Committee of our Board if deemed material or appropriate, (3) containment, (4) eradication, (5) recovery and (6) post-incident review. The Incident Response Plan includes leveraging the Company's cross-functional Cybersecurity Incident Committee that is supported by an organizational structure that includes executives across the Information Security, ERM, Finance, Legal, and Investor Relations functions of the business. The Cybersecurity Incident Committee is responsible for assessing the materiality of any cybersecurity incidents and for communicating any such incidents to the appropriate parties outside the Company. The Company relies on our IT systems and networks in connection with many of our business activities. Some of these networks and systems are managed by third-party service providers and are not under our direct control. The Company has implemented processes to manage the cybersecurity risks associated with its use of third-party service providers, including processes during the contract review phase by both Information Security and Legal teams providing contractual safeguards as well as ongoing monitoring of third-party service providers for incidents that may affect the Company. To date, no cybersecurity incidents have had such a material adverse effect on us, and we are not presently aware of any cybersecurity threats that are reasonably likely to materially affect us. Despite the security measures we have implemented, certain cyber incidents could materially disrupt our operational systems, compromise PHI or PII regarding customers or employees, delay our ability to provide critical services to our customers, and/or jeopardize the security of our facilities. We continuously seek to maintain a robust program of information security and controls, but the impact of a material information technology event could have a material adverse effect on our competitive position, reputation, results of operations, financial condition and cash flows.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	The Company's Enterprise Risk Management Team (the "ERM Team"), led by Internal Audit, works in collaboration with the Company's Information Security Team to set the enterprise risk strategy and make risk-informed decisions, which include the assessment and response to cybersecurity risk. The Company maintains an information security, technology, and cybersecurity risk management program overseen by the Chief Information Security Officer (the "CISO") that uses a risk-based methodology to support the security, confidentiality, integrity, and availability of its information.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Board's Roles and Responsibilities The Audit Committee is responsible for overseeing and monitoring the Company's information security, technology, and cybersecurity program and other IT and data privacy risks, controls, strategies, and procedures. The Audit Committee is comprised of board members with expertise in the areas of risk management, finance and technology, enabling them to effectively oversee such cybersecurity and other IT and data privacy risks. The Audit Committee receives updates from management as needed or at least quarterly which cover the Company's current cybersecurity and other IT and data privacy risk assessments and key risk areas. The Audit Committee also reviews and discusses with management, at least quarterly, and as needed, any material or significant cyber incidents that have occurred or are reasonably likely to occur. In addition, the Audit Committee receives regular updates on cybersecurity trends and emerging threats from the Information Security Team led by the CISO.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee is responsible for overseeing and monitoring the Company's information security, technology, and cybersecurity program and other IT and data privacy risks, controls, strategies, and procedures.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee receives updates from management as needed or at least quarterly which cover the Company's current cybersecurity and other IT and data privacy risk assessments and key risk areas. The Audit Committee also reviews and discusses with management, at least quarterly, and as needed, any material or significant cyber incidents that have occurred or are reasonably likely to occur. In addition, the Audit Committee receives regular updates on cybersecurity trends and emerging threats from the Information Security Team led by the CISO.
Cybersecurity Risk Role of Management [Text Block]	Management's Roles and Responsibilities In collaboration with the ERM team and the Audit Committee, the Company's Information Security Team, overseen by the CISO, is responsible for assessing and managing cybersecurity risks including the prevention, mitigation, detection, and remediation of cybersecurity incidents. The Information Security Team is comprised of various Technology groups with the knowledge and expertise needed to execute the technical aspect of the Incident Response Plan. This team is led by the CISO and other technical leaders with significant experience in the information security field. The CISO has over 19 years of experience serving as a CISO and in other security leadership positions in the information security and cybersecurity fields, including roles as VP of Enterprise Technology, VP of Information Security, Director of Infrastructure and Cybersecurity, Director of Information Security, and Manager of Information Security. In addition to his work experience, the CISO holds a certification as a Certified Information System Security Professional (CISSP). The CISO works closely with other management positions, including the Chief Accounting Officer, Chief Information Officer, Chief Audit Officer, General Counsel, and VP of Investor Relations through the Cybersecurity Incident Committee in order to ensure that the Company has effective communication and understanding of its cybersecurity risk management. The processes by which the Information Security Team and CISO monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents include regular vulnerability assessments and penetration testing, security incident and event management, continuous monitoring, and threat and intelligence gathering. The CISO reports to the Audit Committee on a quarterly basis, and as needed, to provide an overview of our cybersecurity risk posture, the effectiveness of our cybersecurity policies, procedures, and strategies, and any material or significant cybersecurity incidents that have occurred or are likely to occur.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	In collaboration with the ERM team and the Audit Committee, the Company's Information Security Team, overseen by the CISO, is responsible for assessing and managing cybersecurity risks including the prevention, mitigation, detection, and remediation of cybersecurity incidents. The Information Security Team is comprised of various Technology groups with the knowledge and expertise needed to execute the technical aspect of the Incident Response Plan. This team is led by the CISO and other technical leaders with significant experience in the information security field. The CISO has over 19 years of experience serving as a CISO and in other security leadership positions in the information security and cybersecurity fields, including roles as VP of Enterprise Technology, VP of Information Security, Director of Infrastructure and Cybersecurity, Director of Information Security, and Manager of Information Security. In addition to his work experience, the CISO holds a certification as a Certified Information System Security Professional (CISSP). The CISO works closely with other management positions, including the Chief Accounting Officer, Chief Information Officer, Chief Audit Officer, General Counsel, and VP of Investor Relations through the Cybersecurity Incident Committee in order to ensure that the Company has effective communication and understanding of its cybersecurity risk management.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The CISO has over 19 years of experience serving as a CISO and in other security leadership positions in the information security and cybersecurity fields, including roles as VP of Enterprise Technology, VP of Information Security, Director of Infrastructure and Cybersecurity, Director of Information Security, and Manager of Information Security. In addition to his work experience, the CISO holds a certification as a Certified Information System Security Professional (CISSP).
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The processes by which the Information Security Team and CISO monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents include regular vulnerability assessments and penetration testing, security incident and event management, continuous monitoring, and threat and intelligence gathering. The CISO reports to the Audit Committee on a quarterly basis, and as needed, to provide an overview of our cybersecurity risk posture, the effectiveness of our cybersecurity policies, procedures, and strategies, and any material or significant cybersecurity incidents that have occurred or are likely to occur.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Significant Accounting Polici_2

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company follows accounting standards established by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under the authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. References to GAAP issued by the FASB in these notes are to the FASB Accounting Standards Codification (“ASC”), which serves as the single source of authoritative accounting and applicable reporting standards to be applied for non-governmental entities. All amounts are presented in U.S. dollars unless otherwise noted. The Company accounts for its investment in Matrix using the equity method, as the Company does not control the decision-making process or business management practices of Matrix. While the Company has access to certain information and performs certain procedures to review the reasonableness of information, the Company relies on the management of Matrix to provide accurate financial information prepared in accordance with GAAP. The Company receives audit reports relating to such financial information from Matrix’s independent auditors on an annual basis. The Company is not aware of any errors in or possible misstatements of the financial information provided by Matrix that would have a material effect on the Company’s consolidated financial statements. See Note 6, Equity Investment , for further information.
Reclassifications	Reclassifications:
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include ModivCare Inc., its wholly-owned subsidiaries, and entities it controls, or in which it has a variable interest and is the primary beneficiary of expected cash profits or losses. The Company records its investments in entities that it does not control, but over which it has the ability to exercise significant influence, using the equity method. The Company has eliminated significant intercompany transactions and accounts.
Accounting Estimates	Accounting Estimates The Company uses estimates and assumptions in the preparation of the consolidated financial statements in accordance with GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the Company’s consolidated financial statements. These estimates and assumptions also affect the reported amount of net income or loss during any period. The Company’s actual financial results could differ significantly from these estimates. The significant estimates underlying the Company’s consolidated financial statements include revenue recognition; accrued transportation costs; income taxes; recoverability of current and long-lived assets, including equity method investments; intangible assets and goodwill; loss contingencies; accounting for business combinations, including amounts assigned to definite and indefinite lived intangibles and contingent consideration; and loss reserves for reinsurance and self-funded insurance programs.
Fair Value Measurements	Fair Value Measurements The Company follows FASB ASC Topic 820, Fair Value Measurement (“ASC 820”) which establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy categorizes assets and liabilities measured at fair value into one of three different levels depending on the observability of the inputs employed in the measurement. The three levels are defined as follows: – Level 1: Quoted Prices in Active Markets for Identical Assets – inputs to the valuation methodology are quoted prices in active markets as of the measurement date for identical assets or liabilities. – Level 2: Significant Other Observable Inputs – inputs to the valuation methodology are based upon quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. – Level 3: Significant Unobservable Inputs – inputs to the valuation methodology are unobservable and significant to the fair value measurement. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. As of December 31, 2024 and 2023, the carrying amount for cash and cash equivalents, accounts receivable (net of allowance for credit losses), current assets and current liabilities was equal to or approximated fair value due to their short-term nature or proximity to current market rates. Fair values for the Company's publicly traded debt securities are based on quoted market prices, when available, and for the Company's nonpublic debt are based on lender quotes, when available. See Note 11, Debt , for the fair value of the Company's long-term debt.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents Cash and cash equivalents include all cash balances and highly liquid investments with an initial maturity of three months or less. Investments in cash equivalents are carried at cost, which approximates fair value. The Company places its temporary cash investments with high credit quality financial institutions. At times, such investments may be in excess of the federally insured limits. Restricted Cash
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses The Company records accounts receivable amounts at the contractual amount, less contractual revenue adjustments based on amounts expected to be due from payors and less an allowance for credit losses. The Company maintains an allowance for credit losses at an amount it estimates to be sufficient to cover the risk that an account will not be collected due to credit risk. In order to establish the amount of the allowance related to the credit risk of accounts receivable, the Company considers information related to receivables that are past due, past loss experience, current and forecasted economic conditions, and other relevant factors. In circumstances where the Company is aware of a customer’s inability to meet its financial obligation, the Company records a specific allowance for credit losses to reduce its net recognized receivable to an amount the Company reasonably expects to collect. As the Company primarily contracts with Medicaid and Medicare governmental payors, the Company is not subject to significant credit risk in the collection of accounts receivable.
Business Combinations	Business Combinations The Company accounts for acquisitions in accordance with ASC Topic 805, Business Combinations . The acquisition method of accounting requires the Company to make significant estimates and assumptions as of the date of the acquisition related to the determination of the fair values (primarily Level 3) of the tangible and intangible assets acquired and liabilities assumed, and related to the determination of estimated lives of the depreciable assets acquired. The Company recognizes goodwill at the amount by which the purchase price exceeds the fair value of identified assets acquired and liabilities assumed. See Note 3, Acquisitions
Property and Equipment	Property and Equipment Property and equipment are stated at historical cost, net of accumulated depreciation, or at fair value if the assets were initially recorded as the result of a business combination or if the asset was remeasured due to an impairment. Depreciation is calculated using the straight-line method over the estimated useful life of the asset to the Company. Maintenance and repairs are expensed as incurred. Gains and losses resulting from the disposition of an asset are reflected in results of operations.
Internal-use Software	Internal-use Software The Company develops and implements software for internal use to enhance the performance and capabilities of the technology infrastructure. The costs incurred for the development of the internal-use software are capitalized when they meet the internal-use software capitalization criteria outlined in ASC 350-40 and are included within "Property and equipment, net" on the consolidated balance sheets. The capitalized costs are amortized using the straight-line method over the estimated useful life of the software, ranging from 3 to 10 years. As of December 31, 2024 and 2023, capitalized costs associated with the internal-use software, net of accumulated amortization were $26.1 million and $21.3 million, respectively. The amount of accumulated amortization as of December 31, 2024 and 2023 was $7.8 million and $2.6 million, respectively. Amortization expense during the years ended December 31, 2024, 2023, and 2022 totaled $5.2 million, $2.5 million, and $0.1 million respectively.
Recoverability of Goodwill	Recoverability of Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other , the Company reviews goodwill for impairment annually, and more frequently if events and circumstances indicate that an asset may be impaired. Such circumstances could include, but are not limited to: (1) the loss or modification of significant contracts, (2) a significant adverse change in legal factors or in business climate, (3) unanticipated competition, (4) an adverse action or assessment by a regulator, or (5) a significant decline in the Company’s stock price. When evaluating goodwill for impairment, the Company first performs a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative assessment and compares the fair value of the reporting unit to its carrying value and to the extent the carrying value is greater than the fair value, the difference is recorded as an impairment in the consolidated statements of operations. The Company performed a quantitative test comparing the carrying value of the Company's reporting units with their respective fair value. The fair value of the Company's reporting units is estimated using either an income approach, a market valuation approach, or a blended approach. The income approach produces an estimated fair value of a reporting unit based on the present value of the cash flows the Company expects the reporting unit to generate in the future. Estimates included in the discounted cash flow model are primarily Level 3 inputs and include the discount rate, which the Company determines based on adjusting an industry-wide weighted-average cost of capital for size, geography, risk free rates, and company specific risk factors, long-term rates of growth and profitability of the Company’s business, working capital effects and planned capital expenditures. The market approach produces an estimated fair value of a reporting unit based on a comparison of the reporting unit to comparable publicly traded entities in similar lines of business. The Company’s significant estimates in the market approach include the selected similar companies with comparable business factors such as size, growth, profitability, risk and return on investment and the multiples the Company applies to earnings before interest, taxes, depreciation and amortization (“EBITDA”) to estimate the fair value of the reporting unit. As a result of the Company's annual goodwill assessments during the years 2024 and 2023, the Company determined that based on its qualitative assessment for each reporting unit, factors existed which required the Company to test its goodwill and indefinite-lived intangible assets for impairment. Accordingly, the Company performed a quantitative assessment during each annual testing period which resulted in the Company recording a non-cash goodwill impairment charge of $105.3 million within its Monitoring reporting unit during the 2024 annual period and recording a non-cash goodwill impairment charge of $183.1 million, of which $137.3 million was recorded in the PCS reporting unit and $45.8 million was recorded in the Monitoring reporting unit during the 2023 annual period. See Note 9, Goodwill and Intangible Assets , for additional details.
Recoverability of Intangible Assets Subject to Amortization and Other Long-Lived Assets	Recoverability of Intangible Assets Subject to Amortization and Other Long-Lived Assets Intangible assets subject to amortization and other long-lived assets are carried at cost and are amortized or depreciated on a straight-line basis over their estimated useful lives of 2 to 10 years. In accordance with ASC 360, Property, Plant, and Equipment
Accrued Transportation Costs	Accrued Transportation Costs The Company generally contracts with third-party providers to provide transportation services to customers. The cost of transportation is recorded in the month the services are rendered based upon contractual rates and mileage estimates. Once a trip is completed, the third-party transportation providers will furnish invoices for actual mileage incurred. Any trips that have
Deferred Financing Costs and Debt Discounts	Deferred Financing Costs and Debt Discounts
Revenue Recognition	Revenue Recognition Under ASC 606, the Company recognizes revenue as it transfers promised services directly to its customers at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing these services. The Company's performance obligations are driven by its different segments of business and primarily consist of integrated service offerings to provide non-emergency medical transportation, personal care services, or remote monitoring services directly to its customers. The Company receives payment for providing these services from third-party payors that include federal, state, and local governmental agencies, managed care organizations, and private consumers. In the NEMT segment, the Company's performance obligation is to stand ready to perform transportation-related activities, including the management, fulfillment, and recordkeeping activities associated with such services. In the PCS segment, the Company's performance obligation is to deliver patient care services in accordance with the nature and frequency of services outlined in each contract. In the Monitoring segment, the Company's performance obligation is to stand ready to perform in-home clinical monitoring and quality improvement services that leverage personal emergency response systems, vitals monitoring devices, relationship-based care, and data-driven patient engagement solutions, as contractually agreed upon. The Company satisfies substantially all of its performance obligations over time and recognizes revenue over time instead of at points in time which aligns the pattern of transfer of promised services with the value received by the customer for the performance completed to date. The Company holds different contract types under its different segments of business. In the NEMT segment, there are both capitated contracts, under which payors pay a fixed amount monthly per eligible member and revenue is recognized over each distinct service period, and fee-for-service ("FFS") contracts, under which the Company bills and collects a specified amount for each service that is provided and revenue is recognized using the right to invoice practical expedient. In the PCS segment, contracts are also FFS and service revenue is reported at the estimated net realizable amount from patients and third-party payors for services rendered and revenue is recognized using the right to invoice practical expedient. Under Monitoring contracts, payors pay per-enrolled-member-per-month, based on enrolled membership, and revenue is recognized ratably over the contract term. For each contract type, the Company determines the transaction price based on the gross charges for services provided, reduced by estimates for contractual adjustments due to settlements of audits and payment reviews from third-party payors. The Company determines the estimated revenue adjustments at each segment based on its historical experience with various third-party payors and previous results from the claims and adjudication process. The PCS segment uses the portfolio approach to determine the estimated revenue adjustments. See further information in Note 5, Revenue Recognition .
Government Grants	The Company periodically receives government grants and other forms of government assistance which are not generated from the Company's contractual performance obligations under ASC 606, Revenue from Contracts with Customers . Funding received from governmental entities under government programs generally requires that the recipient attests to and complies with certain terms and conditions of receiving the funding. Government grant distributions have been received primarily under the CARES Act Public Health and Social Services Emergency Fund ("Provider Relief Fund" or "PRF") and the American Rescue Plan Act of 2021 ("ARPA") Coronavirus State and Local Fiscal Recovery Fund ("SLFRF"). These funds were established to provide economic relief payments and stimulus to companies to address the health and economic impacts of the COVID-19 pandemic. During the third quarter of 2023, the Company also filed amended payroll tax returns for 2020 and 2021 to claim refunds for Employee Retention Credits ("ERC"). ERC is a U.S. federal tax credit introduced to support businesses and organizations during the COVID-19 pandemic that was initially established under the CARES Act in 2020 and was later expanded and extended by subsequent legislation, including the Consolidated Appropriations Act of 2021 and the American Rescue Plan Act of 2021. The Company has also received government grant distributions from other entities that provide funds with specific stipulations on the usage of these funds. Distributions received under the CARES Act PRF and the ARPA SLFRF are targeted to assist with incremental health care related expenses or lost revenue attributable to the COVID-19 pandemic and/or provide stimulus to support long-term growth and recovery. When received, these government grants are generally recorded on the consolidated balance sheets in "Accrued expenses and other current liabilities" until the time at which there is reasonable assurance the conditions of the grant will be met, at which point they are recognized on the consolidated statement of operations. Once recognized, the Company records these government grants as "Grant income" if the grant is related to the loss of revenues, or as an offset to "Service expense" if the grant is used to offset certain costs for which the grants are intended to compensate. The Company received distributions from government grants of approximately $19.5 million, $21.8 million, $16.3 million during the years ended December 31, 2024, 2023, and 2022, respectively. During the year ended December 31, 2024, no funds were recognized as grant income and $24.1 million were recognized as an offset to " Service expense Grant income Accrued Expenses and Other Current Liabilities . The payments from these acts are subject to certain restrictions and possible recoupment if not used for designated purposes. As a condition to receiving PRF distributions, providers must agree to certain terms and conditions, including, among other things, that the funds are being used for healthcare related expenses and lost revenues attributable to COVID-19, as defined by HHS. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. The Company has submitted the required documents to meet reporting requirements for the applicable reporting periods. The Company received an audit inquiry letter from HHS related to one of the business units that received PRF payments, to which the Company has responded and submitted all requested information and believes that the payments received are substantiated and within the terms and conditions defined by HHS and continues to recognize these amounts as grant income. At this time, the Company is unaware of any other pending or upcoming audits or inquiries related to amounts received under PRF. As a condition to receiving SLFRF distributions, providers must agree to use the funds to respond to the Public Health Emergency ("PHE") or its negative economic impacts, to respond to workers performing essential work by providing premium pay to eligible workers and to offset reduction in revenue due to the COVID-19 PHE as stipulated by the states in which the funds were received. All recipients of SLFRF distributions are required to comply with the reporting requirements that the state in which the funds originated requests in order for the states to meet the requirements as described in the terms and conditions as determined by the Department of the Treasury. The Company is in the process of complying with all known reporting requirements to date.
Stock-Based Compensation	Stock-Based Compensation The Company follows the fair value recognition provisions of ASC Topic 718 – Compensation – Stock Compensation (“ASC 718”), which requires companies to measure and recognize compensation expense for all share-based payments at fair value. • The Company calculates the fair value of stock options using the Black-Scholes option-pricing formula and determines the fair value of restricted stock awards or units ("RSAs" or "RSUs") based on the closing market price of the Company’s Common Stock on the date of grant. Forfeitures for stock options, RSAs, and RSUs are recorded as they occur. The expense for stock-based compensation awards is amortized on a straight-line basis over the requisite service period, which is typically the vesting period. •
Income Taxes	Income Taxes Deferred income taxes are determined by the asset and liability method in accordance with ASC Topic 740 - Income Taxes . Under this method, deferred tax assets and liabilities are determined based on differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings experience by jurisdiction, expectations of future taxable income, and the carryforward periods available for tax reporting purposes, as well as other relevant factors. The Company establishes a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The net amount of deferred tax liabilities and assets, net of the valuation allowance, is presented as non-current in the Company's consolidated balance sheets. Due to inherent complexities arising from the nature of the Company’s businesses, future changes in income tax law or variances between the Company’s actual and anticipated operating results, the Company makes certain judgments and estimates. Therefore, actual income taxes could materially vary from these estimates. The Company has recorded a valuation allowance which includes amounts for certain carryforwards and deferred tax assets, as more fully described in Note 16, Income Taxes, for which the Company has concluded that it is more likely than not that these carryforwards and deferred tax assets will not be realized in the ordinary course of operations. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. The Company accounts for uncertain tax positions based on a two-step process of evaluating recognition and measurement criteria. The first step assesses whether the tax position is more likely than not to be sustained upon examination by the tax authority, including resolution of any appeals or litigation, based on the technical merits of the position. If the tax position meets the more likely than not criteria, the portion of the tax benefit greater than 50.0% likely to be realized upon settlement with the tax authority is recognized in the consolidated financial statements.
Loss Reserves for Certain Reinsurance Programs and Self-Funded Insurance Programs	Loss Reserves for Certain Reinsurance Programs The Company historically reinsured a substantial portion of its automobile, general and professional liability and workers’ compensation costs under certain reinsurance programs. The Company utilizes a report prepared by an independent actuary to estimate the gross expected losses related to these reinsurance policies, including the estimated losses in excess of insured limits, which would be reimbursed to the Company to the extent such losses were incurred. As of December 31, 2024 and 2023, the Company had reserves of $30.0 million and $20.2 million, respectively, for the automobile, general and professional liability and workers’ compensation reinsurance policies. The gross reserve as of December 31, 2024 and 2023 of $58.0 million and $45.7 million, respectively, is classified as current liabilities and other long-term liabilities in the consolidated balance sheets. The estimated amount to be reimbursed to the Company as of December 31, 2024 and 2023 was $28.0 million and $25.5 million, respectively, and is classified as other long-term assets in the consolidated balance sheets. The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, judgment is involved in assessing these reserves, such as in assessing historical paid claims, average lag times between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. Self-Funded Insurance Programs The Company also maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims generally to $0.3 million per person, subject to an aggregating stop-loss limit of $0.4 million. In addition, the program has a total stop-loss limit for total claims, in order to limit the Company’s exposure to catastrophic claims. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2024 and 2023, the Company had $3.3 million and $1.8 million, respectively, in reserves for its self-funded health insurance programs. The reserves are classified as “Accrued expenses and other current liabilities” in the consolidated balance sheets.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company computes basic earnings (loss) per share by taking net income (loss) attributable to the Company available to common stockholders divided by the weighted average number of common shares outstanding during the period, including restricted stock and stock held in escrow if such shares are participating securities. Diluted earnings (loss) per share includes the potential dilution that may occur from stock-based awards and other stock-based commitments using the treasury stock or the as-if converted methods, as applicable. For additional information on how the Company computes earnings (loss) per share, see Note 14, Earnings (Loss) Per Share .
Recent Accounting Pronouncements	Recent Accounting Pronouncements During the year ended December 31, 2024, the Company adopted the following accounting pronouncement: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). This update improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses. The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit or loss, require disclosure of other segment items by reportable segment and a description of the composition of other segment items , require annual disclosures under ASC 280 to be provided in interim periods, clarify use of more than one measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC 280. ASU 2023-07 is effective for public business entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company adopted ASU 2023-07 for the fiscal year ended December 31, 2024. Recent accounting pronouncements that the Company has yet to adopt are as follows: In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). This update enhances the transparency and decision usefulness of income tax disclosures including updates to the disclosures related to the rate reconciliation and income taxes paid. These updates improve transparency by requiring consistent categories and greater disaggregation of information in the rate reconciliation and requiring income taxes paid to be disaggregated by jurisdiction. ASU 2023-09 is effective for public business entities for fiscal years beginning after December 15, 2024, with early adoption permitted. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Purchase Price Allocation	The following table summarizes the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities as of the acquisition date of May 11, 2022 (in thousands): Cash (1) $ 391 Accounts receivable (2) 2,355 Prepaid expenses and other (3) 771 Property and equipment (4) 2,639 Intangible assets (5) 21,950 Goodwill (6) 44,346 Accounts payable (7) (281) Accrued expenses and other current liabilities (7) (577) Total of assets acquired less liabilities assumed $ 71,594 (1) During 2022, the Company received an additional $0.1 million of cash related to net working capital adjustments, and therefore, the initial balance of $0.3 million was increased to $0.4 million. (2) Management has valued accounts receivable based on the estimated future collectability of the receivables portfolio. During 2022, it was determined that $0.6 million of the initial accounts receivable balance was uncollectible, and therefore, the initial balance of $3.0 million was decreased to $2.4 million. (3) Given the short-term nature of the balance of prepaid expenses and other assets, the carrying value represents the fair value. (4) The acquired property and equipment consists primarily of personal emergency response system devices, with the remainder consisting of computer equipment and furniture and fixtures. The Company valued the personal emergency response system devices utilizing the cost approach. Through this valuation, it was determined that $0.1 million of acquired property and equipment did not exist, and therefore, the initial balance of $2.7 million was decreased to $2.6 million. The carrying value of the remainder of the property and equipment, consisting primarily of computer equipment and furniture and fixtures, is assumed to represent the fair value. (5) The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands, except useful lives): Type Useful Life Value Payor network Amortizable 7 years $ 21,600 Trade name Amortizable 2 years 350 $ 21,950 The Company valued the payor network utilizing the multi-period excess earnings method and trade names utilizing the relief-from-royalty method. The weighted average useful life of the acquired intangible assets is approximately 6.9 years. (6) The acquisition initially resulted in $43.7 million of goodwill as a result of expected synergies due to future customers driven by expansion into different markets and an increase in market share. During the measurement period, accounts receivable was reduced by $0.6 million which caused a corresponding increase to goodwill. Also during the measurement period, cash increased by $0.1 million related to working capital adjustments, which caused a corresponding decrease to goodwill, and acquired property and equipment decreased by $0.1 million, which caused a corresponding increase to goodwill. The result of these adjustments was a total goodwill balance of $44.3 million. All of the acquired goodwill is deductible for tax purposes.
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The fair value of the net consideration is as follows (in thousands, except useful lives): Type Useful Life Value Payor network Amortizable 6 years $ 7,297 Assembled workforce Amortizable 6 years 309 $ 7,606

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Financial Information Attributable to the Company's Business Segments	The following table sets forth certain financial information attributable to the Company’s business segments for the years ended December 31, 2024, 2023 and 2022 (in thousands): Year Ended December 31, 2024 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,957,275 $ 745,299 $ 77,739 $ 7,273 $ 2,787,586 Purchased services 1,504,970 — — — 1,504,970 Payroll and related costs 172,800 594,150 17,077 556 784,583 Other service expense 50,214 5,108 15,207 7,133 77,662 Service expense 1,727,984 599,258 32,284 7,689 2,367,215 General and administrative expense 124,475 92,738 20,439 60,739 298,391 Depreciation and amortization 30,170 51,252 26,788 1,255 109,465 Impairment of goodwill — — 105,302 — 105,302 Operating income (loss) 74,646 2,051 (107,074) (62,410) (92,787) Interest expense, net — — — 94,053 94,053 Loss on extinguishment of debt — — — 11,797 11,797 Income (loss) before income taxes and equity method investment 74,646 2,051 (107,074) (168,260) (198,637) Income tax benefit (provision) (14,482) 866 726 18,396 5,506 Equity in net loss of investee, net of tax (316) — — (7,831) (8,147) Net income (loss) $ 59,848 $ 2,917 $ (106,348) $ (157,695) $ (201,278) Balance Sheet Information Equity investment $ 1,441 $ — $ — $ 29,986 $ 31,427 Goodwill $ 135,186 $ 415,444 $ 129,592 $ 30 $ 680,252 Total assets $ 490,947 $ 720,620 $ 232,794 $ 209,971 $ 1,654,332 Year Ended December 31, 2023 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,951,447 $ 715,615 $ 77,941 $ 6,167 $ 2,751,170 Grant income (2) — 5,037 — — 5,037 Purchased services 1,456,796 — — — 1,456,796 Payroll and related costs 203,199 555,606 13,539 285 772,629 Other service expense 49,795 6,313 13,486 5,199 74,793 Service expense 1,709,790 561,919 27,025 5,484 2,304,218 General and administrative expense 115,355 86,767 22,971 79,471 304,564 Depreciation and amortization 27,409 51,402 24,536 924 104,271 Impairment of goodwill — 137,331 45,769 — 183,100 Operating income (loss) 98,893 (116,767) (42,360) (79,712) (139,946) Interest expense, net — — — 69,120 69,120 Income (loss) before income taxes and equity method investment 98,893 (116,767) (42,360) (148,832) (209,066) Income tax benefit (provision) (26,602) (5,403) (1,459) 37,783 4,319 Equity in net income (loss) of investee, net of tax 1,057 — — (770) 287 Net income (loss) $ 73,348 $ (122,170) $ (43,819) $ (111,819) $ (204,460) Balance Sheet Information Equity investment $ 1,653 $ — $ — $ 39,878 $ 41,531 Goodwill $ 135,186 $ 415,444 $ 234,894 $ 30 $ 785,554 Total assets $ 542,100 $ 763,366 $ 344,527 $ 117,282 $ 1,767,275 Year Ended December 31, 2022 NEMT PCS Monitoring Corporate and Other (1) Total Service revenue, net $ 1,768,442 $ 667,674 $ 68,277 $ — $ 2,504,393 Grant income (2) — 7,351 — — 7,351 Purchased services 1,267,006 — — — 1,267,006 Payroll and related costs 180,382 513,748 12,086 — 706,216 Other service expense 40,059 6,317 12,476 — 58,852 Service expense 1,487,447 520,065 24,562 — 2,032,074 General and administrative expense 146,935 91,365 23,156 60,715 322,171 Depreciation and amortization 28,709 51,025 19,854 827 100,415 Operating income (loss) 105,351 12,570 705 (61,542) 57,084 Interest expense, net — — — 61,961 61,961 Income (loss) before income taxes and equity method investment 105,351 12,570 705 (123,503) (4,877) Income tax benefit (provision) (26,855) (2,810) (208) 32,908 3,035 Equity in net income (loss) of investee, net of tax 71 — — (30,035) (29,964) Net income (loss) $ 78,567 $ 9,760 $ 497 $ (120,630) $ (31,806) Balance Sheet Information Equity investment $ 186 $ — $ — $ 41,117 $ 41,303 Goodwill $ 135,186 $ 552,775 $ 280,663 $ 30 $ 968,654 Total assets $ 496,605 $ 950,181 $ 396,944 $ 100,542 $ 1,944,272

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table summarizes disaggregated revenue from contracts with customers by contract type for the years ended December 31, 2024, 2023 and 2022 (in thousands): Year Ended December 31, 2024 2023 2022 NEMT capitated contracts $ 1,583,347 $ 1,663,987 $ 1,553,407 NEMT FFS contracts 373,928 287,460 215,035 Total NEMT service revenue, net 1,957,275 1,951,447 1,768,442 PCS FFS contracts 745,299 715,615 667,674 Monitoring PMPM contracts 77,739 77,941 68,277 Other service revenue 7,273 6,167 — Total service revenue, net $ 2,787,586 $ 2,751,170 $ 2,504,393
Schedule of Accounts Receivable	The following table provides information about accounts receivable, net as of December 31, 2024 and 2023 (in thousands): December 31, 2024 December 31, 2023 Accounts receivable $ 223,756 $ 223,506 Allowance for credit losses (1,439) (969) Accounts receivable, net $ 222,317 $ 222,537
Schedule of Contract with Customer, Asset and Liability	The following table provides information about other revenue related accounts included on the accompanying consolidated balance sheets (in thousands): December 31, 2024 December 31, 2023 Accrued contract payables (1) $ 22,639 $ 117,488 Contract receivables (2) $ 117,795 $ 143,960 Deferred revenue, current $ 300 $ 2,629 (1) Accrued contract payables primarily represent overpayments and liability reserves on certain risk corridor, profit rebate and reconciliation contracts. See the contract payables and receivables activity below. (2) Contract receivables primarily represent underpayments and receivables on certain risk corridor, profit rebate, and reconciliation contracts. See the contract payables and receivables activity below. The following tables provide the summary activity of total contract payables and receivables as reported within the consolidated balance sheets (in thousands): December 31, 2023 Additional Amounts Recorded Amounts Paid or Settled December 31, 2024 Reconciliation contract payables $ 12,294 $ 7,167 $ (16,042) $ 3,419 Profit rebate/corridor contract payables 94,775 (13,257) (68,923) 12,595 Overpayments and other cash items 10,419 45,131 (48,925) 6,625 Total contract payables $ 117,488 $ 39,041 $ (133,890) $ 22,639 Reconciliation contract receivables $ 57,002 $ 99,203 $ (122,456) $ 33,749 Corridor contract receivables 86,958 86,707 (89,619) 84,046 Total contract receivables $ 143,960 $ 185,910 $ (212,075) $ 117,795 December 31, 2022 Additional Amounts Recorded Amounts Paid or Settled December 31, 2023 Reconciliation contract payables $ 25,853 $ 17,723 $ (31,282) $ 12,294 Profit rebate/corridor contract payables 155,161 61,623 (122,009) 94,775 Overpayments and other cash items 13,273 23,322 (26,176) 10,419 Total contract payables $ 194,287 $ 102,668 $ (179,467) $ 117,488 Reconciliation contract receivables $ 48,153 $ 59,184 $ (50,335) $ 57,002 Corridor contract receivables 23,405 64,009 (456) 86,958 Total contract receivables $ 71,558 $ 123,193 $ (50,791) $ 143,960

Equity Investment (Tables)

Equity Investment (Tables)	12 Months Ended
	Dec. 31, 2024
Equity Method Investment, Summarized Financial Information [Abstract]
Schedule of Income Statement and Balance Sheet Disclosure	Summary financial information for Matrix on a standalone basis is as follows (in thousands): December 31, 2024 December 31, 2023 Current assets $ 52,583 $ 112,090 Long-term assets $ 344,977 $ 351,143 Current liabilities $ 38,356 $ 41,584 Long-term liabilities $ 272,354 $ 314,316 Year ended December 31, 2024 Year ended December 31, 2023 Year ended December 31, 2022 Revenue $ 301,084 $ 325,192 $ 300,306 Operating income (loss) $ 9,730 $ 30,418 $ (83,110) Net loss $ (18,963) $ (1,689) $ (98,187)

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets were comprised of the following (in thousands): December 31, 2024 December 31, 2023 Prepaid insurance $ 6,272 $ 7,231 Deferred ERP implementation costs 3,528 2,875 Deferred financing costs on credit facility 2,858 2,638 Other prepaid expenses 12,761 14,284 Total prepaid expenses and other current assets $ 25,419 $ 27,028

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands, except useful lives): Estimated December 31, Life (years) 2024 2023 Software 3 — 10 $ 66,252 $ 57,658 Computer, office and telecommunications equipment 2 — 7 38,930 39,201 Monitoring equipment 3 39,381 33,547 Leasehold improvements Shorter of useful life or lease term 16,834 12,848 Construction and development in progress N/A 6,213 7,136 Automobiles 5 4,899 5,334 Furniture and fixtures 3 — 10 3,643 4,486 Buildings 30 — 40 388 1,886 Land N/A 12 292 Total property and equipment 176,552 162,388 Less accumulated depreciation (94,143) (76,759) Total property and equipment, net $ 82,409 $ 85,629

Goodwill and Intangibles (Table

Goodwill and Intangibles (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill by reportable segment are presented in the following table (in thousands): NEMT PCS Monitoring Corporate and Other Total Goodwill balances as of December 31, 2022, before cumulative loss Goodwill $ 231,186 $ 552,775 $ 280,663 $ 30 $ 1,064,654 Accumulated impairment losses (96,000) — — — (96,000) Goodwill balances as of December 31, 2022, after cumulative loss $ 135,186 $ 552,775 $ 280,663 $ 30 $ 968,654 Balances as of December 31, 2023 Impairment of goodwill — (137,331) (45,769) — (183,100) $ 135,186 $ 415,444 $ 234,894 $ 30 $ 785,554 Balances as of December 31, 2024 Impairment of goodwill — — (105,302) — (105,302) $ 135,186 $ 415,444 $ 129,592 $ 30 $ 680,252
Schedule of Finite-Lived Intangible Assets	As of December 31, 2024 and 2023, intangible assets consisted of the following (in thousands, except estimated useful lives): December 31, 2024 2023 Estimated Gross Accumulated Gross Accumulated Payor networks 3 - 10 $ 540,309 $ (271,289) $ 540,298 $ (209,560) Trademarks and trade names 2 - 10 48,541 (48,541) 48,541 (34,978) Developed technology 3 - 10 29,301 (17,593) 29,389 (14,732) Non-compete agreement 2 - 5 1,610 (1,050) 1,610 (730) New York LHCSA Permit Indefinite 770 — 770 — Assembled workforce 6 - 10 444 (182) 444 (117) Total $ 620,975 $ (338,655) $ 621,052 $ (260,117)
Schedule of Future Amortization Expense	The total amortization expense is estimated to be as follows for the next five years as of December 31, 2024 (in thousands): Year Amount 2025 $ 64,352 2026 55,774 2027 51,226 2028 44,439 2029 23,036 Total $ 238,827

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other current liabilities were comprised of the following (in thousands): December 31, 2024 2023 Accrued compensation and related liabilities $ 35,018 $ 48,033 Insurance reserves 33,350 22,014 Accrued interest 21,187 10,498 Accrued legal fees 15,794 10,148 Accrued operating expenses 10,602 15,884 Accrued government grants (1) 6,284 9,156 Union pension obligation 886 1,573 Deferred revenue 300 2,629 Other 15,755 7,966 Total accrued expenses and other current liabilities $ 139,176 $ 127,901 (1) Accrued government grants include payments received from government entities in relation to the PRF and SLFRF to offset lost revenue or increased expenditures for which the related expenditure has not yet been incurred and thus the related payments are deferred as of December 31, 2024 and 2023.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The Company's long-term debt and short-term debt as of December 31, 2024 and 2023 consisted of the following (in thousands): December 31, Description Date of Issuance 2024 2023 Senior Unsecured Notes $500.0 million 5.875% due November 15, 2025 11/4/2020 $ — $ 494,011 $500.0 million 5.000% due October 1, 2029 (effective interest rate 5.401%) 8/24/2021 491,311 489,746 Term Loan Facility $525.0 million SOFR + 4.750% due July 1, 2031 (1) 7/1/2024 495,125 — Total long-term debt $ 986,436 $ 983,757 Revolving Credit Facility 2/3/2022 $ 269,000 $ 113,800 Current Portion of Term Loan Facility (2) 7/1/2024 5,250 — Total short-term debt $ 274,250 $ 113,800 (1) The $525.0 million Term Loan Facility bears interest at (i) a SOFR-based benchmark plus 4.75% or (ii) a prime rate (or other alternate base rate) benchmark plus 3.75%% in the case of ABR Loans (as such terms are defined in the amended Credit Agreement) and matures on the earlier of (a) July 1, 2031 and (b) July 2, 2029 if any of the Company's 2029 Notes (as defined below) remain outstanding on that date. (2) The Term Loan Facility requires principal payments of $1.3 million on a quarterly basis and accordingly, a portion of the Term Loan Facility in the amount of $5.3 million is classified as a current liability within the "Short-term debt" line item on the consolidated balance sheets as of December 31, 2024.
Schedule of Debt Instrument Redemption	On or after October 1, 2024, the Company may redeem all or a part of the 2029 Notes upon not less than ten plus accrued and unpaid interest, if any, on the 2029 Notes redeemed, to, but excluding, the applicable redemption date, if redeemed during the 12-month period beginning on October 1 of the years indicated below: Year Percentage 2025 101.250% 2026 and thereafter 100.000%
Schedule of Maturities of Long-Term Debt	Annual maturities on all debt outstanding at December 31, 2024, are as follows: Maturities 2025 $ 274,250 2026 — 2027 — 2028 — 2029 500,000 Thereafter 517,125 Total maturities 1,291,375 Unamortized deferred issuance costs 30,689 Total debt outstanding, short-term and long-term 1,260,686 Less short-term debt 274,250 Total long-term debt outstanding $ 986,436

Stock-Based Compensation and _2

Stock-Based Compensation and Similar Arrangements (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Schedule of 2006 Plan Activity	The following table summarizes the activity under the 2006 Plan as of December 31, 2024: Number of shares Number of shares Number of shares of the Company’s Common Stock subject to issuance future grants Stock Options Stock Grants 2006 Plan 5,400,000 601,519 46,579 572,625
Schedule of Stock-Based Compensation Valuation Assumptions	The fair value of each stock option awarded to employees is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following assumptions for the years ended December 31, 2023 and 2022. No stock options were awarded to employees during the year ended December 31, 2024. Year Ended December 31, 2023 2022 Expected dividend yield 0.0% 0.0% Expected stock price volatility 49.6% - 49.6% 39.6% - 46.5% Risk-free interest rate 3.7% - 3.7% 1.6% - 4.4% Expected life of options (years) 3.5 - 3.5 3.5 - 4.5
Schedule of Stock Option Activity	The following table summarizes the stock option activity for the year ended December 31, 2024: Year ended December 31, 2024 Number Weighted- Weighted- Aggregate Balance at beginning of year, January 1 82,586 $ 104.89 Granted — — Exercised — — Forfeited/Canceled (13,623) 74.81 Expired (22,384) 100.05 Outstanding at end of year, December 31 46,579 $ 116.01 1.51 $ — Vested or expected to vest at end of year, December 31 46,579 $ 116.01 1.51 $ — Exercisable at end of year, December 31 39,656 $ 118.08 1.38 $ —
Schedule of Weighted-Average Grant Date Fair Value, Total Intrinsic Value, and Cash Received	The weighted-average grant date fair value for options granted, total intrinsic value and cash received by the Company related to options exercised during the years ended December 31, 2023 and 2022 were as follows (in thousands, except for fair value per share). The Company did not grant any stock options to employees and no stock options were exercised by employees during the year ended December 31, 2024: Year ended December 31, 2023 2022 Weighted-average grant date fair value per share $ 56.43 $ 106.90 Options exercised: Total intrinsic value $ (7) $ 3,057
Schedule of Restricted Stock and Restricted Stock Units Activity	The following table summarizes the activity of the shares and weighted-average grant date fair value of the Company’s unvested RSAs and RSUs during the year ended December 31, 2024: Shares Weighted-average Non-vested at beginning of year, January 1 298,074 $ 44.65 Granted 231,429 $ 41.01 Vested (100,235) $ 52.49 Forfeited or cancelled (113,922) $ 45.04 Non-vested at end of year, December 31 315,346 $ 39.35
Schedule of Performance-Based Restricted Stock Units, Activity	The following table summarizes the activity of the shares and weighted-average grant date fair value of the Company's unvested PRSUs during the year ended December 31, 2024: Shares Weighted-average Non-vested at beginning of year, January 1 206,036 $ 43.24 Granted 148,395 $ 53.43 Vested — $ — Forfeited or cancelled (97,152) $ 51.74 Non-vested at end of year, December 31 257,279 $ 45.91

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	The following table details the computation of basic and diluted loss per share (in thousands, except share and per share data): Year ended December 31, 2024 2023 2022 Numerator: Net loss $ (201,278) $ (204,460) $ (31,806) Denominator: Denominator for basic and diluted earnings per share -- weighted-average shares 14,239,549 14,173,957 14,061,839 Loss per share: Basic loss per share $ (14.14) $ (14.43) $ (2.26) Diluted loss per share $ (14.14) $ (14.43) $ (2.26)
Schedule of Antidilutive Securities	The following weighted-average shares were not included in the computation of diluted earnings per share as the effect of their inclusion would have been anti-dilutive: Year ended December 31, 2024 2023 2022 Stock options to purchase common stock 64,561 100,499 118,260 Restricted stock awards and restricted stock units 308,171 87,056 58,831

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lease Classifications	A summary of all lease classifications in our consolidated balance sheets is as follows (in thousands): Leases Classification December 31, 2024 December 31, 2023 Assets Operating lease assets Operating lease ROU assets $ 36,597 $ 39,776 Liabilities Current: Operating Current portion of operating lease liabilities $ 8,616 $ 8,727 Long-term: Operating Operating lease liabilities, less current portion 32,905 33,784 Total lease liabilities $ 41,521 $ 42,511
Schedule of Operating Lease of Future Maturities	As of December 31, 2024, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2025 $ 10,891 2026 8,910 2027 7,276 2028 6,598 2029 5,075 Thereafter 10,509 Total lease payments 49,259 Less: interest and accretion (7,738) Present value of minimum lease payments 41,521 Less: current portion (8,616) Long-term portion $ 32,905 As of December 31, 2023, future maturities of lease liabilities were as follows (in thousands): Operating Leases 2024 $ 10,434 2025 8,664 2026 7,275 2027 5,894 2028 5,403 Thereafter 13,121 Total lease payments 50,791 Less: interest and accretion (8,280) Present value of minimum lease payments 42,511 Less: current portion (8,727) Long-term portion $ 33,784
Schedule of Lease Cost	The weighted-average remaining lease terms and weighted-average discount rates are as follows: December 31, 2024 December 31, 2023 Weighted-average remaining lease term (years): Operating lease costs 3.60 4.18 Weighted-average discount rate: Operating lease costs 5.62 % 5.43 % A summary of other lease information is as follows (in thousands): Year Ended December 31, 2024 Year Ended December 31, 2023 Operating cash flows from operating leases $ (10,049) $ (12,636) Amortization of operating lease ROU assets $ 11,444 $ 12,344 ROU assets obtained through operating lease liabilities $ 8,265 $ 12,715

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Federal, State and Foreign Income Tax Provision	The federal and state tax benefit (provision) is summarized as follows (in thousands): Year Ended December 31, 2024 2023 2022 Federal income tax benefit (provision): Current $ (9,909) $ (10,296) $ (22,651) Deferred 16,596 14,431 25,291 Total federal income tax benefit 6,687 4,135 2,640 State income tax benefit (provision): Current (5,374) (3,067) (11,500) Deferred 4,193 3,251 11,895 Total state income tax benefit (provision) (1,181) 184 395 Total benefit for income taxes $ 5,506 $ 4,319 $ 3,035
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the benefit (provision) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (in thousands): Year Ended December 31, 2024 2023 2022 Federal statutory rates 21.0 % 21.0 % 21.0 % Federal income tax benefit at statutory rates $ 41,714 $ 43,904 $ 1,024 Change in valuation allowance (21,728) (507) 648 Goodwill impairment (22,113) (38,451) — State income taxes, net of federal benefit 3,825 637 (521) Rate change 3,168 — — Tax credits 1,669 2,258 1,864 Life insurance expense 136 128 (183) Stock-based compensation (507) (791) 1,282 Political activities (357) (149) (197) Meals and entertainment (84) (154) (48) Change in uncertain tax positions (59) 396 (390) Compensation expense — (1,220) (251) Legal settlements — (1,608) — Subsidiary deconsolidation gain — — (148) Other (158) (124) (45) Income tax benefit $ 5,506 $ 4,319 $ 3,035 Effective income tax rate 2.8 % 2.1 % 62.2 %
Schedule of Deferred Tax Assets and Liabilities	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): December 31, 2024 2023 Deferred tax assets: Interest expense carryforward $ 40,317 $ 22,847 Accrued items and reserves 16,638 9,289 Software development/implementation costs 10,426 7,147 Deferred rent 9,914 1,543 Accounts receivable allowance 4,596 3,341 Net operating loss carryforwards 3,233 2,989 Stock-based compensation 2,363 1,861 Deferred financing costs 327 — Tax credit carryforwards 186 412 Deferred revenue 76 2,691 Capital loss carryforward — 957 Project costs — 223 Other 424 — Total deferred tax assets 88,500 53,300 Deferred tax liabilities: Goodwill and intangible assets 41,315 57,115 Property and equipment 15,116 19,051 Right of use asset 8,657 — Equity investment 8,058 11,604 Prepaid expenses 3,859 1,683 Deferred financing costs — 98 Other — 46 Total deferred tax liabilities 77,005 89,597 Net deferred tax assets (liabilities) 11,495 (36,297) Less valuation allowance (25,052) (3,287) Net deferred tax liabilities $ (13,557) $ (39,584)
Schedule of Operating Loss Carryforwards	At December 31, 2024, the Company had no federal net operating loss (“NOL”) carryforwards. The Company also had approximately $49.7 million of state NOL carryforwards which expire as follows (in thousands): 2025 $ — 2026 — 2027 — 2028 — 2029 84 2030 and thereafter 49,658 Total state net operating loss carryforwards $ 49,742
Schedule of Unrecognized Tax Benefits Rollforward	A reconciliation of the liability for unrecognized income tax benefits is as follows (in thousands): December 31, 2024 2023 2022 Unrecognized tax benefits, beginning of year $ 1,284 $ 1,680 $ 1,290 Increase (decrease) related to prior year tax positions (47) 44 108 Increase related to current year tax positions 332 374 415 Statute of limitations expiration (195) (814) (133) Unrecognized tax benefits, end of year $ 1,374 $ 1,284 $ 1,680

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details) - USD ($) $ in Millions	Dec. 31, 2024	Jul. 01, 2024	Dec. 31, 2023
Credit Agreement
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Face amount		$ 255
Fifth Amendment | Credit Agreement
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Face amount	$ 75
Matrix
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Equity method investment, ownership percentage	43.60%		43.60%

Significant Accounting Polici_3

Significant Accounting Policies and Recent Accounting Pronouncements (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jul. 01, 2024
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated Useful Life (Yrs)			7 years 8 months 12 days
Impairment of goodwill			$ 105,302,000	$ 183,100,000	$ 0
Accrued Transportation Costs			96,745,000	97,245,000
Deferred financing costs on credit facility			2,900,000	2,600,000
Unamortized deferred issuance costs			30,689,000
Grant distribution amount			19,500,000	21,800,000	16,300,000
Government assistance, operating income, increase (decrease)			0	5,000,000	7,400,000
Government assistance, operating expense, increase (decrease)			$ 24,100,000	$ 14,200,000	$ 1,600,000
Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]			Service expense	Service expense	Service expense
Government Assistance, Operating Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]			Grant income (Note 2)	Grant income (Note 2)	Grant income (Note 2)
Gross reinsurance liability reserve			$ 58,000,000	$ 45,700,000
Reimbursable reinsurance reserve			28,000,000	25,500,000
Self insurance maximum exposure per claim employee medical			300,000
Self insurance maximum exposure per claim employee medical, stop-loss limit			400,000
Self insurance reserve			3,300,000	1,800,000
Social Services Providers Captive Insurance Company
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Gross reinsurance liability reserve			30,000,000	20,200,000
Unsecured Notes Due 2025 | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Face amount			500,000,000
2025 Senior Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Face amount			500,000,000			$ 7,300,000
Deferred financing costs, noncurrent, net				6,000,000
Unamortized deferred issuance costs						4,500,000
2029 Senior Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Face amount			500,000,000
Deferred financing costs, noncurrent, net				10,300,000
2029 Senior Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Face amount			500,000,000
Deferred financing costs, noncurrent, net			8,700,000
Term Loan Facility | Secured Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Face amount						$ 525,000,000
Unamortized deferred issuance costs			22,000,000	22,000,000
Personal Care and Remote Patient Monitoring
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impairment of goodwill		$ 183,100,000
PCS
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impairment of goodwill		(137,300,000)	0	137,331,000
Monitoring
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impairment of goodwill	$ 105,300,000	$ 45,800,000	105,302,000	45,769,000
Software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capitalized costs, net of accumulated amortization			26,100,000	21,300,000
Capitalized computer software, accumulated amortization			7,800,000	2,600,000
Capitalized costs, amortization expense			5,200,000	2,500,000	$ 100,000
Cloud Computing Arrangements
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capitalized costs, net of accumulated amortization			11,900,000	14,600,000
Capitalized computer software, accumulated amortization			10,300,000	5,200,000
Capitalized costs, amortization expense			$ 5,100,000	2,900,000	1,700,000
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated Useful Life (Yrs)			2 years
Minimum | Software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated Useful Life (Yrs)			3 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated Useful Life (Yrs)			10 years
Maximum | Software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated Useful Life (Yrs)			10 years
Continuing Operations
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Bad debt expense			$ 4,400,000	$ 4,000,000	$ 2,700,000

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands			12 Months Ended
	May 30, 2022	May 11, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Purchase price			$ 0	$ 0	$ 79,200
Cash acquired			0	0	391
Service revenue, net			2,787,586	2,751,170	2,504,393
Net loss			$ (201,278)	$ (204,460)	$ (31,806)
Asset acquisition, consideration transferred	$ 7,600
Guardian Medical Monitoring
Business Acquisition [Line Items]
Percentage of voting interests acquired		100%
Purchase price		$ 71,200
Consideration transferred, net of cash from acquisition excluded		71,600
Cash acquired		400
Service revenue, net		11,900
Net loss		$ 1,800

Acquisitions - Schedule of Purc

Acquisitions - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands		12 Months Ended
	May 11, 2022	Dec. 31, 2024	Dec. 31, 2022	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill		$ 680,252	$ 968,654	$ 785,554
Adjustment to property and equipment		(100)
Guardian Medical Monitoring
Business Acquisition [Line Items]
Cash	$ 391		300
Accounts receivable	2,355		3,000
Prepaid expenses and other	771
Property and equipment	2,639	2,700
Intangible assets	21,950
Goodwill	44,346	44,300
Accounts payable	(281)
Accrued expense and other current liabilities	(577)
Total of assets acquired and liabilities assumed	$ 71,594
Business combination, provisional information, initial accounting incomplete, adjustment, cash		100	100
Initial accounts receivable balance deemed uncollectable			$ (600)
Adjustment to property and equipment		(100)
Useful Life	6 years 10 months 24 days
Adjustment to accounts receivable		$ (600)
Guardian Medical Monitoring | Pro Forma
Business Acquisition [Line Items]
Goodwill	$ 43,700

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Assets Acquired (Details) - USD ($) $ in Thousands	May 30, 2022	May 11, 2022
Business Acquisition [Line Items]
Finite-lived intangibles	$ 7,606
Payor networks
Business Acquisition [Line Items]
Useful Life	6 years
Finite-lived intangibles	$ 7,297
Trade name
Business Acquisition [Line Items]
Useful Life	6 years
Finite-lived intangibles	$ 309
Guardian Medical Monitoring
Business Acquisition [Line Items]
Useful Life		6 years 10 months 24 days
Intangible assets		$ 21,950
Guardian Medical Monitoring | Payor networks
Business Acquisition [Line Items]
Useful Life		7 years
Finite-lived intangibles		$ 21,600
Guardian Medical Monitoring | Trade name
Business Acquisition [Line Items]
Useful Life		2 years
Finite-lived intangibles		$ 350

Segments - Narrative (Details)

Segments - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	4

Segments - Schedule of Financia

Segments - Schedule of Financial Information Attributable to the Company's Business Segments (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Service revenue, net			$ 2,787,586	$ 2,751,170	$ 2,504,393
Grant income			0	5,037	7,351
Purchased services			1,504,970	1,456,796	1,267,006
Payroll and related costs			784,583	772,629	706,216
Other service expense			77,662	74,793	58,852
Service expense			2,367,215	2,304,218	2,032,074
General and administrative expense			298,391	304,564	322,171
Depreciation and amortization			109,465	104,271	100,415
Impairment of goodwill			105,302	183,100	0
Operating income (loss)			(92,787)	(139,946)	57,084
Interest expense, net			94,053	69,120	61,961
Loss on debt extinguishment			11,797	0	0
Loss before income taxes and equity method investment			(198,637)	(209,066)	(4,877)
Income tax benefit			5,506	4,319	3,035
Equity in net loss of investee, net of tax			(8,147)	287	(29,964)
Net income (loss)			(201,278)	(204,460)	(31,806)
Equity investment			31,427	41,531	41,303
Goodwill			680,252	785,554	968,654
Total assets			1,654,332	1,767,275	1,944,272
NEMT
Segment Reporting Information [Line Items]
Service revenue, net			1,957,275	1,951,447	1,768,442
Impairment of goodwill			0	0
Goodwill			135,186	135,186	135,186
NEMT | Operating Segments
Segment Reporting Information [Line Items]
Service revenue, net			1,957,275	1,951,447	1,768,442
Grant income				0	0
Purchased services			1,504,970	1,456,796	1,267,006
Payroll and related costs			172,800	203,199	180,382
Other service expense			50,214	49,795	40,059
Service expense			1,727,984	1,709,790	1,487,447
General and administrative expense			124,475	115,355	146,935
Depreciation and amortization			30,170	27,409	28,709
Impairment of goodwill			0	0
Operating income (loss)			74,646	98,893	105,351
Interest expense, net			0	0	0
Loss on debt extinguishment			0
Loss before income taxes and equity method investment			74,646	98,893	105,351
Income tax benefit			(14,482)	(26,602)	(26,855)
Equity in net loss of investee, net of tax			(316)	1,057	71
Net income (loss)			59,848	73,348	78,567
Equity investment			1,441	1,653	186
Goodwill			135,186	135,186	135,186
Total assets			490,947	542,100	496,605
PCS
Segment Reporting Information [Line Items]
Impairment of goodwill		$ (137,300)	0	137,331
Goodwill			415,444	415,444	552,775
PCS | Operating Segments
Segment Reporting Information [Line Items]
Service revenue, net			745,299	715,615	667,674
Grant income				5,037	7,351
Purchased services			0	0	0
Payroll and related costs			594,150	555,606	513,748
Other service expense			5,108	6,313	6,317
Service expense			599,258	561,919	520,065
General and administrative expense			92,738	86,767	91,365
Depreciation and amortization			51,252	51,402	51,025
Impairment of goodwill			0	137,331
Operating income (loss)			2,051	(116,767)	12,570
Interest expense, net			0	0	0
Loss on debt extinguishment			0
Loss before income taxes and equity method investment			2,051	(116,767)	12,570
Income tax benefit			866	(5,403)	(2,810)
Equity in net loss of investee, net of tax			0	0	0
Net income (loss)			2,917	(122,170)	9,760
Equity investment			0	0	0
Goodwill			415,444	415,444	552,775
Total assets			720,620	763,366	950,181
Monitoring
Segment Reporting Information [Line Items]
Impairment of goodwill	$ 105,300	$ 45,800	105,302	45,769
Goodwill			129,592	234,894	280,663
Monitoring | Operating Segments
Segment Reporting Information [Line Items]
Service revenue, net			77,739	77,941	68,277
Grant income				0	0
Purchased services			0	0	0
Payroll and related costs			17,077	13,539	12,086
Other service expense			15,207	13,486	12,476
Service expense			32,284	27,025	24,562
General and administrative expense			20,439	22,971	23,156
Depreciation and amortization			26,788	24,536	19,854
Impairment of goodwill			105,302	45,769
Operating income (loss)			(107,074)	(42,360)	705
Interest expense, net			0	0	0
Loss on debt extinguishment			0
Loss before income taxes and equity method investment			(107,074)	(42,360)	705
Income tax benefit			726	(1,459)	(208)
Equity in net loss of investee, net of tax			0	0	0
Net income (loss)			(106,348)	(43,819)	497
Equity investment			0	0	0
Goodwill			129,592	234,894	280,663
Total assets			232,794	344,527	396,944
Corporate and Other
Segment Reporting Information [Line Items]
Service revenue, net			7,273	6,167	0
Grant income				0	0
Purchased services			0	0	0
Payroll and related costs			556	285	0
Other service expense			7,133	5,199	0
Service expense			7,689	5,484	0
General and administrative expense			60,739	79,471	60,715
Depreciation and amortization			1,255	924	827
Impairment of goodwill			0	0
Operating income (loss)			(62,410)	(79,712)	(61,542)
Interest expense, net			94,053	69,120	61,961
Loss on debt extinguishment			11,797
Loss before income taxes and equity method investment			(168,260)	(148,832)	(123,503)
Income tax benefit			18,396	37,783	32,908
Equity in net loss of investee, net of tax			(7,831)	(770)	(30,035)
Net income (loss)			(157,695)	(111,819)	(120,630)
Equity investment			29,986	39,878	41,117
Goodwill			30	30	30
Total assets			$ 209,971	$ 117,282	$ 100,542

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Total service revenue, net	$ 2,787,586	$ 2,751,170	$ 2,504,393
Other service revenue
Disaggregation of Revenue [Line Items]
Total service revenue, net	7,273	6,167	0
NEMT
Disaggregation of Revenue [Line Items]
Total service revenue, net	1,957,275	1,951,447	1,768,442
NEMT | Capitated contracts
Disaggregation of Revenue [Line Items]
Total service revenue, net	1,583,347	1,663,987	1,553,407
NEMT | FFS Contracts
Disaggregation of Revenue [Line Items]
Total service revenue, net	373,928	287,460	215,035
PCS | FFS Contracts
Disaggregation of Revenue [Line Items]
Total service revenue, net	745,299	715,615	667,674
Monitoring | Monitoring
Disaggregation of Revenue [Line Items]
Total service revenue, net	$ 77,739	$ 77,941	$ 68,277

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
NEMT
Disaggregation of Revenue [Line Items]
Performance obligation satisfied in previous period, increase (decrease)	$ 1.7	$ (2.8)	$ (0.9)
One US State | Sales Revenue, Net | Government Contracts Concentration Risk | NEMT | Continuing Operations
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	10.90%	11.20%	10.90%
One US State | Sales Revenue, Net | Government Contracts Concentration Risk | PCS | Continuing Operations
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	12.50%	11.30%	12%
One US State | Sales Revenue, Net | Government Contracts Concentration Risk | Monitoring | Continuing Operations
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	18.90%	18.50%	19.90%

Revenue Recognition - Accounts

Revenue Recognition - Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Accounts receivable	$ 223,756	$ 223,506
Allowance for credit losses	(1,439)	(969)
Accounts receivable, net	$ 222,317	$ 222,537

Revenue Recognition - Other Acc

Revenue Recognition - Other Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Accrued contract payables	$ 22,639	$ 117,488
Contract receivables	117,795	143,960
Deferred revenue, current	$ 300	$ 2,629

Revenue Recognition - Contract

Revenue Recognition - Contract Payables and Receivables (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Summary of Contract Payables [Roll Forward]
Contract with customer, liability, beginning of period	$ 117,488	$ 194,287
Contract with customer, liability, additional amounts recorded	39,041	102,668
Contract with customer, liability, amounts paid or settled	(133,890)	(179,467)
Contract with customer, liability, end of period	22,639	117,488
Summary of Receivables [Roll Forward]
Contract with customer, asset, beginning of period	143,960	71,558
Contract with customer, asset, additional amounts recorded	185,910	123,193
Contract with customer, asset, amounts paid or settled	(212,075)	(50,791)
Contract with customer, asset, end of period	117,795	143,960
Reconciliation Contract
Summary of Contract Payables [Roll Forward]
Contract with customer, liability, beginning of period	12,294	25,853
Contract with customer, liability, additional amounts recorded	7,167	17,723
Contract with customer, liability, amounts paid or settled	(16,042)	(31,282)
Contract with customer, liability, end of period	3,419	12,294
Summary of Receivables [Roll Forward]
Contract with customer, asset, beginning of period	57,002	48,153
Contract with customer, asset, additional amounts recorded	99,203	59,184
Contract with customer, asset, amounts paid or settled	(122,456)	(50,335)
Contract with customer, asset, end of period	33,749	57,002
Profit Rebate / Corridor Contract Payables
Summary of Contract Payables [Roll Forward]
Contract with customer, liability, beginning of period	94,775	155,161
Contract with customer, liability, additional amounts recorded	(13,257)	61,623
Contract with customer, liability, amounts paid or settled	(68,923)	(122,009)
Contract with customer, liability, end of period	12,595	94,775
Overpayments and Other Cash Items
Summary of Contract Payables [Roll Forward]
Contract with customer, liability, beginning of period	10,419	13,273
Contract with customer, liability, additional amounts recorded	45,131	23,322
Contract with customer, liability, amounts paid or settled	(48,925)	(26,176)
Contract with customer, liability, end of period	6,625	10,419
Corridor Contract Receivables
Summary of Receivables [Roll Forward]
Contract with customer, asset, beginning of period	86,958	23,405
Contract with customer, asset, additional amounts recorded	86,707	64,009
Contract with customer, asset, amounts paid or settled	(89,619)	(456)
Contract with customer, asset, end of period	$ 84,046	$ 86,958

Equity Investment - Narrative (

Equity Investment - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Operating income (loss)	$ (92,787,000)	$ (139,946,000)	$ 57,084,000
Equity investment	31,427,000	41,531,000	41,303,000
Matrix
Schedule of Investments [Line Items]
Net (loss) income	$ (7,800,000)	$ (800,000)	(30,000,000)
Matrix
Schedule of Investments [Line Items]
Equity method investment, ownership percentage	43.60%	43.60%
Impairment	$ 0	$ 0	82,200,000
Operating income (loss)	(9,400,000)	(1,100,000)	$ (41,000,000)
Equity investment	$ 30,000,000	$ 39,900,000

Equity Investment - Schedule of

Equity Investment - Schedule of Financial Information for Matrix (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Current assets	$ 495,379	$ 404,923
Current liabilities	624,494	520,402
Operating income (loss)	(92,787)	(139,946)	$ 57,084
Net loss	(201,278)	(204,460)	(31,806)
Matrix
Schedule of Investments [Line Items]
Current assets	52,583	112,090
Long-term assets	344,977	351,143
Current liabilities	38,356	41,584
Long-term liabilities	272,354	314,316
Revenue	301,084	325,192	300,306
Operating income (loss)	9,730	30,418	(83,110)
Net loss	$ (18,963)	$ (1,689)	$ (98,187)

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 6,272	$ 7,231
Deferred ERP implementation costs	3,528	2,875
Deferred financing costs on credit facility	2,858	2,638
Other prepaid expenses	12,761	14,284
Total prepaid expenses and other current assets	$ 25,419	$ 27,028

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 176,552	$ 162,388
Less accumulated depreciation	(94,143)	(76,759)
Total property and equipment, net	82,409	85,629
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	66,252	57,658
Computer, office and telecommunications equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 38,930	39,201
Monitoring equipment
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Property and equipment, gross	$ 39,381	33,547
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	16,834	12,848
Construction and development in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,213	7,136
Automobiles
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	5 years
Property and equipment, gross	$ 4,899	5,334
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,643	4,486
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment, gross	388	1,886
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 12	$ 292
Minimum | Software
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Minimum | Computer, office and telecommunications equipment
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	2 years
Minimum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Minimum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	30 years
Maximum | Software
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	10 years
Maximum | Computer, office and telecommunications equipment
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	7 years
Maximum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	10 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	40 years

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 30,927	$ 25,038	$ 20,055

Goodwill and Intangibles - Narr

Goodwill and Intangibles - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Impairment of goodwill			$ 105,302,000	$ 183,100,000	$ 0
Goodwill			680,252,000	785,554,000	968,654,000
Expected tax deductible amount			219,800,000	317,300,000
Impairment					0
Accumulated impairment loss			$ (384,400,000)	(279,100,000)	(96,000,000)
Estimated useful life			7 years 8 months 12 days
Residual value			$ 0
Amortization of intangible assets			78,500,000	79,200,000	80,400,000
Personal Care and Remote Patient Monitoring
Goodwill [Line Items]
Impairment of goodwill		$ 183,100,000
Goodwill			545,000,000
RPM
Goodwill [Line Items]
Impairment of goodwill	$ 105,300,000	45,800,000	105,302,000	45,769,000
Goodwill			129,592,000	234,894,000	280,663,000
Accumulated impairment loss					0
PCS
Goodwill [Line Items]
Impairment of goodwill		$ (137,300,000)	0	137,331,000
Goodwill			$ 415,444,000	$ 415,444,000	552,775,000
Accumulated impairment loss					$ 0

Goodwill and Intangibles - Sche

Goodwill and Intangibles - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Goodwill					$ 1,064,654
Accumulated impairment losses			$ (384,400)	$ (279,100)	(96,000)
Impairment of goodwill			(105,302)	(183,100)	0
Goodwill			680,252	785,554	968,654
NEMT
Goodwill [Roll Forward]
Goodwill					231,186
Accumulated impairment losses					(96,000)
Impairment of goodwill			0	0
Goodwill			135,186	135,186	135,186
PCS
Goodwill [Roll Forward]
Goodwill					552,775
Accumulated impairment losses					0
Impairment of goodwill		$ 137,300	0	(137,331)
Goodwill			415,444	415,444	552,775
Monitoring
Goodwill [Roll Forward]
Goodwill					280,663
Accumulated impairment losses					0
Impairment of goodwill	$ (105,300)	$ (45,800)	(105,302)	(45,769)
Goodwill			129,592	234,894	280,663
Corporate and Other
Goodwill [Roll Forward]
Goodwill					30
Accumulated impairment losses					0
Impairment of goodwill			0	0
Goodwill			$ 30	$ 30	$ 30

Goodwill and Intangibles - Sc_2

Goodwill and Intangibles - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	7 years 8 months 12 days
Gross Carrying Amount	$ 620,975	$ 621,052
Accumulated Amortization	(338,655)	(260,117)
Payor networks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	540,309	540,298
Accumulated Amortization	(271,289)	(209,560)
Trademarks and trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	48,541	48,541
Accumulated Amortization	(48,541)	(34,978)
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	29,301	29,389
Accumulated Amortization	(17,593)	(14,732)
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,610	1,610
Accumulated Amortization	(1,050)	(730)
New York LHCSA Permit
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	770	770
Accumulated Amortization	0	0
Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	444	444
Accumulated Amortization	$ (182)	$ (117)
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	2 years
Minimum | Payor networks
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	3 years
Minimum | Trademarks and trade names
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	2 years
Minimum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	3 years
Minimum | Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	2 years
Minimum | Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	6 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	10 years
Maximum | Payor networks
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	10 years
Maximum | Trademarks and trade names
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	10 years
Maximum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	10 years
Maximum | Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	5 years
Maximum | Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Yrs)	10 years

Goodwill and Intangibles - Sc_3

Goodwill and Intangibles - Schedule of Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 64,352
2026	55,774
2027	51,226
2028	44,439
2029	23,036
Total	$ 238,827

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued compensation and related liabilities	$ 35,018	$ 48,033
Insurance reserves	33,350	22,014
Accrued interest	21,187	10,498
Accrued legal fees	15,794	10,148
Accrued operating expenses	10,602	15,884
Accrued government grants	6,284	9,156
Union pension obligation	886	1,573
Deferred revenue	300	2,629
Other	15,755	7,966
Total accrued expenses and other current liabilities	$ 139,176	$ 127,901

Debt - Schedule of Long Term De

Debt - Schedule of Long Term Debt Instruments (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 01, 2024	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total long-term debt		$ 986,436	$ 983,757
Short-term debt		274,250	113,800
Revolving Credit Facility
Debt Instrument [Line Items]
Short-term debt		269,000	113,800
Current Portion of Term Loan Facility
Debt Instrument [Line Items]
Short-term debt		5,250	0
2025 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Face amount	$ 7,300	$ 500,000
Stated interest rate (as percent)		5.875%
Total long-term debt		$ 0	494,011
2029 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Face amount		$ 500,000
Stated interest rate (as percent)		5%
Effective interest rate (as percent)		5.401%
Total long-term debt		$ 491,311	489,746
Term Loan Facility
Debt Instrument [Line Items]
Line of credit facility, periodic principal payment		1,300
Line of credit facility, periodic payment		5,300
Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Face amount	$ 525,000
Basis spread on variable rate (as percent)	4.75%
Total long-term debt		$ 495,125	$ 0
Term Loan Facility | Secured Debt | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	4.75%
Term Loan Facility | Secured Debt | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as percent)	3.75%

Debt - Senior Unsecured Notes (

Debt - Senior Unsecured Notes (Details) - USD ($)		12 Months Ended
	Jul. 01, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Debt financing fees		$ 30,689,000	$ 16,243,000
Loss on debt extinguishment		11,797,000	0	$ 0
Unamortized deferred issuance costs		30,689,000
Senior Notes
Line of Credit Facility [Line Items]
Debt instrument, covenant, maximum indebtedness principal amount		50,000,000
2025 Senior Notes
Line of Credit Facility [Line Items]
Fair value		$ 0	499,200,000
2025 Senior Notes | Senior Notes
Line of Credit Facility [Line Items]
Percentage of principal required to be repaid		100%
Debt financing fees		$ 14,500,000
Deferred financing costs, noncurrent, net			6,000,000
Redemption price, percentage	1.469%
Repayments of senior debt	$ 507,300,000
Interest expense, debt	3,800,000
Loss on debt extinguishment	11,800,000
Face amount	7,300,000	$ 500,000,000
Unamortized deferred issuance costs	$ 4,500,000
Stated interest rate (as percent)		5.875%
2029 Senior Notes
Line of Credit Facility [Line Items]
Fair value		$ 294,200,000	410,000,000
2029 Senior Notes | Senior Notes
Line of Credit Facility [Line Items]
Debt financing fees		13,500,000
Deferred financing costs, noncurrent, net		8,700,000
Face amount		$ 500,000,000
Stated interest rate (as percent)		5%
2029 Senior Notes | Senior Notes
Line of Credit Facility [Line Items]
Percentage of principal required to be repaid		100%
Deferred financing costs, noncurrent, net			$ 10,300,000
Face amount		$ 500,000,000
Redemption period (in months)		12 months
Stated interest rate (as percent)		5%
2029 Senior Notes | Senior Notes | Minimum
Line of Credit Facility [Line Items]
Notice period for redemption (in days)		10 days
2029 Senior Notes | Senior Notes | Maximum
Line of Credit Facility [Line Items]
Notice period for redemption (in days)		60 days

Debt - Schedule of Debt Instrum

Debt - Schedule of Debt Instrument Redemption (Details) - 2029 Senior Notes - Senior Notes	12 Months Ended
	Dec. 31, 2024
Period One
Debt Instrument [Line Items]
Redemption price, percentage	101.25%
Period Two
Debt Instrument [Line Items]
Redemption price, percentage	100%

Debt - Revolving Credit Facilit

Debt - Revolving Credit Facility (Details)						12 Months Ended
	Jan. 09, 2025 USD ($)	Sep. 30, 2024	Sep. 29, 2024	Feb. 22, 2024 USD ($)	Jun. 26, 2023	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Feb. 03, 2022 USD ($)
Line of Credit Facility [Line Items]
Short-term debt						$ 274,250,000	$ 113,800,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Short-term debt						269,000,000	113,800,000
Debt Instrument, Covenant Period, One | Maximum | Subsequent Event
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio	6.75
Debt Instrument, Covenant Period, Two | Minimum | Subsequent Event
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio	1.65
Credit Agreement
Line of Credit Facility [Line Items]
Remaining borrowing capacity				$ 100,000,000
Face amount								$ 255,000,000
Debt instrument, covenant, minimum liquidity								75,000,000	$ 100,000,000
Fee amount								$ 300,000
Debt instrument covenant, interest coverage minimum		2
Basis spread on variable rate (as percent)		0.25%
Letters of credit outstanding						$ 269,000,000
Debt instrument, weighted average interest rate						8.80%
Debt instrument, covenant, maximum indebtedness principal amount						$ 40,000,000
Debt Related Commitment Fees and Debt Issuance Costs						$ 2,300,000	2,600,000
Credit Agreement | Subsequent Event
Line of Credit Facility [Line Items]
Debt instrument, de-minimis exception for certain asset sale prepayments	$ 5,000,000
Debt instrument, amended minimum liquidity covenant credit agreement	$ 25,000,000
Credit Agreement | Subsequent Event | Secured Overnight Financing Rate (SOFR) - Based Benchmark
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	4.25%
Credit Agreement | Subsequent Event | Secured Overnight Financing Rate (SOFR) Floor
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	1%
Credit Agreement | Subsequent Event | Secured Overnight Financing Rate (SOFR)
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	2%
Credit Agreement | Maximum
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio		6.50	5.25
Unused capacity, commitment fee percentage						0.50%
Credit Agreement | Maximum | Term Benchmark
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)						3.50%
Credit Agreement | Minimum
Line of Credit Facility [Line Items]
Unused capacity, commitment fee percentage						0.30%
Credit Agreement | Minimum | Term Benchmark
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)						1.75%
Credit Agreement | Debt Instrument, Covenant Period, One
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5.50	5.25
Credit Agreement | Debt Instrument, Covenant Period, Two
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5.25	5
Credit Agreement | Debt Instrument, Covenant Period, Three
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5	4.75
Credit Agreement | Debt Instrument, Covenant Period, Thereafter
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio					4.50
Credit Agreement | Debt Instrument, Covenant Period, Four
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				4.75	4.50
Revolving Credit Facility | Maximum
Line of Credit Facility [Line Items]
Unused capacity, commitment fee percentage						3.50%
Revolving Credit Facility | Minimum
Line of Credit Facility [Line Items]
Unused capacity, commitment fee percentage						1.75%
Revolving Credit Facility | Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity										$ 325,000,000
Bridge Loan | Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity										25,000,000
Letter of Credit | Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity										60,000,000
Letters of credit outstanding						$ 55,600,000	$ 40,400,000
Letter of Credit | Credit Agreement | Maximum
Line of Credit Facility [Line Items]
Debt instrument, pro forma net leverage ratio						2.70
Alternative Currency Loan | Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity										$ 75,000,000

Debt - Term Loan Facility (Deta

Debt - Term Loan Facility (Details) $ in Thousands						12 Months Ended
	Sep. 30, 2024	Sep. 29, 2024	Jul. 01, 2024 USD ($)	Feb. 22, 2024	Jun. 26, 2023	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Payment of debt issuance costs						$ 25,786	$ 376	$ 2,415
Unamortized deferred issuance costs						$ 30,689
Credit Agreement
Line of Credit Facility [Line Items]
Face amount			$ 255,000
Basis spread on variable rate (as percent)	0.25%
Debt instrument, weighted average interest rate						8.80%
Debt instrument, covenant, maximum indebtedness principal amount						$ 40,000
Credit Agreement | Minimum | Base Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)						0.75%
Credit Agreement | Maximum
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio	6.50	5.25
Credit Agreement | Maximum | Base Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)						2.50%
Credit Agreement | Debt Instrument, Covenant Period, One
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5.50	5.25
Credit Agreement | Debt Instrument, Covenant Period, Two
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5.25	5
Credit Agreement | Debt Instrument, Covenant Period, Three
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				5	4.75
Credit Agreement | Debt Instrument, Covenant Period, Four
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio				4.75	4.50
Term Loan Facility | Secured Debt
Line of Credit Facility [Line Items]
Face amount			525,000
Payment of debt issuance costs			$ 24,400
Unamortized deferred issuance costs						$ 22,000	$ 22,000
Fair value						$ 500,200
Debt instrument, periodic payment, percentage of principal amount			0.0025
Basis spread on variable rate (as percent)			4.75%
Debt instrument, weighted average interest rate						9.08%
Term Loan Facility | Secured Debt | Secured Overnight Financing Rate (SOFR)
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)			4.75%
Term Loan Facility | Secured Debt | Base Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)			3.75%
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, One
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio			0.750
Debt instrument, covenant leverage ratio			4.40
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Two
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio			0.500
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Two | Minimum
Line of Credit Facility [Line Items]
Debt instrument, covenant leverage ratio			3.90
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Two | Maximum
Line of Credit Facility [Line Items]
Debt instrument, covenant leverage ratio			4.40
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Three
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio			0.250
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Three | Minimum
Line of Credit Facility [Line Items]
Debt instrument, covenant leverage ratio			3.40
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Three | Maximum
Line of Credit Facility [Line Items]
Debt instrument, covenant leverage ratio			3.90
Term Loan Facility | Secured Debt | Debt Instrument, Covenant Period, Four
Line of Credit Facility [Line Items]
Debt instrument, total net leverage ratio			0
Debt instrument, covenant leverage ratio			3.40

Debt - Incremental Term Loan (D

Debt - Incremental Term Loan (Details) - Incremental Term Loan - Secured Debt - Subsequent Event $ in Millions	Jan. 09, 2025 USD ($)
Line of Credit Facility [Line Items]
Face amount	$ 75
Basis spread on variable rate (as percent)	0.50%
Secured Overnight Financing Rate (SOFR) - Based Benchmark
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	7.50%
Secured Overnight Financing Rate (SOFR)
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	1%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Long-Term Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
2025	$ 274,250
2026	0
2027	0
2028	0
2029	500,000
Thereafter	517,125
Total maturities	1,291,375
Unamortized deferred issuance costs	30,689
Total debt outstanding, short-term and long-term	1,260,686
Short-term debt	274,250	$ 113,800
Total long-term debt outstanding	$ 986,436	$ 983,757

Stockholders' Equity (Details)

Stockholders' Equity (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares, issued (in shares)	19,882,026	19,775,041
Treasury stock, shares (in shares)	5,558,898	5,571,004
Restricted Stock
Class of Stock [Line Items]
Shares surrendered by employees to pay employee taxes related to shares released from escrow (in shares)	22,827	10,565	7,486
Common Stock
Class of Stock [Line Items]
Exercise of stock options and restricted stock awards (in shares)	619,204

Stock-Based Compensation and _3

Stock-Based Compensation and Similar Arrangements - Schedule of 2006 Plan Activity (Details) - shares	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock subject to stock options (in shares)	46,579	82,586
Long Term Incentive Plan 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of the Company’s Common Stock authorized for issuance (in shares)	5,400,000
Number of shares of the Company’s Common Stock remaining for future grants (in shares)	601,519
Long Term Incentive Plan 2006 | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock subject to stock options (in shares)	46,579
Long Term Incentive Plan 2006 | Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock subject to stock grants (in shares)	572,625

Stock-Based Compensation and _4

Stock-Based Compensation and Similar Arrangements - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit from compensation expense		$ 1,600	$ 1,800	$ 1,900
Fair value of shares vested		$ 10,000	$ 11,700	2,600
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual maximum payroll deduction amount	$ 25
Purchase price of common stock, percent	85%
Share-based payment award, shares purchased for award (in shares)		50,963	16,030
Total shares of common stock reserved for future issuance (in shares)		949,037
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of employee stock options (in shares)		0
Stock Options and Restricted Stock Units | Non Employee Directors Executive Officers and Certain Key Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested shares		$ 400
Weighted-average remaining contractual term (in years)		1 year 6 months 3 days
Restricted stock awards and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested shares		$ 14,400
Weighted-average remaining contractual term (in years)		1 year 2 months 23 days
Vested (in shares)		100,235
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested shares		$ 4,700
Weighted-average remaining contractual term (in years)		1 year 9 months 29 days
Award requisite service period (in years)		3 years
Minimum | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Vesting expiration period (in years)		5 years
Minimum | Restricted stock awards and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		1 year
Maximum | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Vesting expiration period (in years)		7 years
Maximum | Restricted stock awards and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 6,800	$ 6,500	$ 6,900

Stock-Based Compensation and _5

Stock-Based Compensation and Similar Arrangements - Schedule of Stock-Based Compensation Valuation Assumptions (Details) - Stock Options	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	49.60%	39.60%
Risk-free interest rate	3.70%	1.60%
Expected life of options (years)	3 years 6 months	3 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	49.60%	46.50%
Risk-free interest rate	3.70%	4.40%
Expected life of options (years)	3 years 6 months	4 years 6 months

Stock-Based Compensation and _6

Stock-Based Compensation and Similar Arrangements - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Number of Shares Under Option
Balance at beginning of year (in shares) | shares	82,586
Granted (in shares) | shares	0
Exercised (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	(13,623)
Expired (in shares) | shares	(22,384)
Outstanding at end of year (in shares) | shares	46,579
Vested or expected to vest at end of year (in shares) | shares	46,579
Exercisable at end of year (in shares) | shares	39,656
Weighted- average Exercise Price
Balance at beginning of year (in dollars per share) | $ / shares	$ 104.89
Granted (in dollars per share) | $ / shares	0
Exercised (in dollars per share) | $ / shares	0
Forfeited/Cancelled (in dollars per share) | $ / shares	74.81
Expired (in dollars per share) | $ / shares	100.05
Outstanding at end of year (in dollars per share) | $ / shares	116.01
Vested or expected to vest at end of year (in dollars per share) | $ / shares	116.01
Exercisable at end of year (in dollars per share) | $ / shares	$ 118.08
Weighted- average Remaining Contractual Term
Outstanding at end of year, December 31	1 year 6 months 3 days
Vested or expected to vest at end of year, December 31	1 year 6 months 3 days
Exercisable at end of year, December 31	1 year 4 months 17 days
Aggregate Intrinsic Value (in thousands)
Outstanding at end of year, December 31 | $	$ 0
Vested or expected to vest at end of year, December 31 | $	0
Exercisable at end of year, December 31 | $	$ 0

Stock-Based Compensation and _7

Stock-Based Compensation and Similar Arrangements - Schedule of Weighted-Average Grant Date Fair Value, Total Intrinsic Value and Cash Received (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Weighted-average grant date fair value per share (in dollars per share)	$ 56.43	$ 106.90
Options exercised:
Total intrinsic value	$ (7)	$ 3,057

Stock-Based Compensation and _8

Stock-Based Compensation and Similar Arrangements - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) - Restricted stock awards and restricted stock units	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Shares
Non-vested at beginning of year (in shares) | shares	298,074
Granted (in shares) | shares	231,429
Vested (in shares) | shares	(100,235)
Forfeited or cancelled (in shares) | shares	(113,922)
Non-vested at end of year (in shares) | shares	315,346
Weighted-average grant date fair value
Non-vested at beginning of year (in dollars per share) | $ / shares	$ 44.65
Granted (in dollars per share) | $ / shares	41.01
Vested (in dollars per share) | $ / shares	52.49
Forfeited or cancelled (in dollars per share) | $ / shares	45.04
Non-vested at end of year (in dollars per share) | $ / shares	$ 39.35

Stock-Based Compensation and _9

Stock-Based Compensation and Similar Arrangements - Schedule of PRSUs Activity (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Shares
Balance at beginning of year (in shares) | shares	82,586
Granted (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	(13,623)
Outstanding at end of year (in shares) | shares	46,579
Weighted- average Exercise Price
Balance at beginning of year (in dollars per share) | $ / shares	$ 104.89
Granted (in dollars per share) | $ / shares	0
Forfeited/Cancelled (in dollars per share) | $ / shares	74.81
Outstanding at end of year (in dollars per share) | $ / shares	$ 116.01
Performance-Based Restricted Stock Units
Shares
Balance at beginning of year (in shares) | shares	206,036
Granted (in shares) | shares	148,395
Vested (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	(97,152)
Outstanding at end of year (in shares) | shares	257,279
Weighted- average Exercise Price
Balance at beginning of year (in dollars per share) | $ / shares	$ 43.24
Granted (in dollars per share) | $ / shares	53.43
Vested (in dollars per share) | $ / shares	0
Forfeited/Cancelled (in dollars per share) | $ / shares	51.74
Outstanding at end of year (in dollars per share) | $ / shares	$ 45.91

Loss Per Share - Schedule of Ba

Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net loss	$ (201,278)	$ (204,460)	$ (31,806)
Denominator:
Denominator for basic earnings per share -- weighted-average shares (in shares)	14,239,549	14,173,957	14,061,839
Denominator for diluted earnings per share -- weighted-average shares (in shares)	14,239,549	14,173,957	14,061,839
Loss per share:
Basic loss per share (in dollars per share)	$ (14.14)	$ (14.43)	$ (2.26)
Diluted loss per share (in dollars per share)	$ (14.14)	$ (14.43)	$ (2.26)

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Stock options to purchase common stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities (in shares)	64,561	100,499	118,260
Restricted stock awards and restricted stock units
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities (in shares)	308,171	87,056	58,831

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Leased Assets [Line Items]
Lease, discount rate (as percent)	5.62%
General and Administrative Expense
Operating Leased Assets [Line Items]
Operating lease, cost	$ 12.2	$ 13

Leases - Schedule of Lease Clas

Leases - Schedule of Lease Classification (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease assets	$ 36,597	$ 39,776
Current portion of operating lease liabilities	8,616	8,727
Operating lease liabilities, less current portion	32,905	33,784
Total lease liabilities	$ 41,521	$ 42,511

Leases - Schedule of Lease Liab

Leases - Schedule of Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Operating Leases
Lessee, operating lease, liability, to be paid, year one	$ 10,891	$ 10,434
Lessee, operating lease, liability, to be paid, year two	8,910	8,664
Lessee, operating lease, liability, to be paid, year three	7,276	7,275
Lessee, operating lease, liability, to be paid, year four	6,598	5,894
Lessee, operating lease, liability, to be paid, year five	5,075	5,403
Thereafter	10,509	13,121
Total lease payments	49,259	50,791
Less: interest and accretion	(7,738)	(8,280)
Present value of minimum lease payments	41,521	42,511
Less: current portion	(8,616)	(8,727)
Long-term portion	$ 32,905	$ 33,784

Leases - Schedule of Lease Term

Leases - Schedule of Lease Terms (Details)	Dec. 31, 2024	Dec. 31, 2023
Weighted-average remaining lease term (years):
Operating lease costs	3 years 7 months 6 days	4 years 2 months 4 days
Weighted-average discount rate:
Operating lease costs	5.62%	5.43%

Leases - Schedule of Other Leas

Leases - Schedule of Other Lease Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating cash flows from operating leases	$ (10,049)	$ (12,636)
Amortization of operating lease ROU assets	11,444	12,344
ROU assets obtained through operating lease liabilities	$ 8,265	$ 12,715

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal, State and Foreign Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Federal income tax benefit (provision):
Current	$ (9,909)	$ (10,296)	$ (22,651)
Deferred	16,596	14,431	25,291
Total federal income tax benefit	6,687	4,135	2,640
State income tax benefit (provision):
Current	(5,374)	(3,067)	(11,500)
Deferred	4,193	3,251	11,895
Total state income tax benefit (provision)	(1,181)	184	395
Total benefit for income taxes	$ 5,506	$ 4,319	$ 3,035

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory rates	21%	21%	21%
Federal income tax benefit at statutory rates	$ 41,714	$ 43,904	$ 1,024
Change in valuation allowance	(21,728)	(507)	648
Goodwill impairment	(22,113)	(38,451)	0
State income taxes, net of federal benefit	3,825	637	(521)
Rate change	3,168	0	0
Tax credits	1,669	2,258	1,864
Life insurance expense	136	128	(183)
Stock-based compensation	(507)	(791)	1,282
Political activities	(357)	(149)	(197)
Meals and entertainment	(84)	(154)	(48)
Change in uncertain tax positions	(59)	396	(390)
Compensation expense	0	(1,220)	(251)
Legal settlements	0	(1,608)	0
Subsidiary deconsolidation gain	0	0	(148)
Other	(158)	(124)	(45)
Total benefit for income taxes	$ 5,506	$ 4,319	$ 3,035
Effective income tax rate	2.80%	2.10%	62.20%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Interest expense carryforward	$ 40,317	$ 22,847
Accrued items and reserves	16,638	9,289
Software development/implementation costs	10,426	7,147
Deferred rent	9,914	1,543
Accounts receivable allowance	4,596	3,341
Net operating loss carryforwards	3,233	2,989
Stock-based compensation	2,363	1,861
Deferred financing costs	327	0
Tax credit carryforwards	186	412
Deferred revenue	76	2,691
Capital loss carryforward	0	957
Project costs	0	223
Other	424	0
Total deferred tax assets	88,500	53,300
Deferred tax liabilities:
Goodwill and intangible assets	41,315	57,115
Property and equipment	15,116	19,051
Right of use asset	8,657	0
Equity investment	8,058	11,604
Prepaid expenses	3,859	1,683
Deferred financing costs	0	98
Other	0	46
Total deferred tax liabilities	77,005	89,597
Net deferred tax assets (liabilities)	11,495	(36,297)
Less valuation allowance	(25,052)	(3,287)
Net deferred tax liabilities	$ (13,557)	$ (39,584)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Valuation allowance, deferred tax asset, increase (decrease), amount	$ (21,800,000)
Less valuation allowance	(25,052,000)	$ (3,287,000)
Unrecognized tax benefits	1,374,000	$ 1,284,000	$ 1,680,000	$ 1,290,000
Domestic Tax Jurisdiction
Operating Loss Carryforwards [Line Items]
State net operating loss carryforwards	$ 0
Taxable income projection years	3 years
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
State net operating loss carryforwards	$ 49,742,000
State and Local Jurisdiction | Minimum
Operating Loss Carryforwards [Line Items]
Taxable income projection years	3 years
State and Local Jurisdiction | Maximum
Operating Loss Carryforwards [Line Items]
Taxable income projection years	4 years

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net operating Loss Carryforwards (Details) - State and Local Jurisdiction $ in Thousands	Dec. 31, 2024 USD ($)
Operating Loss Carryforwards [Line Items]
2025	$ 0
2026	0
2027	0
2028	0
2029	84
2030 and thereafter	49,658
Total state net operating loss carryforwards	$ 49,742

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]
Unrecognized tax benefits, beginning of year	$ 1,284	$ 1,680	$ 1,290
Increase (decrease) related to prior year tax positions	(47)	44	108
Increase related to current year tax positions	332	374	415
Statute of limitations expiration	(195)	(814)	(133)
Unrecognized tax benefits, end of year	$ 1,374	$ 1,284	$ 1,680

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
	May 31, 2023 USD ($)	Dec. 31, 2024 USD ($) plan	Dec. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Litigation settlement amount	$ 9.6
Number of deferred compensation plans | plan		1
Other Noncurrent Liabilities
Loss Contingencies [Line Items]
Total participant deferrals		$ 2.3	$ 2.2

Subsequent Events (Details)

Subsequent Events (Details) - Credit Agreement $ in Millions	Jan. 09, 2025 USD ($)	Jul. 01, 2024 USD ($)
Subsequent Event [Line Items]
Face amount		$ 255
Subsequent Event | Coliseum Capital Partners, L.P. and Blackwell Partners LLC
Subsequent Event [Line Items]
Face amount	$ 30
Subsequent Event | Coliseum Investors
Subsequent Event [Line Items]
Face amount	$ 20
Debt instrument, pursuant conditions, purchase agreement	0.6667
5.000% Senior Notes Due 2029 | Subsequent Event
Subsequent Event [Line Items]
Redemption price, percentage	5%
Face amount	$ 251
Second Lien Notes | Subsequent Event | Coliseum Capital Partners, L.P. and Blackwell Partners LLC
Subsequent Event [Line Items]
Redemption price, percentage	100%

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - Allowance for credit losses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 969	$ 2,078	$ 2,296
Charged to costs and expenses	4,395	4,001	2,690
Charged to other accounts	0	0	0
Deductions	(3,925)	(5,110)	(2,908)
Balance at end of period	$ 1,439	$ 969	$ 2,078